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Abstract 
 
The World Health Organisation (WHO) has defined preterm labour as the onset of labour before 
37 completed weeks of gestation with an incidence ranging between 5-10%. Although patient 
care has improved, the rate of preterm birth has slowly been increasing and currently impacts 
significantly on maternal and fetal mortality and morbidity. The complex condition of preterm 
labour involves multiple etiologies and risk factors, which complicates the search for candidate 
markers and / or biomarkers. 
 
The aim of this prospective study was to investigate potential genetic associations with preterm 
labour. The study cohort consisted of consecutive first-time booking, low-risk primigravid 
pregnant women from a restricted geographical region.  
 
The study cohort comprised 421 [306 Coloured and 115 Black] pregnant women presenting at the 
Paarl Hospital Obstetric clinic. Subsequently, DNA was extracted from whole blood and 
investigated for a range of known polymorphisms in pro-inflammatory and anti-inflammatory 
cytokines, as well as the novel LGALS13 gene, for potential variants that may impact on 
pregnancy outcome. Screening techniques involve combinations of allele-specific PCR 
amplification, Multiphor SSCP/HD analysis, restriction enzyme analyses and DNA sequencing. 
 
A significant association was demonstrated between the IL-1RN*2-allele and adverse pregnancy 
outcome, mainly in the preterm labour and hypertension group. The presence TNFα-308 A-allele 
was associated with overall adverse pregnancy outcome and preterm labour. In addition to this, a 
novel IL-1RN allele was identified in the control group. 
 
Mutation screening and subsequent statistical methods revealed an association between a novel 
LGALS13 exonic variant, 221delT, and preterm labour in Coloured women. Two previously-
documented intronic variants (IVS2-22A/G and IVS3+72T/A) demonstrated linkage 
disequilibrium, signifying evolutionary conservation of exon three. Additionally, two novel 
intronic variants, IVS2-36 G/A and IVS2-15 G/A, demonstrated no association with adverse 
pregnancy outcome. 
 iii
In this study we identified rare novel exonic variants; two non-synonymous variants in exon three 
(M44V, [N=2] and K87R, [N=1]) and a silent variant in exon four (P117P, [N=1]) - all identified 
in individuals from the control cohort. Within coding exon three, an interesting variant 
[“hotspot”] was identified, which represents six polymorphic bases within an 11bp stretch. No 
associations were demonstrated with these variants and pregnancy outcome.  
 
Furthermore, a previously documented 5' “‘promoter” variant, -98 A/C, was identified and 
demonstrated no association with adverse pregnancy outcome. However, subdivision of late-
onset pre-eclamptic cases revealed a significant association with the A-allele and late-onset pre-
eclampsia. 
 
Genotype-phenotype investigation demonstrated association between the IL-10 -1082 A/G, IL-4 
C/T and 221delT loci and poor pregnancy progress which manifested as (i) delivery of infants 
weighing <2000g, (ii) before 37 weeks of gestation. 
 
The findings of this study will strengthen our understanding of the pathophysiology underlying 
pregnancy complications and facilitate the further development of effective treatment strategies to 
reduce maternal and fetal morbidity and mortality. 
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Opsomming 
 
Die Wêreld Gesondheid Organisasie (WHO) klassifiseer voortydse kraam as kontraksie voor 37 
volledige weke, met ‘n insidensie tussen 5-10%. Alhoewel pasiënte-sorg verbeter het, neem die 
tempo van voortydse geboorte steeds toe, wat ‘n groot impak het op moederstrefte en fetale 
mortaliteit en morbiditeit. Die komplekse kondisie van voortydse kraam sluit veelvoudige 
oorsake en risiko faktore in, wat die navorsing van kandidaat en / of biologiese merkers 
kompliseer. 
 
Die doel van hierdie prospektiewe studie, was die potensiële navorsing van genetiese assosiasies 
met voortydse kraam. Die studie kohort bevat opeenvolgende eerste bespreking van lae risiko 
primigravida swanger vrouens vanaf ‘n beperkte geografiese omgewing. 
 
Die studie kohort beslaan 421 [306 Kleurling en 115 Swart] swanger vrouens teenwoordig by die 
Paarl Hospitaal Verloskunde kliniek. Vervolgens was DNS geëkstraeer van bloedmonsters en 
geondersoek vir ‘n verskeidenheid van bekende polimorfismes in pro-inflammatoriese en anti-
inflammatoriese sitokiene, insluitend die nuwe sifting van die LGALS13 geen potensiaal vir 
variante wat ‘n impak op swangerskap uitkomste sal hê. Die siftings tegnieke toegepas, sluit in ‘n 
kombinasie van alleel-spesifieke amplifikasie, Multiphor enkelstring konformasie polimorfisme / 
heterodupleks analise, restriksie ensiem verterings en volgorde bepalings tegnieke. 
 
‘n Betekenisvolle assosiasie was gedemonstreer tussen die IL-1RN*2-alleel en nadelige 
swangerskap, beperk tot voortydse kraam en die hipertensie groep. Die teenwoordigheid van die 
TNFα-308 A-alleel was geassosieer met algehele nadelige uitkomste en voortydse kraam. 
Daarby, was ‘n nuwe IL-1RN alleel geïdentifiseer in die kontrole groep. 
 
Mutasie sifting en opeenvolgende statistiese metodes, het ‘n assosiasie getoon tussen ‘n nuwe 
LGALS13 koderende variant, 221delT, en voortydse kraam in Kleurling vrouens. Twee 
voorafbeskryfde introniese variante (IVS2-22 A/G en IVS3+72 T/A), het ‘n betekenisvolle bewys 
opgelewer dat daar koppelings-onewewig bestaan tussen hierdie variante, en toon evolusionêre 
 v
konservasie van ekson drie. Addisioneel was twee nuwe introniese variante ontdek, IVS2-36 G/A 
en IVS2-15 G/A, wat geen assosiasie getoon nie. 
 
In hierdie studie het ons ‘n nuwe seldsame koderende variante geïdentifiseer in die kontrole 
groep, waarvan twee nie-sinonieme variante was in ekson drie (M44V, N=2 en K87R, N=1) en ‘n 
stil variasie in ekson vier (P117P, N=1). Geleë in die koderende area van ekson drie, was ’n 
interessante variant [“hotspot’] ontdek, waarvan ses basisse in ‘n 11 basis paar area polimorfies 
is. Geen assosiasie was getoon met hierdie variante en swangerskap uitkomste nie. 
 
Verder was ‘n voorafbeskryfde 5' ‘promotor’ variant, -98 A/C, geïdentifiseer wat geen assosiasie 
getoon met nadelige swangerskap uitkomste nie. Onderverdeling van laat-aanvangs pre-
eklampsie, het getoon dat die A-alleel ‘n betekenisvolle assosiasie getoon het met die 
ontwikkeling van laat pre-eklampsie. 
 
Genotipe-fenotipe interaksies het ’n assosiasie getoon tussen die IL-10 -1082 A/G, IL-4 C/T en 
221delT lokusse en nadelige swangerskap uitkomste, wat manifesteer as (i) kraam van suigelinge 
wat <2000g weeg, (ii) geboorte voor 37 weke. 
 
Die bevindings van hierdie studie sal ons basiese kennis verbeter oor die patologie beskrywend 
aan swangerskap komplikasies, asook die fasilitering en ontwikkeling van effektiewe 
behandelings strategieë, om moederstrefte en fetale mortaliteit en morbiditeit te verminder. 
 
 
 
 
 
 
 
 
 
 
 vi
NRF acknowledgement 
 
The financial assistance of the National Research Foundation (NRF) towards this research project 
is hereby acknowledged. Opinions expressed and conclusions arrived at, are those of the author 
and not necessarily to be attributed to the NRF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii
Acknowledgements 
 
I would like to express my appreciation for the following persons and institutions; 
 
My Heavenly Father for the strength and courage, during the course of my studies. 
 
My sincere appreciation for my supervisor, Dr. Renate Hillermann, for all your proof-reading, 
support, guidance and words of encouragement. Thank you for allowing me to further my studies, 
in a field that I love. 
 
To my co-supervisor, Dr. Stefan Gebhardt, for all you clinical input and advice. 
 
The NRF and University of Stellenbosch for funding.  
 
To all of my friends, Lizzie, Marika, Erika, Alisa, Megan, Natalie, Veronique, Michelle and 
Nicola, thanks for all your encouragement and advice, it’s much appreciated. Thanks guys!!! 
Especially to Lizzie and Marika thanks for all your support, all the late nights in the lab, keeping 
me sane.  
 
To my sisters, Natasha and Mugeleigh, and my brothers, Richard and Heinrich, thanks for a 
lifetime of memories and love. To my brother in-law, Graeme, thanks for being my ‘big brother’. 
 
To my Mom and Dad, thank you for all the support, believing in me. All the years, it may have 
seemed that all your effort went unnoticed, but you were always in my thoughts. Thank you for 
all the gifts from home and letters, it kept me going. I love you so much Mom and Dad. I’m the 
person I am, because of you. 
  
 
 
 
 
 viii
List of Contents  
               Page number 
Title page           p. i 
Declaration           p. ii 
Abstract           p. iii 
Opsomming           p. v 
NRF acknowledgement         p. vii 
Acknowledgements          p. viii 
List of Contents           p. ix 
List of Figures           p. xiii 
List of Tables           p. xvi 
List of Appendices          p. xxii 
List of Abbreviations          p. xxiii 
 
1. Introduction          p. 1 
 
1.1. Preterm labour         p. 1 
1.1.1. Definitions         p. 1 
1.1.2. Incidence and Trends        p. 2 
1.1.3. Risk factors         p. 3 
 
1.2. The onset of labour        p. 5 
1.2.1. The myometrium        p. 5 
1.2.2. The cervix         p. 6 
1.2.3. Myometrial contractility       p. 7 
1.2.4. Contraction and relaxation       p. 8 
1.2.5. Infection and myometrial contractility     p. 9 
 
1.3. Infection as a cause of preterm labour      p. 9 
1.3.1. Pathways of infection        p. 10 
1.3.2. Microbiology of uterine infection      p. 11 
 ix
1.3.3. Infection of the genital tract       p. 11 
1.3.3.1. Fetal infection        p. 11 
1.3.3.2. Vaginal infection       p. 13 
1.3.3.3. Infection of the fetal membranes     p. 14 
1.3.3.4. Intra-amniotic infection       p. 16 
 
1.4. Inflammation as a reason for preterm labour     p. 16 
1.4.1. Innate immune receptors of the genital tract     p. 16 
1.4.2. The role of pro-inflammatory cytokines     p. 17 
1.4.3. The role of anti-inflammatory cytokines     p. 19 
 
1.5. Molecular studies         p. 20 
1.5.1. Pro-inflammatory cytokines       p. 20 
1.5.1.1. Tumour necrosis factor-α      p. 20 
1.5.1.2. Interleukin-1β        p. 20 
1.5.1.3. Interleukin-6        p. 21 
1.5.2. Anti-inflammatory cytokines       p. 22 
1.5.2.1. Interleukin-1ra        p. 22 
1.5.2.2. Interleukin-4        p. 22 
1.5.2.3. Interleukin-10        p. 23 
1.5.3. Other regulators        p. 24 
1.5.3.1. Matrix metalloproteinase      p. 24 
1.5.3.2. Toll-like receptor 4       p. 24  
1.5.3.3. Beta-2-adrenergic receptor       p. 25 
1.5.3.4. Vascular endothelial growth factor     p. 26 
 
1.6. Pregnancy-related proteins       p. 26 
1.6.1. Placental Protein-13 (PP-13)       p. 27 
1.6.1.1. Biological functions of PP-13      p. 28 
1.6.1.2. Placental vasculopathy       p. 28 
1.6.1.3. Clinical studies        p. 29 
 x
1.7. Treatment of preterm labour       p. 30 
1.7.1. Antibiotics          p. 30 
1.7.2. Betamimetics         p. 31 
1.7.3. Nitric oxide donors         p. 31 
1.7.4. Prostaglandin synthetase inhibitors       p. 33 
1.7.5. Calcium channel blockers       p. 34 
1.7.6. Magnesium sulphate        p. 35 
1.7.7. Oxytocin antagonist         p. 35 
 
1.8. Preterm labour: Where do we stand now?     p. 37 
 
1.9. Aim and Objectives        p. 37 
 
2. Material and Methods         p. 38 
 
2.1. Materials          p. 38 
2.1.1. Patients         p. 38 
2.1.2. Controls         p. 39 
 
2.2. Methods          p. 39 
2.2.1. DNA Extraction        p. 39 
2.2.2. Polymerase Chain reaction       p. 39 
2.2.2.1. Oligonucleotide Primers      p. 39 
2.2.2.2. DNA Amplification       p. 44 
2.2.3. Agarose Gel Electrophoresis       p. 44 
2.2.4. Mutation Screening        p. 44 
2.2.4.1. SSCP/HD analysis       p. 44 
2.2.4.2. Sequencing         p. 45 
2.2.4.3. Restriction Enzyme Analysis  (REA)     p. 45 
2.2.5. Statistical Analysis        p. 46 
2.2.6. Genotype: phenotype correlation      p. 47 
 xi
3. Results and Discussion         p. 47 
 
3.1. Results           p. 47 
3.1.1. Participant’s demographic and clinical characteristics   p. 48 
3.1.1.1. The Paarl Hospital patient PROFILE     p. 48 
3.1.1.2. Discussion        p. 52 
3.1.2. Inflammatory cytokines       p. 53 
3.1.2.1.1. IL-1RN locus       p. 53 
3.1.2.1.2. TNFα-308 G/A variant      p. 56 
3.1.2.2. Discussion        p. 59 
3.1.3. LGALS13 variants        p. 64 
3.1.3.1. Linkage disequilibrium of the IVS2–22 and IVS3+72 variants p. 64  
3.1.3.2. 221delT         p. 68 
3.1.3.3. Discussion        p. 71 
3.1.4. Genotype: phenotype interaction      p. 78 
    
4. Concluding remarks         p. 79 
 
5. References          p. 83 
 
6. Appendices          p. 96 
 
 
 
 
 
 
 
 
 
 
 xii
List of Figures 
  
Figure 1: Graphical representation of the incidence of preterm labour worldwide  p. 3 
 
Figure 2: The ascending route of intrauterine infection.      p. 11 
 
Figure 3: Fetal organs targeted by FIRS.        p. 12 
 
Figure 4: Perinuclear staining of PP13 at the brush border membrane.    p. 27  
 
Figure 5: Graphical representation of the LGALS13 gene.     p. 41 
 
Figure 6: The initial size of the study cohort.      p. 49 
 
Figure 7:  Graphical presentation of the complications observed at Paarl Hospital.  p. 50 
 
Figure 8:  Standard fetal growth chart with clinical characteristics.    p. 51
 
Figure 9: Agarose gel representing the IL-1RN 86 bp repeat.     p. 53
 
Figure 10: Agarose gel representing the TNFα -308 polymorphism detected by   p. 57 
      ARMS PCR   
 
Figure 11: Illustration of the cluster of 5' variants of exon three.    p. 65 
 
 
Figure 12: (a) Multiphor SSCP/HD and (b) Electropherogram of the IVS2-22A/G locus. p. 65 
 
Figure 13: Agarose gel representing the IVS2-22 A/G locus (REA).   p. 66 
 
Figure 14: (a) Multiphor SSCP/HD and (b) Electropherogram of the IVS3+72T/A.  p. 66 
 
 xiii
Figure 15: Agarose gel representing the IVS2+72 T/A locus (REA).   p. 67 
 
Figure 16: (a) Multiphor SSCP/HD and (b) Electropherogram of the 221delT.  p. 69 
 
Figure 17: Sequence alignment of the wild type PP13 and 221delT protein isoforms. p. 69 
 
Figure 18: Agarose gel representing the TNFα -238 G/A variant detected by ARMS. p. 114 
 
Figure 19: Agarose gel representing the TNFα +488 G/A polymorphism (REA).  p. 115 
  
Figure 20: Agarose gel representing the IL-10 -1082 A/G polymorphism (REA).  p. 116 
 
Figure 21: Agarose gel representing the IL-10 -592 C/A polymorphism (REA).  p. 118 
 
Figure 22: Agarose gel representing the IL-1β +3954 C/T polymorphism (REA).  p. 119 
 
Figure 23: Electropherogram of the +3594 C/T polymorphism.     p. 120 
 
Figure 24: Agarose gel representing the IL-4 -590 C/T polymorphism (REA).  p. 121 
 
Figure 25: Multiphor SSCP/HD conformations of the -98 A/C ‘promoter’ variant. p. 124 
 
Figure 26: Agarose gel representing the -98 A/C ‘promoter’ variant (REA).  p. 124 
 
Figure 27: Multiphor SSCP/HD conformations of the IVS2-36A/G variant.  p. 125 
 
Figure 28: Electropherogram depicting the IVS2-36 G/A locus.    p. 126 
 
Figure 29: Agarose gel representing the IVS2-36 G/A variant (REA).   p. 126 
 
Figure 30: Multiphor SSCP/HD conformations of the IVS2-15 G/A variant.  p. 128 
 xiv
Figure 31: Electropherogram depicting the IVS2-15 locus.     p. 128 
 
Figure 32: (a) Multiphor SSCP/HD and (b) Electropherogram of the ‘hotspot’ variant. p. 130 
 
Figure 33: Agarose gel representing the ‘hotspot’ sequence variant.   p. 130 
 
Figure 34: (a) Multiphor SSCP/HD and (b) Electropherogram of the 130A→G variant. p. 133 
 
Figure 35: (a) Multiphor SSCP/HD and (b) Electropherogram of the 260 A→G variant. p. 133 
 
Figure 36: (a) Multiphor SSCP/HD and (b) Electropherogram of the 351 G→A variant. p. 134 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xv
List of Tables  
 
Table 1: Risk factors for preterm labour.       p. 4 
 
Table 2: Primer information of the LGALS13 gene.      p. 41 
 
Table 3: Primer information of the immunological gene variants    p. 42 
 
Table 4:  Cycling conditions.         p. 43 
 
Table 5: REA of immunological variants.       p. 46 
 
Table 6: REA of LGALS13 gene variants.       p. 46 
 
Table 7: Demographic and clinical characteristics of study cohort.     p. 51 
 
Table 8: Genotype distribution of the IL-1RN in the total cohort.    p. 54 
 
Table 9: Genotype and allele frequencies of the IL-1RN in total cohort.    p. 54 
 
Table 10: Genotype and allele frequencies of IL-1RN in the Coloured population.  p. 55 
 
Table 11: Genotype and allele frequencies of IL-1RN in the Black population.   p. 56 
 
Table 12: Genotype and allele frequencies of TNFα-308G/A in the total cohort.   p. 57 
 
Table 13: Genotype and allele frequencies of TNFα-308G/A in the Coloured population.  p. 58 
 
Table 14: Genotype and allele frequencies of TNFα-308G/A in the black population.  p. 58 
 
Table 15: List of novel and documented variants identified in this study.   p. 64 
 xvi
 Table 16: Genotype and allele frequencies of IVS2-22 A/G locus in total cohort.  p. 67 
 
Table 17: Genotype and allele frequencies of IVS3+72 T/A locus in total cohort.  p. 68 
 
Table 18: Linkage disequilibrium of the IVS2-22A/G and IVS3+72T/A loci.  p. 68 
 
Table 19: Genotype and allele frequencies of the 221delT variant for the total cohort.  p. 70 
 
Table 20: Genotype and allele frequencies of 221delT in the Coloured population.  p. 71 
 
Table 21: Genotype and allele frequencies of 221delT in the Black population.   p. 71 
 
Table 22: Genotype and allele frequencies of TNFα-238G/A in the total cohort.   p. 114 
 
Table 23: Genotype and allele frequencies of TNFα-238G/A in the Coloured population.  p. 114 
 
Table 24: Genotype and allele frequencies of TNFα-238G/A in the black population. p. 115 
 
Table 25: Genotype and allele frequencies of TNFα+488G/A in the total cohort.   p. 115 
 
Table 26: Genotype and allele frequencies of TNFα+488G/A in the Coloured population. p. 116   
 
Table 27: Genotype and allele frequencies of TNFα+488G/A in the black population. p. 116  
 
Table 28: Genotype and allele frequencies of IL-10-1082A/G in the total cohort.   p. 117 
 
Table 29: Genotype and allele frequencies of IL-10-1082A/G in the Coloured population. p. 117 
 
Table 30: Genotype and allele frequencies of IL-10-1082A/G in the black population. p. 117  
 
 xvii
Table 31: Genotype and allele frequencies of IL-10-592C/A in the total cohort.   p. 118 
 
Table 32: Genotype and allele frequencies of IL-10-592C/A in the Coloured population. p. 119 
 
Table 33: Genotype and allele frequencies of IL-10 -592 C/A in the black population. p. 119 
 
Table 34: Genotype and allele frequencies of IL-1β+3954C/T in the total cohort.   p. 120 
 
Table 35: Genotype and allele frequencies of IL-1β+3954C/T in the Coloured population. p. 120 
 
Table 36: Genotype and allele frequencies of IL-1β+3954C/T in the black population. p. 121 
 
Table 37: Genotype and allele frequencies of IL-4-590C/T in the total cohort.   p. 121 
 
Table 38: Genotype and allele frequencies of IL-4 -590 C/T in the Coloured population.  p. 122 
 
Table 39: Genotype and allele frequencies of IL-4-590C/T in the black population. p. 122 
 
Table 40: Genotype and allele frequencies of -98 A/C in the total cohort.   p. 124  
 
Table 41: Genotype and allele frequencies of -98 A/C in the Coloured population.  p. 125 
 
Table 42: Genotype and allele frequencies of -98 A/C in the black population.  p. 125 
 
Table 43: Genotype and allele frequencies of IVS2-36G/A in the total cohort.   p. 126 
 
Table 44: Genotype and allele frequencies of IVS2-36G/A in the Coloured population.  p. 127 
 
Table 45: Genotype and allele frequencies of IVS2-36G/A in the Black population. p. 127 
 
Table 46: Genotype and allele frequencies of IVS2-22A/G in the Coloured population.  p. 127 
 xviii
Table 47: Genotype and allele frequencies of IVS2-22A/G in the Black population. p. 128 
 
Table 48: Genotype and allele frequencies of IVS2-15G/A in the total cohort.   p. 129 
 
Table 49: Genotype and allele frequencies of IVS2-15 G/A in the Coloured population.  p. 129 
 
Table 50: Genotype and allele frequencies of IVS2-15 G/A in the Black population. p. 129 
 
Table 51: Genotype and allele frequencies of the ‘hotspot’ in the total cohort.   p. 131 
 
Table 52: Genotype and allele frequencies of the ‘hotspot’ in the Coloured population.  p. 131 
 
Table 53: Genotype and allele frequencies of the ‘hotspot’ in the Black population. p. 131 
 
Table 54: Genotype and allele frequencies of IVS3+72T/A in the Coloured population.  p. 132 
 
Table 55: Genotype and allele frequencies of IVS3+72T/A in the Black population. p. 132 
 
Table 56: Genotype-phenotype interaction of TNFα-308G/A and gestation.  p. 135 
 
Table 57: Genotype-phenotype interaction of TNFα-308G/A and birth weight.  p. 135 
 
Table 58: Genotype-phenotype interaction of TNFα-238G/A and gestation.  p. 136 
 
Table 59: Genotype-phenotype interaction of TNFα-238G/A and birth weight.  p. 136 
 
Table 60: Genotype-phenotype interaction of TNFα +488G/A and gestation.  p. 137 
 
Table 61: Genotype-phenotype interaction of TNFα +488G/A and birth weight.  p. 137 
 
Table 62: Genotype-phenotype interaction of IL-10-1082A/G and gestation.  p. 138 
 xix
Table 63: Genotype-phenotype interaction of IL-10-1082A/G and birth weight.  p. 138 
 
Table 64: Genotype-phenotype interaction of IL-10-592C/A and gestation.  p. 139 
 
Table 65: Genotype-phenotype interaction of IL-10-592C/A and birth weight.  p. 139 
 
Table 66: Genotype-phenotype interaction of IL-1β+3954C/T and gestation.  p. 140 
 
Table 67: Genotype-phenotype interaction of IL-1β+3954C/T and birth weight.  p. 140 
 
Table 68: Genotype-phenotype interaction of IL-1RN and gestation.   p. 141 
 
Table 69: Genotype-phenotype interaction of IL-1RN and birth weight.   p. 141 
 
Table 70: Genotype-phenotype interaction of IL-4 -590C/T and gestation.   p. 142 
 
Table 71: Genotype-phenotype interaction of IL-4 -590C/T and birth weight.  p. 142 
 
Table 72: Genotype-phenotype interaction of -98 A/C and gestation.   p. 143 
 
Table 73: Genotype-phenotype interaction of -98 A/C and birth weight.   p. 143 
 
Table 74: Genotype-phenotype interaction of IVS2-36G/A and gestation.   p. 144 
 
Table 75: Genotype-phenotype interaction of IVS2-36G/A and birth weight.  p. 144 
 
Table 76: Genotype-phenotype interaction of IVS2-22A/G and gestation.   p. 145 
 
Table 77: Genotype-phenotype interaction of IVS2-22A/G and birth weight.  p. 145 
 
Table 78: Genotype-phenotype interaction of IVS2-15G/A and gestation.   p. 146 
 xx
Table 79: Genotype-phenotype interaction of IVS2-15G/A and birth weight.  p. 146 
  
Table 80: Genotype-phenotype interaction of the ‘hotspot’ and gestation.   p. 147 
 
Table 81: Genotype-phenotype interaction of the ‘hotspot’ and birth weight.  p. 147 
 
Table 82: Genotype-phenotype interaction of 221delT and gestation.   p. 148 
 
Table 83: Genotype-phenotype interaction of 221delT and birth weight.   p. 148 
 
Table 84: Genotype-phenotype interaction of IVS3+72 T/A and gestation.   p. 149 
 
Table 85: Genotype-phenotype interaction of IVS3+72 T/A and birth weight.  p. 149 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
    
 xxi
List of Appendices  
  
Appendix 1: Ethical and Institutional consent      p. 96 
 
Appendix 2: Patient consent form        p. 97 
 
Appendix 3: Informed consent for DNA analysis and storage    p. 98 
 
Appendix 4: DNA extraction method        p. 102 
    
Appendix 5: NCBI LGALS13 annotated sequence      p. 104 
 
Appendix 6: Multiphor SSCP/HD protocol       p. 110 
 
Appendix 7: DNA purification protocol       p. 113 
 
Appendix 8: The remaining immunological gene variants screened in this study  p. 114  
 
Appendix 9: LGALS13 gene variants diagrammatically illustrated    p. 123 
 
Appendix 10: The remaining LGALS13 gene variants screened in this study  p. 124 
 
Appendix 11: Genotype-phenotype interactions      p.  135 
 
Appendix 12: 2X2 contingency analyses of associations demonstrated in this study p. 150 
 
Appendix 13: Nomenclature         p. 161 
 
Appendix 14: Fetal growth chart        p. 162 
 
Appendix 15: Outputs from this study       p. 163 
 
 xxii
List of Abbreviations 
 
%   - percentage    
~   - approximately 
@   - at 
˚C   - degree celcius 
'   - prime 
<    - less than 
>   - greater than 
≥   - greater and equal to 
©   - control (primers) 
µL   - microliter 
13P-NMR -  phosphorus-13 nuclear magnetic resonance 
5'UTR   - 5' untranslated region 
 
A   - adenosine 
AA   - arachidonic acid 
AMP   - adenosine monophosphate 
AP   - abruptio placentae 
APS   - ammonium persulphate 
Arg   - arginine 
ARMS   - amplified refractory system 
Asp   - aspartic acid 
ASSP   - alternative splice site predictor 
ATG   - start codon 
ATPase  - adenosine triphosphatase 
 
BLAST  - Basic Local Alignment Search Tool 
bp   - base pairs 
BV   - bacterial vaginosis 
 
 xxiii
C   - cytosine 
Ca2+   - calcium ion 
cAMP   - cyclic adenosine monophosphate 
cGMP   - cyclic guanosine monophosphate 
CI   - confidence interval 
Cl-   - chloride ion 
COX    - cyclooxygenase   
CRD   - carbohydrate recognition domain  
CSFs   - colony stimulating factors 
CVD   - cardiovascular disease 
Cx   - connexin 
Cys   - cystein residues 
 
D'   - measure of linkage disequilibrium 
dbSNP: rs  -  database single nucleotide polymorphism: reference sequence 
ddH2O   - double distilled water 
dH2O   - distilled water 
delT   - deletion of a single thymine base 
DHPLC  - denaturing high performance liquid chromatography 
DNA   - deoxyribonucleic acid 
dNTPs   - 2΄-deoxy-nucleotide-5΄-triphosphates 
 
E   - exon 
EDTA   -  ethylenediaminetetraacetic acid 
ELBW   - extremely low birth weight 
ELISA   -  enzyme-linked immunosorbent assay 
ESE   - exonic splice elements 
EtOH   - ethanol 
 
F   -  forward primer 
FIRS   - fetal inflammatory response syndrome 
 xxiv
 G   - guanosine 
g   - gram 
Gαq   - heterotrimeric G protein α q subunit 
Gln   - glutamine 
Glu   - glutamic acid 
Gly   - glycine 
GTPase  -  guanosine triphosphatase 
    
 
HELLP  - hemolysis, elevated liver enzymes and low platelets 
HIV   - human immuno-deficiency virus 
HLA   - human leukocyte antigen 
hrs   - hours 
HWE   - Hardy Weinberg equilibrium 
 
IDT   - Intergrated DNA Technologies 
IFN-γ   - interferon gamma 
IgE   - immunoglobuline E 
IL-1   - interleukin-1 gene  
IL-1   - interleukin-1 protein 
IL-1ra   - interleukin-1 receptor antagonist protein 
IL-1RN  - interleukin-1 receptor antagonist gene 
IL-1RN*1  - interleukin-1 receptor antagonist allele 1 [410 bp (four repeats)] 
IL-1RN*2  - interleukin-1 receptor antagonist allele 2 [240 bp (two repeats)] 
IL-1RN*3  - interleukin-1 receptor antagonist allele 3 [500 bp (five repeats)] 
IL-1RN*4  - interleukin-1 receptor antagonist allele 4 [325 bp (three repeats)] 
IL-1RN*5  - interleukin-1 receptor antagonist allele 5 [595 bp (six repeats)] 
  
Ile   - isoleucine 
IUD   - intrauterine death 
 xxv
IUGR   - intrauterine growth restriction 
IVS   - intervening sequence 
 
K+   -  potassium ion 
KCl   - potassium chloride 
kDa   - kilo Daltons    
KH2PO4  - potassium dihydrogen phosphate 
KHCO3  - potassium hydrogen carbonate  
 
L   - liter 
LBW   -  low birth weight 
LGALS13  - lectin, galactoside-binding, soluble 13 
LMW   - low maternal weight 
LOD   -  logarithm of odds 
LPS   - lipopolysaccharide stimulated 
 
M   - molar 
MALDI-TOF  - Matrix Assisted Laser Desorption /Ionization- Time of Flight 
MgCl2   - magnesium chloride 
mg   - milligram 
mg/mL  - milligram per milliliter 
min   - minute 
mL   - milliliter 
MLBW  - moderately low birth weight  
MLC   - myosin light chain 
MLCK   - myosin light chain kinase 
mM   - millimolar 
MMPs   - matrix metalloproteinases 
MoM   - multiples of gestation-specific median value 
mRNA   - messenger ribonucleic acid 
 
 xxvi
N   -  total  
Na+   - sodium ion 
NaCl   - sodium chloride 
Na2HPO4  - disodium hydrogen phosphate 
NaOH   - sodium hydroxide 
NCBI   - National Center for Biotechnology Information 
ng   - nanogram 
ng/µL   - nanogram per microliter 
ng/mL   - nanogram per milliliter 
NH4Cl   - ammonium Chloride 
NK-қB  -  nuclear factor kappa B 
nm   - ultra violet detection of DNA 
NO   -  nitric oxide 
NSAID  -  non-steriodal anti-inflammatory drug 
 
OR   - odds ratio 
ORF   - open reading frame 
 
P   - probability 
PAGE   - polyacrylamide gel electrophoresis 
PAMPs  - pathogen-associated molecular patterns 
PAPP-A  - pregnancy-associated plasma protein A 
PBS   - phosphate-buffered saline 
PCR   - polymerase chain reaction 
PDA   - piperazine diacrylamide 
pg/mL   - picogram per milliliter 
PGE2   - prostaglandin E2    
PGF2   - prostaglandin F2
pH   - potential of hydrogen 
PI   - pulsatility index 
PIH   - pregnancy-induced hypertension 
 xxvii
PP13   - placental protein 13 
PPROM  -  preterm premature rupture of membranes 
PROM   - premature rupture of membranes 
PRRs   - pattern recognition patterns 
PTL   - preterm labour (Tables) 
 
R   -  reverse primer 
r2   - measures of linkage disequilibrium (correlation coefficient) 
RE   - restriction enzyme 
REA   - restriction enzyme analysis 
RFLP   - restriction fragment length polymorphism 
Rho   - ras homologous proteins 
rpm   - revolutions per minute 
RR   - relative risk 
 
SBP   -  systolic blood pressure 
SDS   - Sodium dodecyl sulphate  
sec   - second 
SF2/ASF  -  Splicing Factor 2/Alternative Splicing Factor 
SGA   - small-for-gestational-age 
SIFT   - sorting intolerant from tolerant 
SNPs   -  single nucleotide polymorphisms 
SRp40   -  splicing factor, arginine/serine-rich 5 
SRp55   - splicing factor, arginine/serine-rich 6 
SSCP/HD  - single stranded conformational polymorphism and heteroduplex 
 
Ta   - annealing temperature 
TBE   -  Tris-Borate-EDTA  
TE   - Tris-EDTA 
TEMED  - N,N,N',N'-tetramethylethylenediamine 
TGA   - stop codon 
 xxviii
TH2   - helper T Cells  
Thr   - threonine 
TLR   -  toll like-receptors gene 
TLR   -  toll like-receptors protein 
Tm   -  melting temperature 
TNF1   -  tumour necrosis factor common allele 
TNF2   - tumour necrosis factor minor allele 
TNF   - tumour necrosis factor alpha gene 
TNF   - tumour necrosis factor alpha protein 
TRIS   - trishydroxymethylaminomethane 
TRIS-HCl  - Tris hydrochloride 
Tyr   - tyrosine  
 
U   - unit 
 
V   - volts 
VEGF   -  vascular endothelial growth factor gene 
VEGF   - vascular endothelial growth factor protein 
VLBW  - very low birth weight 
 
WHO   - World Health Organisation 
wks   -  weeks  
WT   - wildtype 
 
X   -  times 
 
yrs   - years   
 
β/γ   - beta/gamma 
β2AR   - beta-2-adrenergic receptor 
β-hCG   - human beta-chorionic gonadotrophin 
 xxix
1. Introduction 
 
1.1. Preterm labour 
 
1.1.1. Definitions 
 
The World Health Organisation (WHO) defined preterm labour as the onset of labour before 37 
completed weeks of gestation (Steer, 2005).  However, this term has since been used more 
specifically, viz, “very preterm”, “extremely preterm”, “moderately preterm” and “late preterm” 
(Reedy, 2007). 
 
For many years, newborn infants weighing less than 2500g were regarded premature for 
development.  In 2001, low birth weight (LBW) was sub-divided into the following categories:  
moderate low birth weight (MLBW) for infants weighing between 1500-2499g, very low birth 
weight (VLBW) weighing less than 1500g and extremely low birth weight (ELBW) weighing 
less than 1000g (Cano et al., 2001). 
 
The discrepancies of a valid definition for preterm birth in the literature have resulted in some 
scientist using birth weight as a marker for preterm (Reedy, 2007).  The development of more 
accurate methods determining gestation led to the conclusion that most of the infants that 
delivered at term with a low birth weight were due to intrauterine growth restriction (IUGR) 
(Peltier, 2003).  
 
Classifying neonatal outcome by birth weight does not distinguish between small-for-gestational 
age (SGA) and preterm labour. In a cohort of SGA infants, growth restriction can also be a cause, 
leading to false associations. Thus studies considering gestational age are favored when 
investigating the cause and outcome of preterm labour (Murph, 2007). 
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1.1.2. Incidence and Trends 
 
The incidence of preterm delivery ranges between 5% and 11%. In the developing world, the rate 
overall has been increasing gradually or remained static over the past 10-20 years, but has 
decreased in some developed countries (Danielian and Hall, 2005). 
 
In 2006 Barros and Vélez evaluated a database of 1.7 million births in the period 1985-2003 in 
Latin America. Preterm birth was subdivided according to the presence or absence of maternal 
medical or obstetric complications, spontaneous labour, and preterm labour after premature 
rupture of membranes (PPROM), induction of labour or elective caesarean. The most common 
subgroup for preterm birth was spontaneous preterm labour without maternal complication, 
which accounted for 60% of preterm deliveries. Delivery by elective induction and elective 
caesarean increased from 10% in 1985-1990 to currently, 18.5% (Barros and Vélez, 2006). 
 
The rate of singleton preterm birth in New Zealand increased from 4.3% in 1980 to 5.9% in 1999. 
A notable increase of 72% was observed in the high socioeconomic groups, with only a 3.5% 
increase in disadvantaged groups. This observation may be attributable to the effects of delayed 
childbearing in wealthy career women and the increased use of assisted reproductive technology 
(Danielian and Hall, 2005). In Sweden the rate of preterm birth decreased from 6.3% in 1984 to 
5.6% in 2001, accompanied by a rise in preterm multiple births from 0.34% to 0.71% (Murph, 
2007). The general proportion of preterm deliveries in Denmark increased in the period 1995 - 
2004 from 5.2 % to 6.2%.  Stratification into extremely preterm (22-28 weeks), very preterm (28-
32 weeks) and moderately preterm (32-36 weeks) groups demonstrated an increase of 41%, 22% 
and 22%, respectively. In the same population group, the incidence of spontaneous preterm 
deliveries in primiparous women at low risk rose by 51% from 3.8% in 1995 to 5.7% in 2004 
(Langhoff-Roos et al., 2006). 
 
At Tygerberg Hospital in South Africa, a tertiary referral hospital, preterm delivery accounts for 
20.3% of pregnancies.  At least 37.5% of all neonatal deaths can be accounted by prematurity 
(Schoeman et al., 2005). In the United States, the rate of preterm birth in 2004 for African 
American women was 17.6%, Native Americans 13.2%, Hispanics 12%, non-Hispanic whites 
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11.5% and Asians 10.4%. The increased use of assisted reproductive technology could account 
for the increase of preterm birth throughout 2004. Across the United States, the incidence of 
preterm labour and preterm birth has increased from 9.7% in 1990 to over 10.8% in 2004 among 
singleton and first time pregnancies (Reedy, 2007).  
 
Figure 1: Graphical representation of the incidence of preterm labour worldwide, based on above 
mentioned information (red dots illustrate an increase in preterm labour and green a decrease). 
 
1.1.3. Risk factors 
 
Epidemiological studies have identified certain risk factors that may be associated with preterm 
labour but do not predict labour before term (Table 1). An increasing amount of evidence 
suggests that infection during pregnancy may be a contributing factor for preterm labour 
(discussed later) (Wen et al., 2004). One of the strongest risk factors for preterm labour is a 
previous history of the condition. The expected frequency of preterm labour in subsequent 
pregnancies after one preterm birth is 14.3% and after two preterm births, it increases to 28% 
(Chandraharan and Arulkumaran, 2005b). Women with a previous history of PROM have an 
estimated risk of 16-32% of developing recurrent PROM and a 34-44% risk of developing 
preterm delivery (Danielian and Hall, 2005). Other factors that increase the risk of preterm labour 
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are multiple gestations, polyhydramnios or other causes of distension of the uterus with 
subsequent pressure on the cervix (Reedy, 2007). 
 
Table 1: Risk factors for preterm labour (Reedy, 2007). 
Medical history 
History of birth ≤ 37 completed gestational weeks 
History of preterm premature rupture of membranes
History of threatened preterm labour 
History of cervical surgery 
Factors in present pregnancy 
Artificial reproductive technology 
Uterine anomaly 
Chronic urinary tract infection 
Maternal weight  
Severe socioeconomic stress 
Smoking > 1 pack of cigarettes per day 
Substance abuse 
Polyhydramnios 
Multiple gestation 
 
Low socioeconomic status has been implicated in preterm labour. These socio-economic factors 
include a younger mother not able to work, single without support from family, poor nutritional 
status and higher incidence of substance abuse. Racial differences are also a risk factor for 
preterm labour, but this link is not clearly understood (Reedy, 2007). The reported rates of 
preterm delivery among black and white racial groups indicate a two-fold higher incidence for 
preterm labour or delivery among black women (Robinson et al., 2001). A recent large 
population-based (United States, N=1,577,08) cohort study performed in 2007 by Kistka et al., 
reported that recurrent preterm birth appeared more frequently in black women than in white 
women (adjusted OR, 4.11; 95% CI, 3.78-4.47). An extreme of maternal age is also a possible 
factor with an increased frequency of spontaneous preterm labour in teenage pregnancies, 
whereas the older gravidas experience higher rates of medically induced preterm births 
(Mountquin, 2003). Research on low maternal weight (LMW) found that LMW women who 
conceive are at increase risk of pregnancy complications such as preterm labour, IUGR and 
LBW, compared to women with normal body weight (Ehrenberg et al., 2003).  
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The abuse of tobacco, alcohol and recreational drugs has not been established as an underlying 
cause of preterm labour or preterm birth, but the use of these drugs has been implicated in 
preterm labour due to dangerous effects these substances have, which could place the fetus at risk 
of prematurity. Fetal risks associated with smoking during pregnancy include IUGR and 
oligohydramnios (Reedy, 2007). Odendaal et al. found that smoking during pregnancy increased 
the risk of preterm labour and abruption placentae, which are the two main causes of perinatal 
deaths at Tygerberg Hospital (Odendaal et al., 2001). Alcohol usage of more than nine drinks per 
week places women at risk of preterm labour, but a lower intake in the third trimester lowers the 
incidence of preterm birth possibly due to the use of alcohol as a tocolysis (Reedy, 2007). The use 
of street drugs such as cocaine increases the risk of preterm labour to 17-19% compared to the 
general population risk of 5-11% (Fajemirokun-Odudeyi and Lindow, 2004). 
 
1.2. The onset of labour 
 
The myometrium and the cervix of the human uterus function to maintain pregnancy and deliver 
the fetus at term. Throughout gestation, the myometrium remains relatively inactive regardless of 
progressive cellular growth and stretch needed to accommodate the growing fetus. During this 
time, the cervix is closed, functioning as a protective barrier. Towards the end of gestation, the 
cervix softens and the myometrium switches from inactive to an active organ required to expel 
the fetus and the placenta during labour (Hertelend and Zakar, 2004). 
 
1.2.1. The myometrium 
 
The myometrium consist of a distinctive muscular layer involved in contraction during labour. 
The myometrium mainly consists of smooth muscle cells but also contains fibroblasts, blood and 
lymphatic vessels, immune cells and connective tissue. The connective tissue serves as a 
supportive environment for the bundles of smooth muscle and provides a framework that expands 
as the uterus distends during gestation (Rehman et al., 2003). Surrounding the myometrial 
smooth muscle cells are extracellular substances composed of collagen fibers, fibroblast and bone 
marrow derived cells. As pregnancy progresses, the myometrium expands by means of 
hypertrophy and division of smooth muscle cells.  
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The myometrial cells interact with each other through intercellular channels known as gap 
junctions that link the interiors of two cells (Thomson and Norman, 2005). These channels are 
sites of communication, which allow rapid conduction of electrical impulses and chemical signals 
from one cell to another. This electrical coupling assists with organisation of each individual 
cell’s contraction, necessary to propagate the activity of the organ (Fuchs and Fuchs, 1996). The 
structure of the channels is based on proteins known as connexins, which extend through the 
plasma membranes to form pores. Two connexin proteins are abundant in the pregnant 
myometrium, viz, connexin-43 (Cx-43) and connexin-26 (Cx-26), with sequential different 
patterns of expression. The expression of Cx-43 is low during most of gestation, increasing 
significantly before the start of labour, while Cx-26 expression is higher during late pregnancy 
and low during labour. Cx-43 is believed to regulate electrical coupling of the myometrium 
during labour, whereas Cx-26’s involvement in myometrial contractility remains to be elucidated 
(Thomson and Norman, 2005).  
 
The myometrium consist of thin, intermediate and thick filaments as well as dense bodies, which 
allow the attachment of contractile filaments to α-actinin (Fuchs and Fuchs, 1996). The 
myometrial smooth muscle filaments are not arranged in fibres and fibrils, like striated muscle, 
but rather as random bundles throughout the myocyte. Myometrial contraction occurs from the 
sliding activity of actin and myosin with no change in length of both filaments, much the same as 
with skeletal muscle (Thomson and Norman, 2005). 
 
1.2.2. The cervix 
 
The cervix is structured to keep the cervical canal closed and sustain the integrity of the 
intrauterine space for development of the growing fetus (Hertelendy and Zakar, 2004). The cervix 
is composed of fibrous connective tissue surrounded by an extracellular matrix consisting of type 
I and type III collagen fibers. The other fibrillar structures include elastin, proteoglycans, and a 
cellular portion consisting of smooth muscle, fibroblast, epithelium and blood vessels (Maul et 
al., 2006). The covalent bindings of proteoglycans with numerous glucoseaminoglycan chains 
such as dermatan, eparan and chondroitin sulphates, hyaluronic acid and aggrecan determine the 
stability of the cervix. These compounds are negatively charged to bind large amounts of water, 
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leading to an increased volume in contrast to weight. Remodeling of the cervical structure takes 
place throughout pregnancy and involves the orientation and integrity of collagen fibres. In 
addition to this, water content, proteoglycans and hyaluronic acid is also regulated (Facchinetti et 
al., 2005).  
 
The fibroblasts found within the cervix, synthesise collagenase, which is also released by 
infiltrating neutrophils during labour, facilitated by increased prostaglandin production and 
interleukin-8 under the control of nuclear factor-kappa B (NK-κB). The degradation of 
collagenase and increased amounts of dermatan sulphate proteoglycans partially explain the 
pregnancy-related softening of the cervix (Shennan and Jones, 2004). 
 
1.2.3. Myometrial contractility 
 
The structural basis for uterine contractility is the binding of actin and myosin controlled by the 
enzyme myosin light chain kinase (MLCK), activated by a rise in intracellular calcium (Bernal, 
2003). Receptors for β-sympathomimetics on the cell-surface membrane of the myometrial cell 
assist with maintaining relaxation, promoting the opening of potassium channels and keeping the 
inside of the myocyte relatively electronegative, reducing the likelihood of depolarisation and 
contraction (Smith, 2007). 
 
In the myometrium, at the time of labour, the electrochemical gradient is reduced by the binding 
of prostaglandins to the E- and F-prostaglandin receptors, which permit the opening of ligand-
regulated calcium channels. The binding of oxytocin activates the Gαq protein linked to 
phospholipase C. Activation of phospholipase C activates the protein kinase C pathway, and most 
likely activates the MLCK. The release of inositol triphosphate via the binding of oxytocin 
facilitates the release of intracellular calcium in the stored sarcoplasmic reticulum. As the levels 
of calcium increase in the cell, the electro-negativity drops and activates the opening of more 
voltage-regulated calcium channels leading to an increase intracellular concentration of calcium 
resulting in depolarisation (Smith, 2007). As calcium enters the cell, it binds to calmodulin and 
forms an active complex activating the MLCK, which in turns phosphorylates the myosin light 
chain (MLC) (Bernal, 2003). The phosphorylation of the MLC causes the production of ATPase 
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activity leading to contraction caused the sliding of the myosin over the actin filaments. This 
process is reversible promoting relaxation regulated by the adenylate cyclase pathway, increasing 
intracellular cyclic adenosine monophosphate (cAMP) and activating the protein kinase A, which 
inhibits MLCK (Smith, 2007). 
 
Uterine contractions can also be improved by a calcium-independent pathway relating to the 
activation of small guanosine triphosphatase (GTPase) of the Rho family. The activation of Rho 
A, a monomeric G protein, mediates the phosphorylation of the MLC, stimulating contraction 
(Bernal and TambyRaja, 2000 and Bernal, 2003). 
 
1.2.4. Contraction and relaxation 
 
The cells in the myometrium are electrically volatile and maintain the ionic gradients across the 
plasma membrane. The regulation of the transmembrane gradient of calcium (Ca2+), sodium 
(Na+), chloride (Cl-) and potassium (K+) is sustained by active transport of ions across membranes 
controlled by the actions of pumps and co-transporters (Blanks et al., 2007). 
 
The basis for contraction and relaxation is the rise and fall of intracellular calcium. A complex 
interaction of membrane potential, voltage and receptor operating channels and Ca2+ pumps 
regulate circulating levels of calcium inside the myocyte. The resting intracellular calcium is 
lower than the intracellular calcium threshold for contraction. The rapid decrease of intracellular 
calcium are coordinated by the uptake of calcium into the sarcoplastic reticulum, the release of 
calcium outside the cell via plasma membrane Ca2+/ATPase, and by lesser degree via the 
Na2+/Ca2+ exchange. The myometrial state of relaxation entails the activation of calcium-
activated large conductance K+ channels, resulting in membrane hyperpolarisation (Bernal and 
TambyRaja, 2000). 
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1.2.5. Infection and myometrial contractility 
 
Bacterial species producing endo- and exotoxins have an elevated effect on cytokine and 
prostaglandin production in the amnion, chorion and decidua. As the levels of toxins or cytokines 
increase, myometrial function is impaired and abnormal labour is evident (Newton, 2005). These 
cytokines enhance the regulation of cyclo-oxygenase (COX)-2 in the amnion, decidua and 
myometrium leading to increase production of uterine prostaglandin and consequently the start of 
labour (Rauk and Chiao, 2000). 
 
In two studies evaluating the role of urogenital infections on the contractility of isolated human 
myometrium, it was found that mycoplasma infection decreased while Chlamydia or mixed 
infection of both increased the myometrial contraction induced by oxytocin or prostaglandin F2α 
(Zefirova et al., 2002a and Zefirova et al., 2002b). 
 
1.3. Infection as a cause of preterm labour 
 
Intrauterine infection is found to be a common and important mechanism in the ethiology of 
preterm birth. Evidence supporting the casual relation between infection and spontaneous preterm 
labour include (Romero et al., 2006a): 
 
1. Systemic administration of microbial products to pregnant animals results in 
spontaneous preterm labour and preterm birth. 
2. Preterm births have been associated with several extrauterine maternal infections, such 
as malaria, pyelonephritis, pneumonia and periodontal disease. 
3. Preterm labour and preterm birth have been associated with sub-clinical intrauterine 
infections. 
4. Mid-trimester pregnant women with intra-amniotic infection or intrauterine 
inflammation (defined as an increased concentration of cytokines in the amniotic fluid 
and matrix degrading enzymes) are at increased risk of subsequent preterm birth. 
5. Preterm birth can be prevented in experimental models of chorioamnionitis, by 
treating the intrauterine infection with antibiotics.  
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6. Treating asymptomatic bacteriuria may prevent preterm birth. 
 
1.3.1. Pathways of infection 
 
There are various routes in which microorganisms can gain access to the amniotic cavity and 
fetus: (1) ascending from the vagina and cervix; (2) haematogenous dissemination through the 
placenta; (3) retrograde seeding from the peritoneal cavity through the fallopian tube; and (4) 
accidental introduction at the time of invasive procedures, such as amniocentesis, percutaneous 
fetal blood sampling, chronic villus sampling, or shunting (Romero et al., 2006a).  
 
The most common pathway of intrauterine infection is the ascending route, which is characterised 
by four stages (Figure 1). During the first stage, there’s a change in the vaginal and cervical 
microbial flora or the presence of pathological organisms in the cervix. Bacterial vaginosis (BV) 
may be a first indication of stage I infection. In stage II, as the microorganisms gain access to the 
intrauterine cavity, they inhabit the decidua and cause an inflammatory response leading to 
deciduitis. As infection spreads they invade the fetal vessels or the amnion in the amniotic cavity 
leading to choriovasculitis or amnionitis, respectively. This leads to microbial invasion of the 
amniotic cavity or an intra-amniotic infection known as stage III. As bacteria enter the amniotic 
cavity they gain entry to the fetus (stage IV) by targeting amniotic fluid leading to congenital 
pneumonia. Infection of the amniotic fluid can cause otitis, conjunctivitis and omphalitis in the 
fetus, and via these sites of infection, gain access to fetal circulation causing bacteremia and 
sepsis (Romero et al, 2003). 
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Figure 2: The ascending route of intrauterine infection. (I) Vaginal infection, (II) inflammation of fetal 
membranes, (III) microbial invasion of the amniotic cavity, (IV) and fetal inflammation (Romero et al., 
2006a). 
 
1.3.2. Microbiology of uterine infection 
 
The most frequent microorganisms isolated from the amniotic cavity are genital Mycoplasma 
species, particularly Ureaplasma urealyticum, implicated in women with preterm labour and 
intact membranes. Additional microorganisms encountered in the amniotic cavity include 
Streptococcus agalactiae, Escherichia coli, Fusobacterium species and Gardnerella vaginalis 
(Romero et al., 2006a).  
 
1.3.3. Infection of the genital tract 
 
1.3.3.1. Fetal infection 
 
Fetal infection (stage IV) is the most advanced and severe stage of ascending intrauterine 
infection (Figure 2). In general, the mortality rate of neonates with congenital neonatal sepsis 
ranges between 25% and 90% (Gonçalves et al., 2002). Inflammatory invasion of the umbilical 
cord vessels (funisitis) reflects a more accurate indication of fetal infection in contrast to the 
inflammation of the membranes, which are largely of maternal origin. Funisitis have been 
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associated with amniotic fluid infection, congenital neonatal sepsis and the fetal inflammatory 
response syndrome (Tasci et al., 2006). 
 
The Fetal Inflammatory Response Syndrome (FIRS) is defined as an increase of pro-
inflammatory cytokines in the fetal circulation, with an IL-6 concentration of > 11ng/mL in the 
fetal blood.  It is present in most cases of preterm labour or PPROM and is related to an in utero 
multi-organ dysfunction that can cause septic shock and fetal death (Di Naro et al., 2006). Fetal 
organs targeted during FIRS include the haematopoietic system, adrenals, heart, brain, lungs and 
skin (Figure 3) (Romero et al., 2006b). 
 
 
Figure 3: Fetal organs proposed to be target organs during the fetal inflammatory response syndrome 
(FIRS) are the haematopoietic system, adrenals, heart, brain, lungs and skin. (CSFs, colony stimulating 
factors; MMPs, matrix metalloproteinases) (Romero et al., 2006b). 
 
Fetuses affected by FIRS have an increased rate of severe neonatal morbidities such as 
respiratory distress syndrome, suspected or proven neonatal sepsis, pneumonia, 
bronchopulmonary dysplasia, intraventricular haemorrhage, periventricular leukomalacia and 
necrotising enterocolitis (Romero et al., 2006b). 
 
Suspected cases of FIRS can be diagnosed based on the levels of pro-inflammatory cytokines 
measured in cord blood samples collected at delivery.  Pathological assessment of the umbilical 
cord is another approach to establish whether fetal inflammation was present before birth, since 
funisitis and chorionic vasculitis are histopathological features of FIRS. Additional approaches 
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include determining (i) C-reactive protein concentration in the umbilical cord blood, found to be 
elevated in patients with amniotic fluid infection, funisitis, and congenital neonatal sepsis, as well 
as (ii) neutrophils in the amniotic fluid. The white blood cell count in the amniotic fluid can also 
be applied as an indirect manifestation of fetal inflammation (Romero et al., 2006a). 
 
1.3.3.2. Vaginal infection 
 
Infection of the vaginal tract leads to a condition known as bacterial vaginosis (BV).  Commonly, 
the vaginal flora consists of both aerobic and anaerobic bacteria. The majority of microorganisms 
in the vaginal flora are Lactobacillus spp. representing 95% of all bacteria. These organisms 
provide a defense mechanism against infection by keeping the pH of the vagina acidic. 
Additionally, individuals with normal lactobacilli inhibit the colonisation of BV-associated 
organisms [usually lacking free radical scavengers] by producing high levels of hydrogen 
peroxide (Yudin, 2005). 
 
BV is a clinical condition characterised by a change of vaginal flora, resulting in a decreased 
production of the normal, protective Lactobacillus species (Nelson et al., 2007) and an increased 
growth of pathogenic bacteria such as Gardnerella vaginalis, Bacteriod spp., Mobiluncus spp. 
and Prevotella bivia (Pretorius et al., 2007). The diagnosis of BV is often asymptomatic but may 
result in vaginal discharge that is grey in colour with a characteristic ‘fishy odour’. The clinical 
diagnosis of BV is confirmed by three of the four following criteria (McDonald et al., 2007): 
 
1. Vaginal pH > 4.7 
2. The presence of clue cells (vaginal epithelium cells spotted with bacteria) on a Gram 
stain or wet mount of the vaginal discharge 
3. The presence of thin homogenous discharge 
4. The release of a fishy odour when potassium is added to a sample of discharge 
 
The risk factors associated with BV include black ethnicity, low socioeconomic status, increased 
sexual activity and vaginal douching. These factors are mostly found in cases of symptomatic 
BV, with an uncertainty whether these can be applied to asymptomatic BV (Nelson et al., 2007). 
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BV has frequently been addressed as a risk factor for adverse obstetric outcomes such as preterm 
labour and delivery, PPROM, spontaneous abortion, chorioamnionitis and postpartum 
endometritis (O’Brien, 2005 and Yudin, 2007). Substances produced by BV-related organisms 
include endotoxins and enzymes such as sialidase, collagenase, protease, elastase, phospholipase 
and mucinase. The release of these substances has been shown to cause tissue damage, promoting 
the release of pro-inflammatory cytokines and prostaglandins. Pro-inflammatory cytokines such 
as interleukin (IL)-1, IL-6, IL-8, tumour necrosis factor alpha (TNFα), and prostaglandins E2 and 
F2α are found to be increased in the amniotic fluid of women with BV delivering preterm 
(Pretorius et al., 2007). A case-control study by Macones et al., investigated the role of the TNFα 
-308G/A genotype in women presenting with PPROM and preterm labour in combination with 
symptomatic BV. They found that maternal carriers of the TNF-308A allele were at increased risk 
of developing spontaneous preterm birth (OR 2.7, 95% CI 1.7-4.5). This association was further 
strengthen by the presence of BV (OR 6.1, 95% CI 1.9-21.0) (Macones et al., 2004). Genc et al., 
determined the vaginal TNFα concentration in carriers of the TNF-308A allele with abnormal 
vaginal flora. They showed that individuals with the TNF-308A allele with BV had a 
significantly higher TNFα level (10.94 pg/mL) compared to individuals with the TNF-308A allele 
without BV (1.77 pg/mL) (P=0.02) and 1.72 pg/mL in TNF-308G homozygotes with BV 
(P=0.01) (Genc et al., 2006). 
 
1.3.3.3. Infection of the fetal membranes 
 
The fetal membranes consist of the amnion and chorion, functioning as a defense barrier and 
helping to maintain normal pregnancy (Menon and Fortunato, 2007). Acute inflammation of the 
amnion and chorion membranes results in chorioamnionitis and is the primary cause of maternal 
and fetal complications, including preterm birth and neonatal infection (Lau et al., 2005). The 
result of chorioamnionitis, mostly subclinical, is primarily due to infection via the ascending 
route of the lower genital tract (Lahra et al., 2007) that resides in the choriodecidual space 
(Kidokoro et al., 2006). In other cases, infection crosses the intact chorioamniotic membranes 
into the amniotic fluid where it may infect the fetus.  
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Postpartum examination of the placenta revealed that the incidence of histological 
chorioamnionitis was 18% in women with delivery at term and 32% in women delivering preterm 
(Hung et al., 2005). The prevalence of sub-clinical histological chorioamnionitis is greater in 
earlier gestation: 50% at 24 to 28 weeks, 30% at 28 to 32 weeks, 20% at 33 to 36 weeks and 10% 
at more than 37 weeks. The likelihood that chorioamnioiotic cultures are positive for infection 
following delivery of smaller fetuses at caesarean section with intact membranes is 80% at less 
than 1000g, 60% at 1000 to 1499g, 35% at 1500 to 2499g and 30% at more than 2500g (Newton, 
2005). Severe acute morbidity, including sepsis, necrotising enterocolitis and lung disease place 
the preterm infants at risk of developing intraventricular hemorrhage and periventricular 
leukomalacia, which is a strong predictor of mental retardation and cerebral palsy (Hagberg et al., 
2002). 
 
Microorganisms ascending from the vaginal cavity produce phospholipase A2 and C which 
cleave arachidonic acid in the fetal membranes, releasing free arachidonic acid available for 
production of prostaglandin, which in turn, could trigger preterm labour. Activated macrophages 
and lymphocytes in response to choriamnionitis induce an inflammatory cascade of effects, which 
play important role in the initiation of preterm labour (Saji et al., 2000). Patients presenting with 
choriamnionitis have elevated levels of pro-inflammatory cytokines such as IL-1β, IL-6, TNFα 
and chemokine IL-8 in the amniotic fluid, cervical secretion, placenta and other sections of the 
placental-maternal unit. In a study performed by Willi et al., they evaluated the concentrations of 
IL-6 and IL-8 in patients with choriamnionitis compared to those without. They found that the 
levels of IL-6 (61.5pg/mL vs. 19.4 pg/mL, P<0.01) and IL-8 (162.3 pg/mL vs. 13.4 pg/mL, 
P>0.001) were significantly higher in patients with choriamnionitis (Willi et al., 2002).  
 
Similar finding were reported by Jacobsson et al., who determined the levels of IL-6 and IL-8 in 
cervical and amniotic fluid in relation to the presence of bacteria in membranes of women with 
preterm labour. They found that the levels of IL-6 in cervical fluid and IL-6 and IL-8 in amniotic 
fluid were higher in women with preterm labour in whom bacteria could be detected in the 
chorioamniotic membranes (Jacobsson et al., 2005). 
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1.3.3.4. Intra-amniotic infection 
 
Substantial evidence exists for support that intra-amniotic infection and the immune response 
induced by infectious agents contribute to the initiation of pregnancy complications such as 
preterm labour, PPROM and premature birth (Hadar et al., 2006). In patients with preterm labour, 
approximately 10% have microbial invasion of the amniotic cavity. These patients are at 
increased risk of future preterm delivery, clinical chorioamnionitis, neonatal morbidity, 
bronchopulmonary dysplasia and cerebral palsy (Gomez et al., 2005).  The complex mechanism 
leading to preterm labour caused by intra-amniotic infection needs to be elucidated. Current 
evidence suggests that intra-amniotic infection initiates an immune response leading to increased 
production of cytokines, prostaglandins and metalloproteinase’s that in turn leads to cervical 
softening, rupture of fetal membranes, uterine contractions and preterm birth (Hermansen and 
Hermansen, 2006). 
 
The most frequent organism detected in the amniotic cavity is Ureaplasma urealyticum. The host 
response towards these organisms in amniotic fluid, maternal and fetal compartments has been 
linked to preterm labour and PPROM. Patients with positive amniotic Ureaplasma urealyticum 
cultures have elevated levels of pro-inflammatory cytokines (TNFα, IL-1β, IL-6) in their 
amniotic fluid, increased plasma concentration of IL-6 in umbilical cord blood, a higher incidence 
of developing chorioamnionitis, increased risk of preterm delivery and adverse perinatal outcome, 
in contrast to patients with a sterile amniotic environment (Gomez et al., 2005).   
 
1.4. Inflammation as a reason for preterm labour 
 
1.4.1. Innate immune receptors of the genital tract 
 
The first line of defense against microbial infection is the innate immune system, whereas the 
adaptive immune system develops about four-seven days later. The innate immune system 
provides protection against a broad diversity of pathogens, using pattern recognition receptors 
(PRRs) to recognise conserved microbial components known as pathogen-associated molecular 
patterns (PAMPs). The PRRs include, among others, members of the Toll-like receptors (TLRs) 
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(Albiger et al., 2007), which are important components of the innate immune system (Kim et al., 
2006). The family of TLRs elicits intracellular activation of NK-κB and several others kinases, 
initiating the release and production of cytokine and anti-microbial peptides. These peptides are 
expressed in the endometrium and production is induced after intrauterine infection in preterm 
and term pregnancies, supporting the indirect involvement of the innate immunity (Hagberg et 
al., 2005). 
 
To date, 10 different TLRs have been identified in humans (Ma et al., 2007). TLR-1, -2, -3, -5 
and -6 are found in epithelia from the vagina, ecto- and endocervix, endometrium and uterine 
tubes. TLR-4 has been identified in the endocervix, endometrium, fallopian tubes and ectocervix 
(Romero et al., 2006a). TLR-2 mostly recognises products of Gram-positive bacteria, such as 
peptidoglycans and products of Mycoplasma and fungi, whereas TLR-4 distinguishes bacterial 
endotoxin from components of Gram-negative bacterial cell wall. The expression of TLR-2 and -
4, in combination with activation of NK-κB, is significantly elevated in preterm deliveries with 
chorioamnionitis, demonstrating that the innate immune system manifests an inflammatory 
response during normal spontaneous labour (Kim et al., 2006). In the first trimester, apoptosis of 
cytotrophoblast (observed in miscarriage, IUGR and pre-eclampsia (Romero et al., 2006a)) is 
promoted by TLR-2-dependent signaling, while TLR-4 signaling stimulates production of 
cytokines. These observations suggest that intrauterine infection may lead to either trophoblast 
apoptosis or synthesis of cytokines that recruit immune cells and maintain trophoblast survival 
(Ma et al., 2007). 
 
1.4.2. The role of pro-inflammatory cytokines 
 
An increasing body of data implicates the role of cytokines in the mechanisms underlying 
preterm parturition linked to intrauterine infection. Pro-inflammatory cytokines including IL-1, 
TNFα, IL-6 and IL-8 in the intrauterine tissue are secreted in response to infection, and increased 
amounts are found in the amniotic fluid of women with infection-related preterm labour. The 
presence of sub-clinical intrauterine infection, implicated in a proportion of preterm birth, is 
associated with increased release of pro-inflammatory cytokines in the amniotic fluid leading to 
activation and synthesis of prostaglandins that can provoke uterine contractions (Makhseed et al., 
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2003). The release of prostaglandins can further display uterotonic effects and increase the 
production of matrix metalloproteinases (MMPs), which are implicated in connective tissue 
degradation in the amnionchorion and cervix, related to membrane rupture and cervical ripening 
(Hernandez-Guerrero et al., 2003). IL-8 acts as a chemotactic factor attracting neutrophils to the 
cervix, stimulating the synthesis of proteases such as collagenase and elastase and promoting 
uterine changes in the cervix during labour (Gonzalez Bosquet et al., 2005). 
 
The first cytokine to be associated with spontaneous preterm labour related to infection is IL-1. 
Evidence supporting this include: (a) human decidua produces IL-1 in response to bacterial 
products; (b) production of prostaglandin by the human amnion and decidua are stimulated by IL-
1; (c) IL-1 in the amniotic fluid of women with preterm labour and infection has increased 
concentrations and bioactivity; (d) myometrial contractions can be stimulated by IL-1; and (e) 
administration of IL-1 to pregnant animals induces preterm labour and preterm birth, which can 
be blocked by administering IL-1 receptor antagonist (IL-1ra).  
 
The roles of TNFα supporting the mechanism of preterm labour include: (a) prostaglandin 
production in the human amnion, decidua and myometrium are stimulated by TNFα; (b) TNFα is 
produced by human decidua in response to bacterial products; (c) the activity and concentrations 
of TNFα in the amniotic fluid are elevated in preterm labour and intra-amniotic infection; (d) 
during labour TNFα levels are higher in women with PPROM and intra-amniotic infection; (e) 
the production of MMPs is increased by TNFα; (f) in the cervix, TNFα stimulates changes similar 
to cervical ripening; and (g) in animal models, TNFα is associated with bacterial-induced  
preterm parturition (Romero et al., 2006a). 
 
IL-6 is the strongest cytokine associated with preterm labour in the setting of intra-amniotic 
infection, produced by a selection of cells in response to bacterial infection, viruses and second 
messenger agonists. The production of IL-6 is increased by TNFα and IL-1β, and higher levels 
are found in umbilical cord blood, representing an independent risk factor for spontaneous 
preterm delivery and also neonatal morbidity (Jamie et al., 2005). 
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1.4.3. The role of anti-inflammatory cytokines 
 
Anti-inflammatory cytokines such as IL-10, IL-4 and IL-1ra regulate the effect of the pro-
inflammatory cytokines during pregnancy. The two most potent cytokines are IL-4 and IL-10, 
produced by the TH2 lymphocytes. These cytokines stimulate differentiation of T lymphocytes via 
the TH2 pathway, blocking production of interferon (IFN)-γ that regulates pro-inflammatory 
cytokine synthesis. IL-4 and IL-10 activate B-lymphocytes leading to B-cell proliferation and 
antibody production during pregnancy. The genes encoding IL-4 and IL-10 are both polymorphic 
and can lead to altered cytokine levels in different individuals. These discrepancies may alter the 
degree of the anti-inflammatory immune response during pregnancy and induce susceptibility to 
PPROM, preterm labour and subsequent preterm birth (Kalish et al., 2004). These cytokines 
reduce the production of prostaglandin by lipopolysaccharide (LPS)-stimulated human monocytes 
and neutrophils, thereby inhibiting the production of COX-2.  Consequently, low circulating 
levels of IL-4 and IL-10 may initiate labour (Annells et al., 2004). 
 
In response to an alteration in the vaginal flora, both, the levels of IL-1β and IL-1ra increase. IL-
1ra, a competitive inhibitor of IL-1β, modulates the action of the pro-inflammatory response, 
destroying pathogenic microorganism while structural tissue and function are maintained (Genc 
et al., 2004a). Studies performed in animals demonstrated that IL-1β-induced preterm labour is 
inhibited by IL-1ra. Furthermore, in vitro studies established that IL-1ra inhibits the production of 
prostaglandin in the amnion and chorion cells stimulated by IL-1β (Murtha et al., 2006). Thus, an 
imbalance between IL-1β and IL-1ra can result in a persistent pro-inflammatory response related 
to adverse clinical outcomes (Genc et al., 2004a). 
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1.5. Molecular studies 
 
1.5.1. Pro-inflammatory cytokines 
 
1.5.1.1. Tumour necrosis factor-α 
 
A number of DNA-based polymorphisms in the TNFα gene have been identified; of these the 
most extensively researched are the G/A promoter variant at position -308 relative to the ATG 
start site. The substitution of the guanine (G) for an adenine (A) nucleotide has been shown to 
increase the production of this cytokine, thereby increasing susceptibility and severity of septic 
shock. Thus individuals harbouring the TNFα (-308A) (TNF2) allele react upon stimulation by 
infection with an intense inflammatory response and demonstrate an increased risk of developing 
preterm labour and delivery (Speer et al., 2006). 
 
Macones et al., demonstrated an association between the TNF2 allele and preterm birth in the 
presence of an environmental stimuli, BV, with an increased odds of preterm birth compared to 
those without the carrier status (OR 6.1, 95% CI 1.9-21.0) (Macones et al., 2004). Similar results 
were obtained by Boston et al., suggesting that the TNF2 allele (genetically determined) 
influences a local TNFα response to a change in the vaginal flora (Genc et al., 2006). 
 
1.5.1.2. Interleukin-1β 
 
The production of pro-inflammatory cytokines, such IL-1β, can initiate infection-related preterm 
labour. The infusion of IL-1β in the amniotic cavity of a non-human primate pregnancy model 
results in the synthesis of TNFα and prostaglandins leading to uterine contractions. The gene 
encoding IL-1β contains, among others, a polymorphic site at position +3953 C/G which is 
associated with an increase in expression of the protein in vitro (Genc et al., 2002). 
 
In a recent study, Edwards et al., demonstrated an association between increased levels of IL-1β 
and spontaneous preterm delivery (P=0.001) and preterm delivery (P=0.017). Carriage of the 
maternal IL-1β polymorphism was not associated with preterm delivery (P=0.43) or with cervical 
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levels (P=0.35). No association was demonstrated with the fetal genotype and cervical levels in 
relation to preterm delivery (Edwards et al., 2006). Engel et al., demonstrated that two other 
polymorphisms at position -581 C/T and -1061 T/C, were associated with 1.7 (0.9-3.2) times 
higher risk of spontaneous preterm delivery in women with the +3953C/-581C/-1061T haplotype 
and individuals with the +3953C/-581T/-1061C haplotype had an 2.1 (0.9-5.2) times higher risk 
of spontaneous preterm delivery. In hierarchical regression, carrier status of the IL-1β -581C or 
IL-1β -1061T was not associated with spontaneous preterm delivery (Engel et al., 2005). 
 
1.5.1.3. Interleukin-6 
 
IL-6 is an important cytokine involved in the host response to infection, which activates the acute 
phase response, stimulates T lymphocytes, and induces differentiation of B-lymphocytes and 
production of C- reactive protein. The DNA polymorphism located in the promoter region of the 
IL-6 gene at position -174, correlates with IL-6 synthesis. The substitution of a cytosine (C) for a 
guanine (G) nucleotide at position -174, decreases promoter activity. Individuals with a G/G or 
G/C genotype produce “normal” levels, whereas the C/C genotype is associated with lower levels 
and furthermore, has been linked to the severity of inflammatory conditions such as juvenile 
chronic arthritis and end-stage renal disease (Simhan et al., 2003).  
 
Simhan and colleagues investigated the relationship between the IL-6 promoter variant in 156 
controls and 51 cases with spontaneous preterm birth before 34 weeks gestation. In the control 
group the C/C genotype was present in 30 individuals (19.2%) and in two individuals (6.3%) of 
the preterm birth group (OR 0.17, 95% CI 0.04-0.74). In the control group of white women, the 
C/C genotype was present in 30 (27.2%) and only 2 (5.2%) of cases. There was no C/C genotype 
detected in the African American women, with the racial difference statistically significant 
(P<0.001). The -174 C/C genotype was less common in women with spontaneous preterm birth 
before 34 weeks (Simhan et al., 2003). The finding of this study contradicts with the findings of 
Jamie et al., who did not demonstrate an association with the -174 C allele and the incidence of 
preterm delivery at 23-32 weeks’ gestation. In this study the cervical fluid levels were not 
elevated and the presence of the maternal -174 C allele was not associated with IL-6 cervical 
fluid levels or the risk of spontaneous preterm birth (Jamie et al., 2005). 
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1.5.2. Anti-inflammatory cytokines 
 
1.5.2.1. Interleukin-1ra 
 
The gene encoding IL-1ra displays different alleles of a fragment length polymorphism in intron 
two and is associated with varying levels of the cytokine (Witkin et al., 2003). Individuals with 
the IL-1RN allele 2 (IL-1RN*2) have increased levels of the cytokine (Genc et al., 2002). Patients 
with chronic pro-inflammatory disorders who habours the IL-1RN*2 allele experience delayed 
and more severe pro-inflammatory immune responses than those who do not, therefore the 
increased production of IL-1β in individuals with IL-1RN*2 might increase vulnerability to 
preterm birth (Witkin et al., 2003). 
 
Murtha et al., examined the relationship between preterm labour before 37 weeks [or PPROM] 
and the polymorphism in the IL-1RN gene. In the cohort of 95 cases, 26.8% had at least one copy 
of allele 2, in contrast to 12.4% in the control group (P<0.0004). The results implied that one 
copy of the maternal IL-1RN allele might be linked to an increased risk of preterm birth (Murtha 
et al., 2006). 
 
Genc et al., evaluated the association between IL-1RN*2 and preterm birth in vaginal samples of 
212 women (18-22 weeks). The initial results showed that IL-1RN*2 was linked to an increase in 
vaginal pH in black (P<0.001) and white women (P=0.005). The response of IL-1β in the 
presence of infection was reduced (P<0.01) with a decrease rate of spontaneous preterm 
deliveries (6% versus 18%, P=0.02). In conclusion, carrier status of IL-1RN*2 was linked with a 
blunted IL-1β response to irregular vaginal flora, possibly suggesting a reduce susceptibility to 
infection-related preterm birth (Genc et al., 2004a). 
 
1.5.2.2. Interleukin-4 
 
During normal pregnancy, the levels of IL-4 increase. The single nucleotide change representing 
a cytosine (IL-4*C) to a thymine (IL-4*T) substitution in the promoter region of the gene is 
associated with increased transcriptional activity leading to increased production of the cytokine. 
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The presence of an IL-4*T allele has been linked to increased serum immunoglobulin E (IgE) 
levels and increased severity of asthma. The IL-4*T carrier also has a higher rate and increased 
risk of childhood respiratory syncytial viral infections, caused by the reduction in pro-
inflammatory cytokine activity. 
 
Kalish et al., investigated the association between this IL-4 -590 polymorphism and pregnancy 
outcome in multifetal gestations including 73 mother-infant pairs. The frequency of the 
interleukin-4 T allele was higher in spontaneous preterm birth compared to term pregnancies 
(36.2% vs. 18.2%, P=0.02, OR 2.6, 95% CI, 1.1-5.9). In addition, 20.7% of individuals with 
spontaneous preterm birth were homozygous for the IL-4*T allele, compared to 2.3% of 
individuals with term pregnancies (P=0.01, OR 11.2, 95% CI, 1.2-69.5) (Kalish et al., 2004). 
 
1.5.2.3. Interleukin-10 
 
IL-10 is an important cytokine for the regulation and maintenance of pregnancy. In the term 
placenta, the production of IL-10 is reduced in contrast to first and second trimester tissue. The 
physiological initiation at labour underlies the down regulation of IL-10 (Romero et al., 2006a). 
 
Various polymorphisms in the IL-10 gene have been linked to a change in transcriptional levels 
and the best documented of these are the promoter variants viz, -1082 G/A, -819 C/T and -592 
C/A. Annells et al., demonstrated the presence of different genetic risk factors for preterm birth at 
different gestational periods.  In their study, no association with the IL-10 G-C-C haplotype in 
labour before 35 weeks (P=0.1) could be demonstrated, while the IL-10 A-T-A haplotype was 
associated with early preterm birth before 29 weeks (P=0.04, OR 2.1, 95% CI, 1.0-4.1) (Annells 
et al., 2004). 
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1.5.3. Other regulators 
 
1.5.3.1. Matrix metalloproteinase 
 
The rupture of fetal membranes involves MMP-mediated interstitial collagen degradation (Crider 
et al., 2005) and has therefore been researched in PPROM. Fujimoto et al., investigated African 
American women for the promoter variant of the MMP-1 gene at position -1067, identified as an 
insertion of a G allele (2G), which is found to increase gene expression in PPROM and preterm 
birth (Fujimoto et al., 2002 and Crider et al., 2005). Fetal carriage of the 2G allele and PPROM 
showed a significant association (P=0.028, OR 2.29, 95% CI 1.09-4.82) and was associated with 
a stronger promoter activity in amniotic cells.  
 
In pregnancies complicated by preterm labour, MMPs activate a cytokine-mediated inflammatory 
response, leading to rupture of the fetal membranes and cervical dilation or ripening. 
Consequently, it has been proposed that future studies focus on MMPs as candidate markers for 
preterm labour (Orsi et al., 2007). 
 
1.5.3.2. Toll-like receptor 4 
 
TLR4 is the main endotoxin-signal receptor, which initiates the innate immune response against 
Gram-negative bacteria. A DNA polymorphism in the TLR4 gene, Asp299Gly, has been linked to 
severe respiratory syncytial viral diseases in infants and increased risk of acquiring gram-negative 
infection in acutely-ill hospital patients.  
 
Lorenz et al., reported the investigation of two TLR4 polymorphisms, viz, Asp299Gly and 
Thr399Ile:  the study group consisted of 351 term infants and 440 premature infants (gestational 
age <35 wk; 282 singletons, 158 multiples) and 94 maternal individuals. The two polymorphisms 
investigated were shown to be in linkage disequilibrium. Allelic variation could be associated 
with increased risk of premature birth, specifically with PPROM (P=0.021) compared with the 
preterm birth group (P=0.045) (Lorenz et al., 2002). 
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1.5.3.3. Beta-2-adrenergic receptor  
 
The human beta-2-adrenergic receptor (β2AR) is a common therapeutic agent for the treatment of 
many disease conditions, with various coding polymorphisms that can alter receptor function. In 
the coding region of the gene at amino acid position 16, the arginine (Arg) residue is replaced 
with a glycine (Gly), with increase desensitisation in vitro upon stimulation. At position 27, a 
glutamine (Gln) residue is replaced with a glutamate (Glu), causing decreased desensitisation and 
in vitro down-regulation (Landau et al., 2002). These polymorphisms, documented as Arg16Gly 
and Gln27Glu, respectively, have been shown to be associated with increased risk of developing 
asthma, diabetes mellitus and hypertension (Ozkur et al., 2002).  
 
In a case-control study reported in 2002, Landau et al., investigated the Arg16Gly and Gln27Glu 
genotype distribution in Hispanic women. The study consisted of 28 women who delivered 
spontaneously before 37 weeks of gestation and 251 control individuals with no history of 
preterm birth. No association was demonstrated with the Gln27Glu polymorphism and preterm 
labour. Only one individual in the preterm labour group was homozygous for the Arg16Arg 
genotype in comparison with 79 individuals in the control group (P=0.01, OR 0.08, 95% CI 0.01-
0.58). The Arg16 allele frequency was significantly lower in the preterm labour group (29%) 
compared to controls (50%, P=0.002). This observation could possibly demonstrate a protective 
function in preterm delivery, due to the down-regulation of the β2AR.  
 
Conflicting results were reported by Ozkur et al, who had examined 80 cases of preterm labour 
and 76 control individuals. The Gln27Glu polymorphism was significantly associated with 
preterm labor (P=0.001). The allele frequency of Gly16 and Glu27 were elevated in cases vs. 
controls (0.54 vs. 0.48 and 0.42 vs. 0.26, respectively). The odds of developing preterm labour 
were 2-fold greater for the Glu 27 allele (OR 2.14, 95% CI, 1.32-3.46; P=0.002). The 
contradictory findings at the Arg16Gly locus could be due to the different populations examined 
in these studies (Hispanic vs. Turkish women), exclusion criteria or small sample size (preterm 
labour 28 vs. 80) (Ozkur et al., 2002). 
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1.5.3.4. Vascular endothelial growth factor 
 
Vascular endothelial growth factor (VEGF) is a major angiogenic factor, regulating endothelial 
cell proliferation. VEGF is expressed during gestation, with strong immunoreactivity in both the 
amnion and chorion, and at increased levels at term spontaneous labour compared with either 
term or not in labour (Papazoglou et al., 2004). Identified polymorphisms in the VEGF gene 
include -1879 G/A, -1498 T/C, -1190 G/A, -1154 G/A, -634 G/C, -7 C/T and 936 C/T, of which 
the -634 C/G locus has been linked to increased levels of serum VEGF (Crider et al., 2005). 
 
Papazoglou et al., investigated polymorphisms -634 G/C and 936 C/T in spontaneous preterm 
birth. The case-control study included 54 women with preterm deliveries and 79 women with two 
term births with no history of obstetric complications. No significant association was 
demonstrated with the -634 G/C polymorphism and spontaneous preterm birth. In contrast, either 
the homozygous C/C or heterozygous C/T 936 genotype status could be associated with 
spontaneous preterm birth (P=0.0009, OR 2.05, 95% CI 1.37-3.06) (Papazoglou et al., 2004). 
 
1.6. Pregnancy-related proteins 
 
Members of pregnancy-related proteins are produced in measurable amounts during pregnancy 
and can include maternal, fetal or feto-maternal proteins. The proteins differ both in function and 
structure but inter-relate to play an important role in the development of the fetus and placenta 
and / or to sustain pregnancy. To date, 56 different pregnancy-related proteins have been 
identified and sub-grouped into different categories according to location: fetal-, pregnancy-, 
soluble placental tissue- and membrane-associated placental proteins (Than et al., 1999).  
 
The study described in this dissertation focused on the soluble placental protein 13 (PP13), which 
has been implicated as a promising serum biomarker for IUGR, pre-eclampsia and preterm 
delivery (Burger et al., 2004). 
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1.6.1. Placental Protein-13 (PP-13) 
 
The gene, “lectin, galactoside-binding, soluble 13” (LGALS13), is located on human chromosome 
19q13.1 in close vicinity to the galectin -10,-7,-4 and placental protein 13-like genes (Than et al., 
2004a). The coding regions of LGALS13 are represented by four exons, with exon three encoding 
the critical carbohydrate recognition domain (CRD) (Visegrady et al., 2001).  
 
The protein, PP13 consists of two identical 16kDa subunits held together by disulphide bonds.  
During pregnancy PP13 is highly expressed in the placenta and tissues such as the fetal liver and 
spleen (Than et al., 2004a). 
 
Similar to its homologous counterpart, Charcot-Leyden crystal protein/galectin-10, PP13 exhibits 
weak lysophospholipase activity [confirmed by 13P-NMR], which is not found in other galectins. 
Sugar binding assays revealed that PP13 strongly binds N-acetyl-lactosamine, mannose and N-
acetyl-glucosamine residues, which are widely expressed in human placenta. Affinity 
chromatography, PAGE and MALDI-TOF mass spectrometry demonstrated that annexin II and 
β/γ actin specifically bind to PP13 in the placenta and fetal hepatic cells. Perinuclear staining of 
syncytiotrophoblast brush border membrane (Figure 4) established PP13’s externalization to the 
outer cell surface (Than et al., 2004a). 
 
 
Figure 4: Intense PP13 staining (green) at the brush border membrane of the syncytiotrophoblasts 
(arrows) and also a discrete perinuclear labelling of the syncytiotrophoblasts with both the monoclonal (C) 
and polyclonal (D) antibodies to PP13 (from Than et al., 2004a). 
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Due to the localisation and specific complex formation, it is believed that PP13 is excreted into 
the maternal circulation by means of ectocytosis of microvesicles containing actin, annexin II and 
PP13 (Than et al., 2004a).  Since other galectins demonstrate immunobiological functions, in the 
same way PP13 and its homologues may have immune functions at the feto-maternal interface 
(Than et al., 2004b). 
 
1.6.1.1. Biological functions of PP-13 
 
The galectins are considered important for cell adhesion functions such as cell-cell and cell-
matrix interactions (Rabinovich et al., 2002). The binding capability of PP13 for sugar residues in 
the placenta and localisation to the outer surface of the invading trophoblasts at implantation, 
suggest that PP13 may also play a role in implantation.  
 
The weak lysophospholipase activity accompanied by calcium mobilisation, including free fatty 
acid release and elevation of prostaglandins, imply a potential role in the regulation of 
vasoconstriction / vasodilation balance and maternal artery remodeling (Than et al., 2005). The 
strong cytolytic and membrane perturbing properties of lysophospholipids, suggest that the 
lysophospholipase activity of PP13 may present a protective function during implantation in 
pregnancy and the maintenance thereof (Than et al., 1999). 
 
1.6.1.2. Placental vasculopathy 
 
During normal pregnancy, the level of PP13 slowly increases. In the 1st trimester reduced levels 
of PP13 were observed in pregnancy subsequently complicated by IUGR and pre-eclampsia 
(predominantly the early form). However, as pregnancy reached the 2nd and 3rd trimesters, the 
levels of PP13 increase in pre-eclampsia, IUGR and preterm delivery, compared to 
uncomplicated pregnancies. Abnormal PP13 levels are associated with pregnancy complications 
such as placental insufficiency related to LBW, gestational hypertension, proteinuria, newborn 
mortality and morbidity. These results demonstrate the significance and potential use of PP13 as a 
biomarker to detect placental insufficiency. The unusual pattern of PP13 levels during 
complicated pregnancy may be attributed to impaired synthesis, impaired passage from the 
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placenta to serum, impaired primary structure or a combination of these factors (Burger et al., 
2004). 
 
1.6.1.3. Clinical studies 
 
Nicolaides et al., conducted a case-control prospective study evaluating the combined use of 
Doppler ultrasound and serum PP13 measurement in pregnant women.  The pulsatility index (PI) 
of blood flow in the uterine arteries and the maternal serum concentration of PP13 were measured 
in 10 individuals who subsequently developed PE (>34 weeks) and in 423 control individuals. In 
the control group, PP13 and PI were measured and expressed in multiples of gestation-specific 
median value (MoM). In the patient group, the median uterine artery PI was higher (1.43 MoM, 
P<0.001) and the median serum PP13 level lower (0.07 MoM, P<0.001). The screening false-
positive rate was calculated to be 12% for PP13 and 31% for uterine artery PI; with a 
combination of the two methods, the rate was 9%.  Screening by PP13 measurement only, 
identified 14% of the 10 pre-eclamptic women as “high risk” - combining this data with Doppler 
ultrasound, increased the detection rate to 90%, with an overall false-positive rate of 6%.  This 
combined assessment resulted in effective first trimester screening for pre-eclampsia before 34 
weeks (Nicolaides et al., 2006). 
 
Similar results were reported by Spencer et al., who used first trimester PP13 levels in pre-
eclamptic patients combined with second trimester Doppler assessment (Spencer et al., 2007). 
They performed a nested case-control study involving 73 controls and 12 pre-eclampsia cases of 
which 5 represented early pre-eclampsia (with their delivery induced at 35 weeks) and 7 those in 
which delivery was not induced. The median PP13 levels in controls and all cases were 295.9 and 
212.6 pg/mL, respectively, and in early pre-eclampsia, 171.2 pg/mL [with MoM 1.00, 0.94 and 
0.63 (P<0.001)]. The detection rate for pre-eclampsia was not improved using additional markers 
such as PI, pregnancy-associated plasma protein-A (PAPP-A), Activin, Inhibin or β-hCG in the 
22-24 week period. The use of late second trimester PP13 measurement alone, did not improve 
the prediction of pre-eclampsia; neither did the use of Doppler or other biochemical markers 
(Spencer et al., 2007). 
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1.7. Treatment of preterm labour 
 
The main objective in the treatment of preterm labour is to prolong pregnancy in order to improve 
neonatal outcome. This is usually achieved by admitting the mother to hospital, followed by 
antenatal corticosteroid administration to enhance lung maturation (Anotayanonth et al., 2004). 
 
1.7.1. Antibiotics  
 
During bacterial infection the biosynthesis of prostaglandins or substances such as IL-1, TNF and 
platelet activating factor are stimulated, which may lead to preterm delivery (Kenyon et al., 
2003). In a Cochrane Collaborative group review by King and Flenady including 11 trials with 
7428 women randomised to receiving either antibiotics or placebo, they concluded that the use of 
antibiotics for inhibiting preterm labour with intact membranes might have minimal 
effectiveness. There was no improvement in the reduction of preterm birth, delaying delivery for 
48 hours (hrs) or for seven days, incidence of LBW, perinatal mortality or neonatal morbidity. No 
differences were observed in neonatal outcome wr.t. respiratory distress syndrome, days on a 
ventilator, more than 28 days of oxygen supplementation, necrotising enterocolitis or 
intraventricular hemorrhage. However, maternal benefits included a reduction in infection and a 
clinically insignificant increase in gestation (King and Flenady, 2002 and Newton, 2005).  
 
Kenyon et al., in 2003, examined 22 trials involving the administration of antibiotic treatment to 
women who had developed PPROM before 37 weeks, to evaluate the long-term effects on 
maternal infectious morbidity, fetal and neonatal morbidity and mortality, and childhood 
development. Management with antibiotic was associated with a significant reduction in 
chorioamnionitis and infants born within 48hrs. A reduction in neonatal infection, use of 
surfactant, oxygen therapy and abnormal cerebral ultrasound scan prior to hospital discharge was 
observed. The routine use of antibiotics for the treatment of PPROM is supported due to the 
delayed delivery and reduction of neonatal morbidity but not perinatal mortality. 
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1.7.2. Betamimetics 
 
Betamimetics such as ritodrine, salbutamol and terbutaline are β-adrenergic drugs acting on both 
β1 and β2 receptors. Uterine myocytes contains β2 receptors and facilitate myometrial relaxation 
by stimulation of cyclic adenosine monophosphate (AMP) (Mohan and Bennett, 2006). This 
prevents the release of calcium from the sarcoplasmic reticulum, causing muscle relaxation 
(Chandraharan and Arulkumaran, 2005). Although both β1 and β2 receptors are localised within 
the myometrium of the uterus, they are also found in other human tissues.  It is this lack of uterine 
specificity that can potentially cause undesirable effects (Mohan and Bennett, 2006 and Oei, 
2006).  
 
Maternal side effects to betamimetic treatment include tachycardia, tachypnoea, hypertension, 
nausea and vomiting, hyperglycemia and pulmonary oedema (Dodd et al., 2006). Of these, 
pulmonary oedema is the most serious, with an estimated incidence of 1:350 to 1:400 treated 
patients (Oei, 2006). Furthermore, betamimetics are able to cross the placenta and cause fetal 
tachycardia, hypoglycemia and hyperinsulinism after birth (Anotayanonth et al., 2004). A meta-
analysis has shown that betamimetics are effective in delaying delivery for 24hrs, 48hrs or seven 
days compared with placebo but have no beneficial effect on neonatal outcome and preterm 
delivery rates (Anotayanonth et al., 2004 and Mohan and Bennett, 2006).  
 
1.7.3. Nitric oxide donors  
 
Nitric oxide (NO) is a potent endogenous compound that (i) causes non-striated muscles to relax 
and (ii) acts synergistically with progesterone to inhibit uterine contractility. Nitric oxide 
activates the enzyme guanylate cyclase by circulating freely into the vascular smooth muscle 
catalysing the conversion from guanosine triphosphate to 3'5'-guanosine monophosphate (cGMP), 
which leads to calcium-mediated relaxation (Leszeczynska-Gorzelak et al., 2001), preventing 
actin-myosin interaction (Chandraharan and Arulkumaran, 2005a). The therapeutic doses for 
nitric oxide are used to facilitate external cephalic version, difficulty with vaginal or caesarean 
section delivery and manual exploration of the uterus, and finally as a tocolytic agent (Helmer, 
2005). The stimulation of uterine contractions at term is related to a decrease production of nitric 
 31
oxide in the uterus and placenta, initiating labour. Nitric oxide is thought to play a role in cervical 
ripening and the preparation of the uterus for labour, since the production of nitric oxide in the 
cervix increases near the end of gestation. Consequently, nitroglycerine as a donor of nitric oxide 
has been investigated as treatment for preterm labour and relaxation of the uterus because 
decreased synthesis of nitric oxide has been linked with the initiation of uterine contractions and 
the incidence of labour prematurely, or at term (Leszeczynska-Gorzelak et al., 2001). 
 
In a Cochrane review, Duckitt and Thorton evaluated five randomised controlled trials examining 
the use of nitroglycerine as a donor of nitric oxide. Nitric oxide reduced the risk of delivery 
before 37 weeks (RR 0.69, 95% Cl 0.53-0.888) but did not delay delivery before 32-34 weeks. 
There was no improvement in neonatal outcome when compared with placebo, no treatment or 
alternative tocolysis such as ritodrine, albuterol and magnesium sulphate. Adverse side effects in 
the nitric oxide group were relatively reduced when compared to the other tocolysis, but 
significantly more women experienced headaches (RR 0.47, 95% Cl 0.37-0.61) in the nitric oxide 
treated group. The authors concluded that there is currently insufficient evidence supporting the 
use of nitric oxide as treatment for threatened preterm labour (Duckitt and Thorton, 2002). Bisits 
et al., performed a multicentered, multinational, randomised controlled trial with women who 
tested positive for fetal fibronectin or ruptured membranes between 24 and 35 weeks. These 
women were either given betamimetics (117 women) or nitroglycerine (121 women). After two 
hrs of treatment, 27% of women receiving betamimetics had moderate or stronger contractions 
compared to 53% in the nitroglycerine group. Rescue tocolysis was administered to 35% of 
women in the nitroglycerine group.  If the requirements for betamimetic rescue were regarded as 
treatment failure, then nitroglycerine was not an effective tocolysis compared to betamimetics 
(Bisits et al., 2004). The infant follow-up study found no difference in psychometric performance 
of infants at 18 months of age enrolled in either the nitroglycerine (81 infants) and betamimetic 
(75 infants) arms of the study. Infant assessment was based on the Griffiths Mental development 
scale (Gill et al., 2006).  
 
In a recent randomised double-blind placebo controlled trial, Smith et al., found that the use of 
transdermal nitroglycerine patches reduced birth prior to 28 weeks (RR 0.50, 95% CI 0.23-1.09). 
They suggest that the improvement in neonatal outcome was not due to a difference in delivery 
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within 48 hrs or the administration of corticosteroids but rather due to the maintenance of 
pregnancy and the potential non-tocolytic effect of nitroglycerine, having a direct effect on 
uterine blood flow of the placenta (Smith et al., 2007).  
 
1.7.4. Prostaglandin synthetase inhibitors  
 
Prostaglandin production occurs in the myometrium and other gestational tissues and is 
implicated in cervical ripening, membrane rupture and uterine contractility (Groom et al., 2005). 
Prostaglandins are formed from free arachidonic acid (AA) catalyzed by cyclo-oxygenase (COX) 
enzyme. This conversion, mediated by COX enzymes, is the committing step of prostaglandin 
synthesis (Mohan and Bennett, 2006).  
 
The first most widely used non-steroidal anti-inflammatory drug (NSAID) was indomethacin, a 
reversible COX inhibitor, influencing both COX-1 and COX-2 (Mohan and Bennett, 2006). 
However, the use of indomethacin as a tocolytic drug for the prevention of preterm labour 
included fetal side effects such as oligohydramnios, renal failure, and premature closure of the 
ductus arteriosus associated with pulmonary hypertension, patent ductus arteriosus, necrotising 
enterocolitis and intraventricular haemorrhage (King et al., 2005). Although indomethacin delays 
pregnancy for more than seven days, the use of this drug in the clinical setting is limited, due to 
harmful effects on the fetus (Mohan and Bennett, 2006). 
 
During the onset of labour, at both term and preterm, the expression of COX-2 increases while 
COX-1 remains constant. COX-2 inhibitors lead to a decrease production of prostaglandin E2 in 
human fetal membranes but not COX-1. This demonstrates the importance of COX-2 controlling 
the production of prostaglandin and consequently labour. This regulation step led to the 
development of COX-2 inhibitors in the prevention of preterm labour (Groom et al., 2005). 
Although it was thought that COX-2 inhibitors would display fewer side effects, the use of this 
drug has been found to be associated with fetal ductal closure and reduced renal blood flow 
(Caritis, 2005). Following a randomised, double-blind, placebo-controlled trial, Groom et al., 
concluded that the use of rofecoxib, a COX-2 inhibitor, was not effective in preterm labour 
management and was associated with a greater risk of delivery before 37 weeks. The agent also 
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demonstrated considerable but reversible effects on fetal renal function and ductus arteriosus. On 
these grounds, the author does not support the use of this drug in the management of preterm 
labour (Groom et al., 2005). 
 
1.7.5. Calcium channel blockers 
 
Calcium antagonists such as nifedipine and nicardipine were developed to treat coronary heart 
disease, chronic stable angina pectoris and hypertension. These compounds are identified 
structurally as dihydropyridines acting on the L-type channels, mostly found in cardiac and 
smooth muscle. Binding to these types of channels slows down the inward action potential 
reducing the intracellular amount of calcium leading to decreased myocardial contractions. The 
physiological changes include the lowering of blood pressure, increased heart rate and 
contractility as well as increased cardiac output mainly due to vasodilation. Adverse side effects 
include excessive vasodilation causing dizziness, hypotension, headache, flushing and oedema 
(Oei, 2006). 
 
Nifedipine is the most common calcium antagonist used as tocolysis for preterm labour. When 
administered, nifedipine blocks the influx of extracellular calcium into myometrial cells (Mohan 
and Bennett, 2006) by binding to the inside of the myometrial L-type voltage-dependent calcium 
channels, keeping them closed and inhibiting uterine contractility (Oei, 2006). In human trials 
there is no significant evidence to support (i) any adverse effect on the fetus and (ii) that antenatal 
nifedipine exposure may offer some protection against neonatal morbidity and mortality. The 
amounts of nifedipine deposited in breast milk are less than 5% of the therapeutic dose. 
Administration of calcium antagonists does not have any teratogenic effect on the fetus (Mohan 
and Bennett, 2006). Maternal side effects reflect the vasodilation caused by nifedipine and mostly 
include headache and facial flushes, disappearing within 24 hrs. Additional side effects include 
hypotension, reflex tachycardia, dizziness, nausea and increased levels of liver transaminases 
(van Geijn et al., 2005). 
 
In a Cochrane review evaluating the use of calcium channel blockers as tocolysis for preterm 
labour, it was demonstrated that nifedipine was more effective than betamimetics in delaying 
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delivery and reducing the risk of neonatal morbidities. The incidence of respiratory distress 
syndrome, intraventricular haemorrhage, necrotising enterocolitis and neonatal jaundice were also 
reduced in the nifedipine group compared to betamimetic group. Unfortunately, in this review no 
comparison was made between nifedipine and placebo or no treatment groups (King et al., 2003).  
 
1.7.6. Magnesium sulphate 
 
Magnesium sulphate acts as a calcium antagonist inhibiting the movement of calcium ions 
through the voltage-gated calcium channels. The release of calcium ions from the sarcoplasmic 
reticulum is prevented and leads to decreased activity of the calmodulin-dependent myosin light-
chain kinase. The interaction between actin-myosin is inhibited; hence muscle relaxation occurs 
(Chandraharan and Arulkumaran, 2005a).  Side effects of magnesium sulphate administrations 
may include flushing, a sensation of warmth, headache, blurring of vision, drowsiness, nausea, 
palpitations and rarely, pulmonary oedema. At increased therapeutic levels it can cause 
respiratory depression, respiratory and cardiac arrest (Anwar et al., 2006). Neonatal effects such 
as hypermagnesaemia can cause hyporeflexia, poor sucking and respiratory depression (Crowther 
et al., 2002).   
 
1.7.7. Oxytocin antagonist  
 
Oxytocin production occurs in the hypothalamus and in other peripheral tissues including 
choriodecidua (Gullam et al., 2005). The receptor binding sites for oxytocin are localised mainly 
in the uterine smooth muscle and the myoepithelial cells of the mammary gland (Bernal and 
TambyRaja, 2000). The effects of oxytocin are regulated through a transmembrane receptor 
coupled to G-proteins that activate phospholipase C, resulting in an increase of intracellular 
calcium and increased activity of protein kinase C. These regulation patterns lead to myometrial 
smooth muscle contraction and furthermore, oxytocin stimulates the release of prostaglandins that 
are responsible for cervical ripening and enhancing smooth muscle contractions (Mohan and 
Benett, 2006). During both term and preterm labour, the expression of oxytocin receptors 
increases and for this reason oxytocin antagonists were studied and developed as a tocolytic agent 
in the prevention of preterm labour. Of all the oxytocin antagonists under study, atosiban has 
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been the most extensively studied in animal, preclinical and clinical trials as tocolysis for preterm 
labour (King, 2004). Atosiban binds to the oxytocin receptor and interrupts the action of this 
receptor on G-proteins, which delays the activity of the phospholipase C enzyme, inhibiting the 
release of calcium from the sarcoplasmic reticulum. The end result is down-regulation of 
intracellular calcium leading to muscle relaxation (Chandraharan and Arulkumaran, 2005a).  
 
In pregnant women the amount of bound plasma protein is 46-48%, and has limited crossover 
into fetal circulation with no direct effects on the fetus (Mohan and Benett, 2006). On the basis of 
adequate evidence, it was recommended that atosiban is just as effective as betamimetics in 
delaying preterm labour with minimal side effects including chest pain, palpitations, tachycardia, 
hypotension, nausea, vomiting and headache (Chandraharan and Arulkumaran, 2005b).  A 
Korean multicentred, parallel group, randomised, single blind study of the safety and efficacy of 
atosiban versus ritodrine found that the efficacy after seven days was significantly better in the 
atosiban group than in the ritodrine group (60.3 versus 34.9%), but not at 48 hrs (68.3 versus 
58.7%). Maternal side effects were less common in the atosiban group (7.9 versus 70.8%; 
P=0.0001), with fewer earlier drug terminations due to adverse effects (0 versus 20.0%; 
P=0.0001). There was no difference in the treatments w.r.t. neonatal morbidities, despite the fact 
that infection, intraventricular haemorrhage, respiratory distress syndrome and patent ductus 
arteriosus were reported more frequently in the atosiban group. The authors concluded that the 
efficacy and safety of atosiban as a tocolytic treatment for preterm labour were superior to those 
of ritodrine (Shim et al., 2006).  
 
A randomised controlled trial performed in 2005 by Kashanian et al., compared the use of 
atosiban and nifedipine for treatment of preterm labour and found no significant difference 
between the two groups. Effectiveness in delaying delivery for 48 hrs was 82.5% in the atosiban 
and 75% in the nifedipine groups (P=1.000), and delaying for more than seven days was 75% in 
the atosiban and 65% in the nifedipine group. Maternal side effects were 17.5% in the atosiban 
and 40% in the nifedipine group. Atosiban was found to be more effective and safe for the 
treatment of preterm labour, especially in patients with heart disease and multi-fetal pregnancies. 
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1.8. Preterm labour: Where we stand now? 
 
Despite genetic research in perinatal medicine, current investigations are analytically limited in 
regards to performance and output compared to the field of autoimmunity, oncology and 
cardiovascular disorders. These boundaries are brought about due to the moderately small size of 
our research field, influencing funding, expertise and analytical capacity (Orsi et al., 2007). 
 
Although neonatal and maternal care has improved, the rate of preterm birth has increased slowly 
(Pennell et al., 2007). Worldwide, infection is the single most frequent cause of spontaneous 
preterm labour, with HIV globally becoming an increasing problem, particularly in Africa (Steer, 
2005). 
 
Recent advances in the field of clinical genetics in the hope to identify maternal risk, predictive 
and management strategies have been limited by heterogeneity, as well as the complex nature of 
genetic and environmental predispositions (Lyndon et al., 2006). 
 
1.9. Aim and Objectives 
 
The present study was designed to incorporate the clinical setting and investigate potential 
genetic associations with preterm labour. The study cohort comprised consecutive first-time 
booking low-risk pregnant women from a restricted geographical region.  
 
This data set will be scrutinised by clinicians and policy-makers at Paarl Hospital who will be 
able to compare these data with their previous hospital records, to enable them to identify current 
trends, strengths and weaknesses in their services, facilities and resources.  Ultimately, this will 
impact on their planning for the future.  
 
The aim of this project was to establish a predictive marker profile for pregnancy outcome. 
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This will be achieved by: 
 
1. Evaluating whether selected polymorphisms in pro-inflammatory and anti-
inflammatory genes predispose to poor pregnancy outcome. 
2. Investigating whether sequence variants in the PP13 encoding gene impact on 
pregnancy outcome. 
3. Use appropriate statistical tools to evaluate 1 and 2. 
 
2. Material and Methods 
 
2.1. Materials 
 
2.1.1. Patients 
 
The project was approved by the Institutional Review and Ethics board (N04/09/147) (Appendix 
1) and study participants provided written consent (Appendix 2 and 3). The study cohort 
comprised 421 pregnant females presenting at the Paarl Hospital Obstetric clinic (Western Cape 
region of South Africa) during the period 2005 - 2007.  To reduce genetic heterogeneity, patient 
recruitment focussed on the South African Coloured (San, Khoi, Madagascan, Javanese and 
European ancestry: Loubser et al., 1999) [N=306] and Black (Xhosa speaking) [N=115] 
population groups. These two population groups are served within the Paarl and Tygerberg 
Hospital catchment areas. 
 
Gestational assessment was made using current clinical protocols such as menstrual dates, clinical 
examination and early ultrasound. Exclusion criteria included women with multiple gravidity, 
known uterine or cervical abnormalities and HIV positive status. 
 
To simplify the genotyping analysis, the following complication subgroups were combined:  (i) 
preterm labour with PPROM, and (ii) pre-eclampsia with eclampsia and PIH (representing 
hypertension). 
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2.1.2. Controls 
 
The control cohort comprised individuals within the study cohort who delivered at term, with a 
healthy pregnancy outcome.  
 
2.2. Methods 
 
2.2.1. DNA Extraction 
 
Maternal whole blood was drawn from peripheral veins and stored in BD vacutainer K2E tubes 
with EDTA (Belliver Industrial State, Plymouth, UK). Blood samples were kept at -20°C until 
required. Genomic DNA was extracted from 5mL of whole blood using a salting-out extraction 
method described by Miller et al., 1988 (Appendix 4) and dilutions prepared in sterile distilled 
water at a final concentration of 20ng/μL. The DNA concentration had been established using a 
NanoDrop® Spectrophotometer (NanoDrop Technologies, USA).   
 
2.2.2. Polymerase Chain reaction 
 
2.2.2.1. Oligonucleotide Primers 
 
Reference sequences for LGALS13 (NM_013268.2) were obtained from the NCBI website 
(http://www.ncbi.nlm.nih.gov/) and primer pairs for PCR amplification (designed to encompass 
the promoter and intronic sequences flanking the encoding regions under investigation (Figure 5, 
Table 2 and Appendix 5) were designed using Primer3 (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi) software.  The primers (synthesised by the Department of 
Molecular and Cell Biology, University of Cape Town) were analysed for hairpin, homo- and 
hetero-dimer formation using IDT® (Integrated DNA Technologies, Inc, Coralville, IO, USA) 
(http://www.idtdna.com/) OligoAnalyzer and sequence specificity using NCBI Basic Local 
Aligment Search Tool (BLAST) (http://www.ncbi.nlm.nih.gov/BLAST/). 
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The immunological gene variants (IL-4 -590, IL-1β +3953, IL-1RN, IL-10 -1082; -819; -592 and 
TNFα -308; -238; +488 were amplified using primers sets described by Kalish et al., 2004, Genc 
et al., 2002, Hellmig et al., 2005, Koch et al., 2001, Yamanoto-Furusho et al., 2004 and 
Manchanda et al., 2006, respectively (Tables 3A&B). 
 
Table 2: LGALS13 designed primers, annealing temperatures and amplicon sizes.  
 
Coding region Primer Primer Sequence [5’-3’] Tm (°C) Ta (°C) Fragment (bp) Reference 
LGALS 13 gene           
Exon 1 E1F  GCTGCAAGGAAATCTTGCTG  52   
 E1R CCACACCTCAATAGCTCTAAG  52 52 292 
Exon 2 E2F CAACCTCCTGCACCATGAG  53     
  E2R CATCACCCACATGTAAGGTC  52 52 245 
Exon 3 E3.1F GGCCATCAGTATTATCTGGGAG  55   
 E3.1R GATTGCCAAAGTGCACTCGG  54 54 213 
 E3.2F GGATGAGGATTCAGATATTGCC  53     
 E3.2R CCCTGACGGACTACTGAG  53 53 265 
Exon 4 E4.1F TGTACCAGGACAGAGTGGAG  54     
 E4.1R CTATTGCAGACACACACTGA  50 52 196 
 E4.2F GAGAGATATCTCCCTGACCTC  54   
 E4.2R  CCTGATGCCTCCCATAGAATG  54 54 258 
G Rebello, Personal 
Communication 
E (exon); F (forward); R (reverse); Tm (melting temperature); Ta (annealing temperature) 
 
 
   5' 3' 
Figure 5: Graphical representation of the LGALS13 gene, indicating the primer sets and their relative positions used in this study. Start (ATG) and 
stop (TGA) codons are also indicated. Black indicates coding and the grey boxes non-coding regions. 
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Table 3: (A) Documented primer sequences, annealing temperatures and amplicon sizes (RFLP analysis). (B) Documented allele specific primer 
sequence, annealing temperatures and amplicon sizes (ARMS assay). 
 
A
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B
Polymorphism Primer Sequence [5’-3’] Tm (°C) Ta (°C) Amplicon (bp) Reference 
IL-1RN (86 bp repeat) F: CTCAGCAACACTCCTAT  45       
 Alleles 1-5 * R: TCCTGGTCTGCAGGTAA 47 54 (a)  Hellmig et al., 2005 
IL-4 -590 (C/T) F: ACTAGGCCTCACCTGATACG 54       
 R: GTTGTAATGCAGTCCTCCTG 52 57 252 Kalish et al., 2004 
IL-1β +3954 (C/T) F: GTTGTCATCAGACTTTGACC 50       
 R: TTCAGTTCATATGGACCAGA 48 54 250 Genc et al., 2002 
IL-10 -1082 (A/G) F:  CCAAGACAACACTACTAAGGCTCCTTT 58       
 R: GTGGGCTAAATATCCTCAAAGTT 52 55 377 Koch et al., 2001  
IL-10 -819 (C/T) F: CAACTTCTTCCACCCATCTTT 50       
          -592 (C/A) R: GTGGGCTAAATATCCTCAAAGTT 52 52 477 Koch et al., 2001 
TNFα +488 G/A) F: TGCACTTTGGAGTGATCGGC 54       
 R: AACAGCTGGCTGCCTGTCT 53 55 588 Manchanda et al., 2006    
*  410bp (allele 1), 240bp (allele 2), 500bp (allele 3), 325bp (allele 4) or 595bp (allele 5)         
Polymorphism Allele specific primers [5’-3’] Tm (°C) Ta (°C) Amplicon (bp) Reference 
TNFα -308 (G/A) F: GGCAATAGGTTTTGAGGGGCGTGG (G) 63  216  
 R: ACCCTGGAGGCTGAACCCCGGCCT (A) 66  139  
 F:  GCCCCTCCCAGTTCTAGTTCTAT ©  57  308  
 R: AAGCGGTAGTGGGCCCTGCACCTT ©  61 62  Yamamoto-Furusho et al., 2004 
TNFα -238 (G/A) F: AGACCCCCCTCGGAATCG (G) 67   449   
 R: CACACTCCCATCCTCCCTGGTCT (A) 61  209  
 F: GCCCCTCCAGTTCTAGTTCTATC © 57  608  
  R: CCGGATCATGCTTTCAGTGC © 54 61  Yamamoto-Furusho et al., 2004 
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Table 4: PCR cycling conditions used to amplify each polymorphic locus. 
 
    Time at temperatures 
Gene 
primer 
(pmol) Ta (°C) 
No. 
cycles 
94°C 
(min) 94°C (sec) Ta°C (sec) 72°C (sec) 
72°C 
(min) 
IL-1RN 10 54 35X 3 20 30 30 5 
IL-4 -590 10 57 32X 3 30 30 30 5 
IL-1β +3953  20 54 35X 3 20 30 30 5 
IL-10 -1082  10 55 35X 5 30 30 30 3 
IL-10 -819/-592  10 52 35X 5 30 45 45 6 
TNFα -308  20 62 35X 1 30 30 30 2 
TNFα -238  20 61 35X 3 30 30 30 5 
TNFα +488  10 55 40X 5 30 45 45 8 
PP13 E1 10 52 35X 3 30 30 30 5 
PP13 E2 10 52 35X 3 30 45 30 5 
PP13 E3.1 10 54 35X 5 30 30 30 7 
PP13 E3.2 10 53 30X 3 20 30 30 5 
PP13 E4.1 10 52 35X 3 30 30 40 5 
PP13 E4.2 10 54 35X 3 30 30 30 5 
sec (seconds); min (minutes); X (times i.e. number of cycles) 
 
2.2.2.2. DNA Amplification 
 
DNA amplification was performed using the GeneAmp® PCR System 2700 (Applied 
Biosystems, California, USA) in a total volume of 50μL, which contained 0.5U GoTaq® DNA 
Polymerase (Promega, Madison, WI, USA), 1X commercial buffer and 0.25mM of each dNTP 
(Promega, WI, USA); or 0.5U GoTaq® Flexi DNA Polymerase (Promega, Madison, WI, USA), 
1X commercial buffer, 0.5, 1 or 2mM MgCl2, 0.25mM of each dNTP (Promega, WI, USA) and 
~20ng of genomic DNA. The cycling conditions and primer concentration are indicated in Table 
4. The polymorphisms listed in Table 2b were evaluated by the amplification refractory system 
polymerase chain reaction (ARMS-PCR).  
 
2.2.3. Agarose Gel Electrophoresis 
 
For confirmation of successful amplification, five microliters of each PCR product was mixed 
with 5μL of loading dye (95% Formamide, 20mM EDTA, 0.05% Xylene Cyanol, 0.05% 
Bromophenol Blue) and resolved by electrophoresis on 1% agarose gels in 1X TBE buffer 
(90mM Tris-HCl, 90mM Boric acid and 1mM EDTA, pH 8.0) for 20 minutes at 90V and stained 
with 0.5 μg/mL Ethidium bromide (Sigma, Missouri, USA). The gels were photographed under 
ultraviolet light (260nm) using a Multigenius Bio Imaging System (Syngene, Cambridge, UK). 
 
2.2.4. Mutation Screening 
 
2.2.4.1. Single Stranded conformational polymorphism (SSCP) and  
 heteroduplex analysis 
 
The amplification products selected for mutation analysis were added to SSCP loading buffer 
(95% formamide, 100mM NaOH, 0.25% bromphenol blue and 0.25% xylencyanol) in a 1:1 ratio 
and denatured at 95°C for 5 min followed by rapid quenching on ice for 3 min. A 12% non-
denaturing polyacrylamide gel (99% acrylamide, 1% piperazine diacrylamide [PDA], TEMED 
and 10% ammonium persulfate was used to resolve bands. Electrophoresis was performed on a 
Pharmacia LKP 2117 Multiphor II Electrophoresis Unit at 355 V for ~120 min (4-11°C). The 
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single stranded conformational polymorphisms (SSCP) and heteroduplex (HD) conformation 
patterns were obtained by 0.1 % silver staining (Liechti-Gallati et al. 1999) (Appendix 6).   
 
2.2.4.2. Sequencing  
 
PCR amplicons displaying aberrant banding patterns following SSCP and HD analysis were 
subjected to semi-automated sequencing and restriction enzyme digestion, where applicable 
(Table 6). Prior to sequencing, the products were purified using Bioline Quick Clean (Bioline, 
UK) (Appendix 7) and recovery was confirmed on a 1% agarose gel. Sequencing reactions were 
carried out using the BigDye® Terminator V3.1 Cycle Sequencing Kit (Applied Biosystems, 
California, USA) and the products were analysed using an ABI 3130xl Genetic Analyzer 
(Applied Biosystems, California, USA). Sequencing was bi-directional, when required. 
Sequencing reactions were performed at the University of Stellenbosch, DNA Sequencing 
Facility.  
 
2.2.4.3. Restriction Enzyme Analysis  (REA) 
 
Table 5 is a summary of the restriction enzymes and conditions used to screen each documented 
polymorphisms and Table 6 shows the conditions required for REA to confirm variations 
detected by Multiphor analysis. 
 
Restriction enzyme sites for conformational variants of the LGALS13 gene were characterised 
using the BioEdit Sequence Alignment Editor (Isis Pharmaceutical, Carlsbad, California, USA). 
For each restriction, 10-15 μL of PCR product was digested overnight with 1 or 2 units of 
restriction enzyme in a total reaction of 20μL. Restricted products (and appropriate size ladders) 
were subsequently resolved on a 2 or 3.5% agarose gel (dependent on size), in 1X TBE, at 70V 
for 90 minutes.  
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Table 5: Restriction enzymes (RE) and allele description used to genotype each polymorphism. 
 
Genes Position and nature  RE and condition dbSNP/Reference Recognition site (5’-3’) 
IL-1β  +3954 (C/T) TaqαI    (37°C) a rs: 1143634 T↓CGA 
IL-4  -590 (C/T) BsmFI   (65°C) a rs: 2243259 GGGAC(N)10↓  
IL-10  -1082 (A/G) EcoNI    (37°C) a rs: 1800896 CCTNN↓NNNAGG 
   -592 (C/A) RsaI       (37°C) a rs: 1800871 GT↓AC 
TNFα  +488 (G/A) NlaIII    (37°C) a Mullighan et al. 1997 CATG↓ 
New England Biolabs a    
     
 
Table 6: Restriction enzymes (RE) and allele description used to confirm variations identified in this 
study.  
 
Genes Region Position and nature RE and condition dbSNP Recognition site (5'-3') 
LGALS13 E1 -98 (A/C), 5'UTR AvaI    (37°C ) a rs: 3764843 C↓YCGRG 
 E3.1 IVS2-36 (G/A) NlaIV  (37°C) a novel GGN↓NCC 
  IVS2-22 (A/G) AciI     (37°C ) a rs: 2233706 AA↓CGTT 
  IVS2-15 (G/A) NlaIII  (37°C ) a novel CATG↓  
 E3.2 Hotspot ApoI    (55°C) a novel R↓AATTY 
  IVS3+72 (T/A) StuI     (37°C) a rs: 2233708 AGG↓CCT 
New England Biolabs a     
E = exon      
 
2.2.5. Statistical Analysis 
 
Statistical analysis was performed using the Hardy-Weinberg Equilibrium Chi squared test to 
compare the genotype and allelic frequency distribution in the study groups. Genotypes and 
alleles were considered to be in Hardy-Weinberg equilibrium if the observed frequencies did not 
differ significantly from the expected (P>0.05). The study cohort was divided into groups with 
(1) good pregnancy outcome (controls) and (2) poor pregnancy outcome (patients) for each 
population group (Coloured and Black [Xhosa speaking]). Subgroup analysis was subsequently 
performed, grouping related pregnancy complications, using 2 × 2 contingency table analyses 
and the Chi square test for independence using EpiInfo 6 statistical software 
(http://www.cdc.gov/epiinfo/Epi6/ei6.htm ). Odds ratio (OR) and relative risk (RR) at 95% 
confidence intervals (CI) were also determined to describe the strength of association. Any 
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association demonstrated was confirmed by Fisher's exact test. Descriptive analyses were 
performed using Student’s independent t test for continuous variables using Statistica 8 software 
(http://www.statsoft.co.uk/). A P value of < 0.05 was considered statistically significant. 
Haploview 3.32 (http://broad.mit.edu/mpg/haploview) was used to calculate haplotype 
associations and the measures of linkage disequilibrium (D' and r2) between SNPs, a LOD score 
> 3 were considered as evidence of linkage.  
 
2.2.6. Genotype: phenotype association 
 
Association of genotypic and clinical information were assessed to determine whether certain 
loci were linked to clinical parameters which included gestational age at complication and birth 
weight of infant, among others. 
 
3. Results and Discussion 
 
3.1. Results  
 
In the analysis of the raw data, four significant findings were obtained: 
 
1. Clinical profiles in two distinct South African population groups serviced by the Paarl 
Hospital region could be established and will be used for monitoring “trends”. 
2. A novel IL-1RN allele was identified. 
3. The following significant associations were demonstrated: 
i. Preterm labour and the IL-1RN*2 
ii. Pre-eclampsia the IL-1RN*2 
iii. Preterm labour and the TNFα-308 allele 2 
iv. Preterm labour and the LGALS13 221delT 
4. Linkage disequilibrium was identified between LGALS13 intronic variants IVS2-22 and 
IVS3+72. 
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3.1.1. Participant’s demographic and clinical characteristics 
 
3.1.1.1. The Paarl Hospital patient PROFILE 
 
Good perinatal intensive care requires the close collaboration of obstetricians, midwives, 
anaesthetists, neonatologists and the availability of appropriate equipment. The frequency of 
pregnancy complications at special referral centres such as Tygerberg hospital mostly represents 
a “cluster” of cases that could not be dealt with at primary or secondary level care.  Hence the 
incidence of complications documented at Tygerberg hospital do not accurately reflect that of the 
general population. 
 
Establishing a specific profile of the spectrum of complications encountered in the primary and 
secondary health care setting will assist with improvement of hospital infrastructure, regarding 
staffing and facilities and is more “aligned” with potential patients’ needs. These improved 
changes will inevitably have an impact on clinical practice and policy development, offering 
effective treatment and management programs, thereby lowering the incidence of maternal/fetal 
morbidity and mortality. 
 
The “Westernisation” of lifestyle has brought about an increase in cardiovascular disease (CVD), 
diabetes and obesity (Mutch et al., 2005), possibly worsening the health status of individuals in 
South Africa. The current rates and forms of pregnancy complications in Coloured and Black 
women in the Paarl region may not be the same now as in the past. This study was design to (i) 
assess which complications prevail now and (ii) determine whether there is a genetic component 
contributing to their development. 
 
The study cohort is shown diagrammatically in Figure 6 and reflects the population delivering at 
Paarl Hospital.  
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Figure 6: The initial size of the study cohort was 476 (data collected at first booking). Of these, 27 
transferred to another clinic and / or were lost to follow-up. At the time of data analysis, 421 patients had 
delivery outcome, with 28 still pregnant. The cohort (N=421) was sub-divided according to ethnicity and 
subsequently, outcome of pregnancy (good or adverse). 
 
 
 
Complications arose in 19.4% of all the participants.  The adverse outcomes represented preterm 
labour (N=30, 7.1%), pre-eclampsia (PE) (N=29, 6.8%), intrauterine death (IUD) (N=6, 1.4%), 
miscarriage (N=6, 1.4%), preterm premature rupture of membranes (PPROM) (N=3, 0.7%), 
pregnancy-induced hypertension (PIH) (N=3, 0.7%), eclampsia (N=3, 0.7%), intrauterine growth 
restriction (IUGR) (N=2, 0.5%) and abruption placentae (N=1, 0.2%).  
 
The incidence of complications in this study was higher in Coloured (22.5%) than in Black 
women (12.2%). In our cohort, Coloured ethnicity with its related culture appears to increase an 
individual’s risk of developing various pregnancy pathologies. A summary of the maternal 
pregnancy complications is presented in Figure 7. In the Coloured group, 8.2% developed 
preterm labour; the presence of hypertension disorders was 7.8%, 1% and 0.7% representing pre-
eclampsia, eclampsia and PIH, respectively. The prevalence of IUGR in this group was 0.7%, 
with the incidence of PPROM and AP, 0.7% and 0.3%, respectively.  Miscarriage and 
intrauterine death accounted for 2.0% and 1.3% of cases, respectively. The incidence of 
complications in the Black group was 4.4% each for preterm labour and pre-eclampsia, 1.7% for 
IUD and 0.9% for PPROM and PIH, respectively. 
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 Demographic and clinical data on the cohort are summarised in Table 7.  As expected, the mean 
gestational age and birth weight of complicated pregnancies were significantly lower than 
deliveries at term. There were too few Black patients in the “complications group” to perform 
subgroup analysis. However, there was a significant difference in the mean gestational age 
(P=0.022) and birth weight (P=0.003) for healthy Black vs. healthy Coloured individuals. There 
was no significant difference in maternal age at delivery in either healthy or complicated 
outcomes.  In contrast, there was a significant difference in maternal age in the Coloured preterm 
labour group (P=0.023), representing a trend towards lower maternal age.  
 
 
PTL (preterm labour), PE (pre-eclampsia), IUD (intrauterine death), Misc (miscarriage), PPROM (preterm 
premature rupture of membranes), PIH (pregnancy-induced hypertension), E (eclampsia), IUGR (intrauterine growth 
restriction) and AP (abruption placentae). 
Figure 7: Graphical presentation of the prevalence of various pregnancy complications observed at Paarl 
Hospital within the period 2005-2007. 
Paarl Region, Western Cape: South Arican Coloured vs. Black (N = 421)
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Controls Preterm Labour Pre-eclampsia Intrauterine death Characteristic 
Coloured Black Coloured Black Coloured Black Coloured Black 
Maternal age 
(mean yrs [range]) 
N=238 
21.9 [16-39] 
N=101 
22.7 [16-36] 
N=27 
20.3 [17-26] 
N=6 
22.0 [19-25] 
N=29 
22.9 [16-42] 
N=6 
21.0 [16-24] 
N=4 
22.8 [21-26] 
N=2 
28.5 [24-33] 
Gestational age 
(mean wks [range]) 
N=226 
39.7 [38-42] 
N=101 
39.9 [38-42] 
N=27 
35.7 [28-40A] 
N=6 
36.2 [28-40A] 
N=25 
38.4 [30-40] 
N=6 
38.5 [36-40] 
N=3 
28.7 [24-33] 
N=2 
22.0 [22] 
Birth weight 
(mean g [range]) 
N=224 
2959.0 
 [1820-4050] 
N=101 
3113.5  
[2100-4400] 
N=27 
2108.1  
[980-3640] 
N=5 
2502.0  
[1780-3580] 
N=24 
2636.9  
[1440-3700] 
N=6 
2543.3  
[2300-2820] 
N=4 
1294.0  
[426-3010] 
N=2 
503.0    
[446-560] 
Caesarean delivery 58/478 (12.1%) 
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Figure 8: Based on the results of Table 7, the mean gestational age and birth weight for each group (controls, preterm labour, pre-eclampsia and 
intrauterine death) were plotted on a standard growth chart.  This chart had been specifically designed for the Tygerberg patient (G Theron, 
personal communication). 
 
Table 7: Demographic and clinical characteristics of study cohort.  
A Labour suppressed 
 
 
Control and preterm labour Black infants weighed more than the Coloured infants, while the 
trend was reversed in cases of pre-eclampsia, where the Coloured infants weighed more. 
 
3.1.1.2. Discussion 
 
This study has shown a particular order in the presentation of pregnancy-related complications in 
this cohort, viz, IUD (week 22-28), preterm labour (up to 36 weeks) and pre-eclampsia (up to 
term).  Pre-eclampsia (early and late onset forms) often further complicated by AP or IUGR and 
the more sudden eclampsia, followed closely in frequency by preterm labour, represent the major 
complications at Paarl hospital. 
 
Within this geographical region, Black women generally had healthier pregnancy outcomes 
compared to Coloured women. The poor pregnancy outcome in the Coloured group could be 
caused by a combination of genetic and environmental factors. In our study, maternal age of 
Coloured women was identified as a risk factor for early labour, with younger women more 
prone to early delivery. In a survey, smoking during pregnancy was reported by 47% of 
Coloured women attending public service clinics.  Within this population, smoking during 
pregnancy was shown to significantly increase the risk of developing AP and preterm labour, 
with a mean birth weight reduction of 256 g (Evertt et al., 2005).  
 
Based on these data, smaller public obstetric clinics serving Coloured women should be 
specifically equipped to (i) identify and (ii) manage and / or treat cases of preterm labour and the 
various forms of hypertension.  Concurrently, there should be a drive to educate women 
(specifically Coloured women) about pregnancy complications and the link with environmental 
factors such as smoking and alcohol abuse.  Collectively, these initiatives could minimise 
maternal and fetal mortality and morbidity. 
 
The general observation of healthier Black pregnant women within the Paarl region, should be 
investigated to establish whether there is an underlying protective effect: either at a genetic and / 
or environmental level.  
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3.1.2. Inflammatory cytokines 
 
Significant associations were demonstrated between pregnancy complications and selected 
polymorphisms within genes encoding two cytokines.  These data will be presented and 
discussed together. Information on the remaining loci screened in this study cohort is in 
Appendix 8. 
 
3.1.2.1.1. IL-1RN locus 
 
Various IL-1RN genotypes were identified in this study (Figure 9).  
 
 
1 2 3 4 5 6 7 8 9 10 11 12
 
~950bp 
592bp (*5) 
500bp (*3) 
 
410bp (*1) 
 
325bp (*4) 
 
240bp (*2) 
 
Figure 9: 2% Agarose gel reflecting the different IL-1RN genotypes as assigned by Hellmig et al., 2005. 
Lane 1: 100bp ladder (Fermentas), Lane 2: 1/1 (410bp), Lane 3: 1/2 (410bp and 240bp), Lane 4: 1/3 
(410bp and 500bp), Lane 5: 1/4 (410bp and 325bp), Lane 6: 1/5 (410bp and 592bp), Lane 7: 2/2 (240bp), 
Lane 8: 2/3 (240bp and 500bp), Lane 9: 2/4 (240bp and 352bp), Lane 10: 2/novel (240bp and ~950bp), 
Lane 11: 4/4 (325bp) and Lane 12: 3/3 (500bp).  
 
The distribution of the IL-1RN genotypes in the combined study population (Coloured and 
Black) as well as the adverse pregnancy outcome [N=83] and subgroups (preterm labour [N=33] 
and hypertension [N=35]) are shown in Table 8.  The remaining 15 cases represented a diverse 
“other complication” group of cases, such as IUGR and AP.  Genotypes containing the IL-
1RN*3, IL-1RN*4 and IL-1RN*5 alleles were rare and therefore excluded from the analysis (in 
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keeping with international trends). Analysis was performed as previously documented (Witkin et 
al., 2003). 
 
Table 8: Genotype frequencies determined at the IL-1RN locus. The 3 individual rows (in blue) were 
extracted from the dataset and further analysed, in keeping with international trends.   
 
Genotype Total (N=421) 
Controls 
(N=338) 
Adverse 
outcome 
(N=83) 
Preterm labour 
(N=33) 
Hypertension 
(N=35) 
1/1 254 (60.3%) 212 (62.7%) 42 (50.6%) 15 (45.5%) 15 (42.9%) 
1/2 109 (26.0%)  77 (22.8%) 32 (38.6%) 15 (45.5%) 15 (42.9%) 
1/3 13 (3.1%) 12 (3.6%)  1 (1.2%)  1 (3.0%) 0 
1/4 17 (4.0%) 15 (4.4%)  2 (2.4%)  1 (3.0%)  1 (2.9%) 
1/5   3 (0.7%)  2 (0.6%)  1 (1.2%) 0 0 
2/2  18 (4.3%)      13 (3.8%)  5 (6.0%)  1 (3.0%)  4 (11.4%) 
2/3    1 (0.2%)  1 (0.3%) 0 0 0 
2/4    2 (0.5%)  2 (0.6%) 0 0 0 
2/novel    1 (0.2%)  1 (0.3%) 0 0 0 
3/3    2 (0.5%)  2 (0.6%) 0 0 0 
4/4    1 (0.2%)  1 (0.3%) 0 0 0 
 
The novel allele in one control individual (shown in blue) is currently being characterized by 
automated DNA sequencing. The estimated amplicon size is ~950bp, which is equal to 
approximately ten 86-bp tandem repeats.   
 
Table 9: Genotype and allele frequencies determined for the IL-1RN polymorphism for the total cohort. 
Hardy Weinberg Equilibrium was determined for each individual group and is shown in the last row of 
the table. Statistical analysis was performed using Fisher's exact test analog to determine associations at 
both genotype and allele level. The corresponding P values are shown at the bottom of the table.  
Statistically significant P values are shown in bold.  
 
Total Cohort (N=381) 
Genotype Total 
(N=381) 
Controls 
(N=302) 
Adverse 
(N=79) 
PTL 
(N=31) 
Hypertension 
(N=34) 
1/1 254 (66.7%) 212 (70.2%) 42 (53.2%) 15 (48.4%) 15 (44.1%) 
1/2 109 (26.6%)   77 (25.5%)   32 (40.5%) 15 (48.4%)     15 (44.1% 
2/2 18 (4.7%) 13 (4.3%) 5 (6.3%) 1 (3.2%)   4 (11.8%) 
1-allele 0.809 0.829 0.734 0.726 0.662 
2-allele 0.191 0.171 0.266 0.274 0.338 
HWE 0.376 0.229 0.945 0.486 0.996 
Controls vs. Adverse: P=0.017 (genotype) and P=0.007 (allele); Controls vs. Preterm labour: P=0.025 (genotype) 
and P=0.043 (allele); Controls vs. Hypertension: P=0.006 (genotype) and P=0.0008 (allele). 
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Distribution of the IL-1RN genotypes for the total group is shown in Table 9 and was shown to 
be in Hardy-Weinberg Equilibrium (P>0.05). The genotype and allele frequencies in the controls 
compared to the adverse pregnancy outcome differed significantly (P=0.017 and P=0.0066, 
respectively). Carriage of the IL-1RN*2 (1/2 and 2/2) were associated with an increased odds 
(OR 2.08, 95% CI 1.20-3.55) and relative risk (RR 1.76, 95% CI 1.20-2.60) for developing a 
pregnancy complication (P=0.004). The enrichment of the IL-1RN *2 were more prevalent in the 
adverse outcome, preterm labour and hypertension versus the controls groups, 26.6%, 27.4%, 
33.8% and 17.1%, respectively. 
 
Further subgroup analysis revealed the association was contained within both the preterm labour 
(P<0.05) and strengthened in the hypertension group (P<0.01). The presence of the IL-1RN *2 
had an increase odds (OR 2.51, 95% CI 1.12-5.64) and relative risk (RR 2.28, 95% CI 1.17-4.44, 
P=0.013) for developing preterm labour. In the hypertension group, P=0.002, the OR was 2.98 
(95% CI 1.37-6.51) and the RR was 2.64 (95% CI 1.39-4.99).  
 
Table 10: Genotype and allele frequencies of the IL-1RN polymorphism in the Coloured population. 
Hardy Weinberg Equilibrium (HWE) was determined for each individual group. Statistical analysis was 
performed using Fisher's exact test analog to determine associations at both genotype and allele level. The 
corresponding P values are shown at the bottom of the table.  Statistically significant P values are shown 
in bold. 
 
Coloured Females (N=279) 
Genotype Total 
 (N=279) 
Controls  
(N=212) 
Adverse 
 (N=67) 
PTL 
(N=26) 
Hypertension 
(N=28) 
1/1 172 (61.6%) 138 (65.1%)     34 (50.7%)   12 (46.2%) 11 (39.3%) 
1/2  90 (32.3%)  62 (29.2%)    28 (41.8%)     13 (50%) 13 (46.4%) 
2/2 17 (6.1%) 12 (5.7%)    5 (7.5%)   1 (3.8%)   4 (14.3%) 
1-allele 0.778 0.797 0.716 0.712 0.625 
2-allele 0.222 0.203 0.284 0.288 0.375 
HWE 0.536 0.379 0.973 0.539 0.999 
Controls vs. Adverse: P=0.108 (genotype) and P=0.050 (allele); Controls vs. Preterm labour: P=0.099 (genotype) 
and P=0.154 (allele); Controls vs. Hypertension: P=0.021 (genotype) and P=0.0036 (allele). 
 
Table 10 is a summary of genotype and allele frequencies within the Coloured population.  All 
the groups were found to be in Hardy Weinberg Equilibrium. An association was observed with 
the allele frequency in the control versus the adverse pregnancy outcome group (P=0.050). The 
carrier status frequency between controls and adverse outcome group differed significant 
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(P=0.028) with an OR of 1.86 (95% CI 1.03-3.39) and RR of 1.60 (95% CI 1.05-2.43). Subgroup 
analysis demonstrated no association with the preterm labour group. Carrier status of the minor 
allele revealed no association but an increased odds ratio of 2.18 (OR 95% CI 0.89-5.33) and 
relative risk of 1.99 (RR 95% CI 0.96-4.10) of developing preterm labour. A significant 
association was demonstrated in the hypertension group with both genotype and allele 
frequencies (P=0.021 and P=0.0036). Maternal carriage of the IL-1RN*2 was associated 
(P=0.0083) with an increased odds (2.88, 95% CI 1.20-6.99) and relative risk (2.53, 95% CI 
1.24-5.16) of developing pregnancy related hypertension. 
 
Table 11: Genotype and allele frequencies of the IL-1RN polymorphism in the Black population. Hardy 
Weinberg Equilibrium (HWE) was determined for each individual group. 
 
Black Females (N=102) 
Genotype Total  
(N=102) 
Controls  
(N=90) 
Adverse 
 (N=12) 
PTL 
(N=6) 
Hypertension 
(N=6) 
1/1 82 (80.4%) 74 (82.2%) 8 (66.7%) 3 (60%) 4 (66.7%) 
1/2 19 (18.6%) 15 (16.7%) 4 (33.3%) 2 (40%) 2 (33.3%) 
2/2      1 (1%) 1 (1.1%) 0 0 0 
1-allele 0.897 0.906 0.833 0.800 0.833 
2-allele 0.103 0.094 0.167 0.200 0.167 
HWE 0.996 0.971 0.787 0.855 0.887 
Sample size insufficient to perform association analysis (P<0.05). 
 
Genotype frequencies of black individuals (Table 11) at the IL-1RN locus were in Hardy 
Weinberg Equilibrium and no significant association could be demonstrated. Subgroup analysis 
was not performed due to the limited sample size. In the total group, ethnic disparity was 
observed in the distribution of alleles. The frequency of alleles in Black individuals was 89.7% 
for IL-1RN*1 and 10.3% for IL-1RN*2 versus 77.7% and 22.3% in Coloured individuals, with a 
significant difference of P<0.001 (Black vs. Coloured). 
 
3.1.2.1.2. TNFα-308 G/A variant 
 
The TNFα-308 genotypes identified are illustrated in Figure 10 and the distribution of the 
genotype and allele frequencies for the total cohort is shown in Table 12. The control group 
genotypes deviated from Hardy Weinberg equilibrium (and this was also reflected in the “total 
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cohort” genotypes), which restricted further analysis.  Within the total cohort, the A/A genotype 
was very rare, although heterozygosity was fairly common in each group. 
 
  
1            2a           b            3a          b           4a           b 
 
308bp (constant band) 
 
216bp 
139bp 
 
Figure 10: Agarose gel (2%) demonstrating the three genotypes of TNFα-308 locus detected by ARMS 
PCR (Yamamoto-Furusho et al., 2004). Lane 1 represents a 100 bp ladder (Fermentas). Lanes 2a and b 
represents homozygosity for the TNFα-308 G-allele (216 bp), Lanes 3a and b represent a heterozygous 
genotype (216 and 139 bp) and Lanes 4a and b represents homozygosity for the TNFα-308 A-allele (A at 
139 bp). 
 
Table 12: Genotype and allele frequencies of the TNFα-308 G/A polymorphism for the total cohort. 
Hardy Weinberg Equilibrium (HWE) was determined for each individual group. 
 
Total Cohort (N=421) 
Genotype Total 
(N=421) 
Controls 
(N=338) 
Adverse 
 (N=83) 
PTL 
(N=33) 
Hypertension 
(N=35) 
G/G 307 (72.9%) 253 (74.9%) 54 (65.1%) 20 (60.6%) 24 (68.6%) 
G/A 113 (26.9%)   85 (25.1%) 28 (33.7%) 12 (36.4%) 11 (31.4%) 
A/A       1 (0.20%) 0 1 (1.2%)      1 (3%) 0 
G-allele 0.863 0.874 0.819 0.788 0.843 
A-allele 0.137 0.124 0.183 0.212 0.157 
HWE 0.018 0.030 0.436 0.880 0.544 
Total cohort and controls did not reach HWE significance (P<0.05). 
 
Table 13 shows the frequencies of the genotypes and alleles in the Coloured population. All 
genotype distributions were in Hardy Weinberg Equilibrium. The segregation of the TNFα-308 
A-allele (TNF2) in the adverse outcome (16.7%), preterm labour (20.4%) and hypertension 
(15.5%) groups were higher than controls (10.1%). A significant difference was observed in the 
comparison of control versus adverse pregnancy outcome, in terms of the genotype and allele 
frequencies (P=0.033 and P=0.035, respectively). The occurrence of both G/A and A/A 
genotypes showed an association with adverse pregnancy outcome (OR 1.84, 95% CI 0.96-3.47 
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and RR 1.58, 95% CI 1.03-2.43, P=0.043). Statistical analysis revealed a significant association 
between the preterm labour and TNF2 at both genotype (P=0.003) and allele (P=0.024) level. 
The presence of TNF2 was associated (P=0.047) with an increased odds (2.32, 95% CI 0.92-
5.78) and relative risk (2.09, 95% CI 1.01-4.31) for preterm labour. The association did not 
extend to the hypertension group (P=0.210). 
 
Table 13: Genotype and allele frequencies of the TNFα-308 G/A polymorphism in the Coloured 
population. Hardy Weinberg Equilibrium (HWE) was determined for each individual group. Statistical 
analysis was performed using Fisher's exact test analog to determine associations at both genotype and 
allele level. The corresponding P values are shown at the bottom of the table.  Statistically significant P 
values are shown in bold. 
Coloured Females (N=306) 
Genotype Total 
 (N=306) 
Controls  
(N=237) 
Adverse 
 (N=69) 
PTL 
(N=27) 
Hypertension 
(N=29) 
G/G 236 (77.1%) 189 (79.7%) 47 (68.1%) 17 (63%) 20 (69%) 
G/A   69 (22.6%)   48 (20.3%) 21 (30.4%)      9 (33.3%)   9 (31%) 
A/A     1 (0.30%) 0 1 (1.5%)    1 (3.7%) 0 
G-allele 0.884 0.899 0.833 0.796 0.845 
A-allele 0.116 0.101 0.167 0.204 0.155 
HWE 0.221 0.222 0.729 0.990 0.613 
Controls vs. Adverse: P=0.033 (genotype) and P=0.035 (allele); Controls vs. Preterm labour: P=0.003 (genotype) 
and P=0.024 (allele); Controls vs. Hypertension: P=0.210 (allele). 
 
Genotype and allele frequencies of the Black individuals are shown in Table 14 and no 
significant association could be demonstrated in the adverse pregnancy group. The distribution 
of GG and GA genotypes differed significantly in Black versus Coloured individuals, 61.7% and 
38.3% versus 77.1% and 22.6%, respectively (P<0.01). 
 
Table 14: Genotype and allele frequencies of the TNFα-308 G/A polymorphism in the Black population. 
Hardy Weinberg Equilibrium (HWE) was determined for each individual group. 
 
Black Females (N=115) 
Genotype Total  
(N=115) 
Controls 
(N=101) 
Adverse 
 (N=14) 
PTL 
(N=6) 
Hypertension 
(N=6) 
GG 71 (61.7%) 64 (63.4%) 7 (50%) 3 (50%) 4 (66.7%) 
GA 44 (38.3%) 37 (36.6%) 7 (50%) 3 (50%) 2 (33.3%) 
AA 0 0 0 0 0 
G-allele 0.809 0.817 0.750 0.750 0.833 
A-allele 0.191 0.183 0.250 0.250 0.167 
HWE 0.004 0.079 0.459 0.717 0.887 
Sample size insufficient to perform association analysis (P<0.05). 
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3.1.2.2. Discussion 
 
In this cohort, maternal carriage of the IL-1RN*2-allele could be associated with adverse 
pregnancy outcome. Upon closer inspection of the genotype distribution in the adverse outcome 
group, the association was restricted to both the preterm labour and particularly in the 
hypertension group. After adjusting for ethnicity, the association was only demonstrated in the 
hypertension group of Coloured individuals. The presence TNFα-308 A-allele was associated 
with overall adverse pregnancy outcome and preterm labour in the Coloured group. 
 
Strengths of the study included the analysis of 421 individuals in two distinct population groups 
for the comparison of allele and genotype distribution at different loci. All the immunological 
variants were detected either by allele-specific or restriction enzyme analysis, with reproducible 
results. Consequently, these results can be applied as a general population reference dataset.   
 
However, as expected in studies like these, the sample size of the different complication 
subgroups becomes restricted; in addition to the inclusion criteria limited to low risk primigravid 
pregnant women.  This study also lacks measured TNFα and IL-1 levels to correlate with the 
genotypes. In relation to patient information, data on “infection” were not available. Another 
limitation was the exclusion of corresponding fetal samples to establish fetal genotype status. 
 
Homozygosity for IL-1RN*2 has been associated with various inflammatory conditions including 
inflammatory bowl disease, alopecia areata, psoriasis, lichen sclerosus, lupus erythematosus, 
vulvar vestibulitis and multiple sclerosis (Witkin et al., 2002). The regulation of both IL-1β and 
IL-1ra production has been associated with IL-1RN genotype, with conflicting results. 
Mononuclear cells positive for the IL-1RN*2 produced higher levels of IL-1β after stimulation in 
vitro. In second trimester amniotic fluid, the amounts of IL-1β and IL-1ra are increased leading 
to an increased IL-1β and IL-1ra ratio in fetal samples containing the IL-1RN*2. In relation to 
maternal carrier status, the vaginal concentration of IL-1ra is elevated with an increase isolation 
rate of Ureaplasma urealyticum. These interpretations are consistent with the results of IL-
1RN*2 and the variety of inflammatory conditions (Witkin et al., 2002 and Nguyen et al., 2004).  
In contrast to these results, two studies had reported that IL-1RN*2 leads to a decrease in 
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production of circulating levels (Rider et al., 2000 and Vamvakopoulos et al., 2002). The 
functional effect of the IL-1RN polymorphism on IL-1β, which is not fully understood, could be 
explained by linkage disequilibrium with another locus in the IL-1 gene complex regulating the 
production of IL-1β (Nguyen et al., 2004).  
 
Similar results were found by Genc et al., who demonstrated a blunted IL-1β response in 
maternal carriage of the IL-1RN*2, with a reduced probability of spontaneous preterm delivery. 
In this study, Genc et al., demonstrated association between preterm labour and IL-1RN*1 (Genc 
et al., 2004a), compared to our current study demonstrating an association with the IL-1RN*2 
and preterm labour. In the Genc study, the association established in the total group could be 
explained by the difference in the carrier and non-carrier frequency in the different ethnicities; 
White (43.7% and 56.3%), Hispanic (44.3% and 55.7%) and Black (10.9% and 89.1%) 
individuals (Genc et al., 2004a). The association with IL-1RN*1 in the total group most likely 
rests on the frequencies in the Black individuals. The common IL-1RN allele appears to be more 
frequent in the Black population, as seen in our study and others (Genc et al., 2002 and Nguyen 
et al., 2004). 
 
The results of our study concurs with the evaluation of the maternal genotype by Murtha et al., 
(cases, N=95) who described an association between preterm birth and the IL-1RN*2 in all 
ethnicities (P=0.0004) and white (P=0.001) individuals (Murtha et al., 2006).  Although the 
association in our study was based on a much smaller sample size, in the case of the Coloured 
cohort, a non-homogenous population, the level of significance supports the observation found 
by Murtha and colleagues. Similar IL-1RN*2 frequencies in the controls vs. preterm labour of the 
black individuals was observed in our study compared to Murtha et al., (0.094 vs. 0.200 versus 
0.097 vs. 0.174). However, the sample size of our Black preterm labour group was too small to 
be analyzed for ethnic-specific differences. 
 
The production of cytokines by the fetal component of the placenta can lead to the initiation of 
myometrial contractions. For that reason, fetal contribution can initiate preterm labour (Witkin et 
al., 2003).  Witkin et al., evaluated the concentrations of IL-1β and IL-1ra in amniotic fluid in 
conjunction with IL-1RN fetal genotypes in white Europeans. A significant association was 
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demonstrated in birth before 37 weeks (P<0.0001) and fetuses carrying the IL-1RN*2, 
illustrating the importance of corresponding fetal samples. Possession of the IL-1RN*1 in 
homozygous state was linked to low levels of each, IL-1β (P=0.0006) and IL-1ra (P=0.01) in 
relation to one or two copies of IL-1RN*2. The increase in the pro-inflammatory response in the 
presence of the IL-1RN fetal genotype demonstrates the relationship of IL-1β mediated preterm 
labour and augments the importance of fetal samples and measured cytokines (Witkin et al., 
2003). However, this association was based on a much smaller patient size (N=7) than our study 
and the collection of fetal DNA was done by amniocentesis, which increases the risk of preterm 
delivery (Medda et al., 2003). As in many other studies, our investigation mainly focused on the 
maternal genotype. 
 
In vitro studies have demonstrated that IL-1ra production during the pre-implantation stage of 
human embryos inhibits implantation into the uterine decidua. Individuals in possession of the 
IL-1RN*2 genotype or with elevated production, may be at a selective disadvantage at the start of 
pregnancy and at increase risk for early-stage pregnancy loss (Witkin et al., 2002). In pre-
eclamptic patients, levels of circulating IL-1ra are noticeably increased, but with no correlation 
to disease severity (Faisel et al., 2003). Pregnancy-related conditions such as pre-eclampsia and 
preterm labour, are thought to mainly originate from abnormalities in (a) implantation, which is 
immunologically regulated (Roberts and Cooper, 2001), and (b) development of the placenta in 
early pregnancy (Norwitz, 2006). The results from our study concur with Faisel et al., who 
demonstrated an association with the IL-1RN*2 and pre-eclampsia in the Finnish population. In 
the setting of their case-control study, comparative analysis did not reach statistical significance. 
Significance was only demonstrated when a control group, representing an existing reference 
database of the general population, was used in the analysis (Faisel et al., 2003).  
 
Another IL-1RN*2 case control association study was reported by Hefler et al., (2001).  Their 
study population was of Hispanic decent (cases, N=59) and the frequency of the IL IL-1RN*2 
was much lower compared to those determined by Nguyen et al., (Hefler et al., 2001 and Nguyen 
et al., 2004). However, IL-1RN*2 was associated with a higher systolic blood pressure (BP) in 
early onset pre-eclampsia. A general problem in association studies is the choice and 
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stratification of controls, which could inevitably create or eradicate an association (Faisel et al., 
2003).  
 
The process leading to preterm labour is brought forward by a combination of different 
pathophysiologic actions, such as intrauterine infection. Preterm labour is often preceded by pro-
inflammatory cytokines secreted by both the fetal and maternal counterparts, in response to 
infection (Makhseed et al., 2003). Previous research focused generally on single nucleotide 
polymorphisms (SNPs) within pro-inflammatory cytokine genes (Annells et al., 2005). The level 
of heterogeneity within genes in the pathway of infectious and inflammatory response 
complicates the search for genetic variants leading to inflammation-related preterm birth (Amory 
et al., 2004). In our study we demonstrated an association with the TNFα -308 G/A 
polymorphism, which concurs with the findings by Moore and colleagues. The investigation by 
Moore et al., was performed in a mixed ethnic group, and subgroup analysis was not performed 
in the different ethnic groups due to inadequate cohort size (Moore et al., 2004). Macones et al., 
demonstrated a similar trend between, TNF2 allele and spontaneous preterm birth. The 
significance by Macones et al., was based on a larger sample size (N=125), compared to Moore 
et al., and our cohort. The Macones study included clinical diagnosis of bacterial vaginosis (BV), 
lacking in our study. The presence of symptomatic BV and TNF2 allele increased the odds of 
developing preterm birth by 6-fold, illustrating the importance of interaction between genetic and 
environmental factors and the etiology of spontaneous preterm birth (Macones et al., 2004). The 
findings of our study contrast with three other studies, which indicated no association with the 
TNF2 allele (Amory et al., 2004, Annells et al., 2004 and Valdez et al., 2004). The statistical 
power of association in our study, compared to investigations by other two larger studies 
showing no association (Menon et al., 2006) should be addressed by further sampling of patients. 
The lack of association with the TNF2 allele in previous studies could be related to the 
possibility that TNFα -308 variant is not functionally significant, or is in linkage disequilibrium 
with other polymorphisms (e.g. lymphotoxin alpha and HLA genes)  (Annells et al., 2005) or 
part of an extended haplotype (Amory et al., 2004). A meta-analysis by Menon et al., suggest 
that maternal possession of the minor allele is not a strong risk factor for preterm birth, and if 
this SNP contributes, it is probably due to other interacting factors including fetal involvement 
(Menon et al., 2006), which was not assessed in our study. 
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In conclusion, the present findings possibly suggest that TNFα -308 and IL-1RN gene variants in 
our population, may confer predisposition to complications such as preterm labour and 
preeclampsia. These results should be treated with caution, as they need validation. The 
maintenance of normal pregnancy is characterised by low levels of TNFα. This cytokine is 
involved in remodeling of the cervix and fetal membranes by stimulating the production of 
MMP-1 and -9. During normal functioning, TNFα stimulates trophoblast differentiation, 
invasion and adhesion, implantation, placental development as well as growth and remodeling of 
fetal membranes. However, a change in circulating levels may activate endocrine function 
inhibition, protease activation and degrading of extracellular matrix. Dysfunctional regulation 
caused by polymorphisms in this gene, may possibly result in pregnancy complications such as 
preterm labour (Crider et al., 2005). IL-1ra functions as a competitive inhibitor of IL-1β, a key 
cytokine modulating the pro-inflammatory cascade (Genc et al., 2004a). The imbalance between 
both IL-1β and IL-1ra has been implicated in the development of infection-related preterm 
labour (Genc et al., 2004b). Conflicting results regarding functional effect, describe previously, 
need to be resolved. Thus, if IL-1RN*2 is associated with decrease circulating levels, then more 
IL-1β will be available, increasing prostaglandin production and subsequently leading to 
myometrial contractions (Genc et al., 2004b). 
 
The association demonstrated in our study, was based on an “admixed population”, which may 
introduce further complexity. Clinicians have to rely on patients self-reporting their ethnicity on 
documentation. The combined effects of these factors increase heterogeneity and complexity 
within the study and probably lessen any association established. 
 
Confirmation of these associations may identify those individuals at risk of specific pregnancy 
complications and help clarify the possible mechanisms of genetic and biochemical pathways 
which lead to these adverse pregnancy outcomes in the South African Coloured population. 
Additionally, establishing a marker profile for women at risk will further assist clinicians to asses 
the problem before any clinical symptoms arise and thereby initiate timeous treatment and 
management to minimise adverse pregnancy and neonatal outcome. 
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3.1.3. LGALS13 variants 
 
A total of ten DNA sequence variants were identified in the screening of the LGALS13 gene, of 
which seven are novel and three are previously-documented polymorphisms (Table 15).  A 
diagram of the LGALS13 gene, with the sequence variants identified, is shown in Appendix 9. 
 
 Table 15: List of novel and previously documented (dbSNP database) sequence variants identified in our 
study.  
 
LGALS13 gene variants Region Amino acid change 
NumberA of 
individuals 
(N=421) 
-98 A/C (rs: 3764843) Promoter - 201 
IVS2-36 G/A (novel) Intron 2 - 31 
IVS2-22 A/G (rs:2233706) Intron 2 - 121 
IVS2-15 G/A (novel) Intron 2 - 8 
130 A→G (novel) Exon 3 M44V 2 
221delT (novel) Exon 3 L74W 14 
Hotspot (novel) Exon 3 T77N, T78L, D79H 30 
260 A→G (novel) Exon 3 K87R 1 
IVS3+72 T/A (rs:2233708) Intron 3 - 120 
351 G→A (novel) Exon 4 P117P 1 
A Number of individuals with heterozygous and / or homozygous variant genotypes. 
 
In this thesis detailed information will be reported on the following three of the identified 
LGALS13 sequence variants: 
 
 IVS2-22 A/G  
 IVS3+72 T/A 
 221delT/L74W (novel) 
 
Information on the remaining loci screened in this study cohort is in Appendix 10. 
 
3.1.3.1. Linkage disequilibrium of the IVS2-22 and IVS3+72 variants 
 
Conformational variants were detected by Multiphor SSCP/HD analysis (Figure 12a and 14a). 
These variants were further characterised by automated sequencing (Figure 12b and 14b), 
followed by restriction enzyme analysis for confirmation (Figure 13 and 15).  
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The IVS2-22 locus falls within a cluster of sequence variants identified within close proximity to 
the exon 5' 3' boundary (Figure 11). 
 
Exon 3 (211bp)
  IVS2-36   IVS2-22    IVS2-15                                                                  IVS3+72 
Amplicon 3.1 
Amplicon 3.2  
 
  
5' 3' 
 
Figure 11: Illustration of the cluster of variants identified in the 5' flanking region of exon three. 
Amplification of exon three was performed separately (two amplicons) to keep fragment size under 300bp 
for effective SSCP/HD analysis. 
 
The different multiphor conformations shown in Figure 12a reflect the status of the three 
polymorphic loci upstream of exon three. 
 
(a)  
Conformations 
 
    1          2         3         4         5        6 Conformation IVS2-15 G/A IVS2-22 A/G IVS2-36 G/A
1 G/G A/A G/A
2 G/A A/A G/G
3 G/G A/G G/A
4 G/G G/G G/G
5 G/G A/G G/G
6 G/G A/A G/GA/A    A/A    A/G    G/G    A/G  A/A 
 
IVS2-22 A/G genotypes 
 
 
-36 -22  -15 (WT) 
Figure 12: (a) Multiphor SSCP/HD gel illustrating the different conformations of the IVS2-22A/G 
variant detected in only the SSCP component of the gel. The different conformations observed for the 
IVS2-22 locus are due to the additional variants identified within the same genomic amplicon (b) 
Electropherogram depicting the individual genotypes within the exon 3.1 genomic amplicon. 
Heterozygous status is shown at loci IVS2-36 and IVS2-22, and homozygous status for variant IVS2-15.  
Sequence is shown in the forward (5'→3') orientation. 
(b) 
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 1 2 3 4
 
213bp 
 
111bp 
102bp 
 
Figure 13: Agarose gel (3.5%) demonstrating the three genotypes of the IVS2-22 A/G variant, detected 
by restriction enzyme analysis with AciI (37˚C). Lane 1 represents a 100 bp ladder (Fermentas). Lane 2 
represents the A/A genotype at 213bp, Lane 3 the heterozygous genotype (A/G) and Lane 4 
corresponding to the homozygous G/G genotype at 102 and 111bp.
 
 (a)  
 A/A    T/T     T/A 
(b) 
 
Figure 14: (a) Three conformational banding patterns for the IVS3+72T/A variant detected by Multiphor 
SSCP/HD analysis and (b) the corresponding electropherogram demonstrating the heterozygous form of 
the variant (arrowed) sequenced in the forward (5'→3') orientation. 
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 265bp 
246bp 
 
Figure 15: Agarose gel (2%) demonstrating the different genotypes of the IVS2+72 T/A variant, detected 
by restriction enzyme analysis with StuI (37˚C). Lane 1 is a 100 bp ladder (Fermentas). Lanes 2 and 3 
corresponding to the T/T genotype at 265bp, Lanes 4-6 the heterozygous genotype (T/A) and Lane 7 
representing the homozygous A/A genotype at 246bp.
 
Tables 16 and 17 summarise the genotype and allele frequencies of two previously documented 
intronic IVS2-22A/G (dbSNP: rs 2233706) and IVS3+72T/A (dbSNP: rs 2233708) variants 
identified in the total cohort. No significant difference was demonstrated in the different 
subgroups compared to controls. 
 
Table 16: Observed genotype and allele frequencies at the IVS2-22 A/G locus in total cohort. Hardy 
Weinberg Equilibrium (HWE) was determined for each individual group. Statistical analysis was 
performed using Fisher's exact test analog to determine associations at both genotype and allele level. The 
corresponding P values are shown at the bottom of the table.   
 
Total Cohort (N=421) 
Genotype Total  
(N=421) 
Controls  
(N=338) 
Adverse   
(N=83) 
PTL 
(N=33) 
Hypertension 
(N=35) 
A/A 300 (71.4%) 233 (68.9%) 67 (80.7%) 28 (84.8%) 26 (74.3%) 
A/G 111 (26.4%)  97 (28.7%) 14 (16.9%)   4 (12.2%)   8 (22.9%) 
G/G 10 (2.4%)  8 (2.4%) 2 (2.4%)     1 (3%) 1 (2.8%) 
A-allele 0.844 0.833 0.892 0.909 0.857 
G-allele 0.156 0.167 0.108 0.091 0.143 
HWE 0.997 0.853 0.509 0.309 0.925 
Controls vs. Adverse: P=0.089 (genotype) and P=0.061 (allele); Controls vs. Preterm labour: P=0.124 (genotype) 
and P=0.107 (allele); Controls vs. Hypertension: P=0.761 (genotype) and P=0.602 (allele). 
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Table 17:  Observed genotype and allele frequencies at the IVS3+72 T/A locus in total cohort. Hardy 
Weinberg Equilibrium (HWE) was determined for each individual group. Statistical analysis was 
performed using Fisher's exact test analog to determine associations at both genotype and allele level. The 
corresponding P values are shown at the bottom of the table.   
 
Total Cohort (N=421) 
Genotype Total  
(N=421) 
Controls 
(N=338) 
Adverse   
 (N=83) 
PTL 
(N=33) 
Hypertension 
(N=35) 
TT 300 (71.3%) 234 (69.2%) 66 (79.5%) 26 (78.8%) 26 (74.3%) 
TA 113 (26.8%)     98 (29%) 15 (18.7%)  6 (18.2%)  8 (22.8%) 
AA   8 (1.9%)   6 (1.8%) 2 (2.4%)      1 (3%) 1 (2.9%) 
T-allele 0.848 0.837 0.886 0.879 0.857 
A-allele 0.152 0.163 0.114 0.121 0.143 
HWE 0.827 0.499 0.614 0.702 0.925 
Controls vs. Adverse: P=0.129 (genotype) and P=0.122 (allele); Controls vs. Preterm labour: P=0.387 (genotype) 
and P=0.379 (allele); Controls vs. Hypertension: P=0.693 (genotype) and P=0.667 (allele). 
 
A total of 478 typings were performed.  Almost identical typing was scored in most cases, 
suggesting the possibility of linkage disequilibrium. The IVS2-22A/G and IVS3+72T/A are 
located 305bp apart, on either side of exon three. In 97.1% of typings, IVS2-22 A/A, A/G and 
G/G genotypes corresponded to IVS3+72T/A genotypes T/T, T/A and A/A, respectively. 
 
The frequencies of observed A-T, A-A, G-A and G-T haplotypes were 84.4%, 0.5%, 14.1% and 
0.9%, respectively. The measure of linkage disequilibrium between the two observed loci was 
0.96, measured as D', with r2>0.8 and a maximum LOD score >3 (Table 18). These findings 
provide genetic (and possibly evolutionary) evidence for the significance of the region 
encompassed by these two loci. 
 
Table 18: Linkage disequilibrium parameters determined at the IVS2-22A/G and IVS3+72T/A loci. 
 
Locus 1 Locus 2 D' LOD r2 P 
IVS-22A/G IVS+72T/A 0.958 109.88 0.887 0.000 
 
3.1.3.2. 221delT 
 
A novel sequence variant was identified in the coding region of LGALS13 exon three, apparent in 
both the SSCP and HD component of the gel and characterised by subsequent automated 
sequencing (Figure 16a&b).  
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   delT 
(a) 
(b)  
Figure 16: (a) Multiphor SSCP/HD conformation demonstrating the heterozygous form of the 221delT, 
detected in both the SSCP and HD component of the gel. (b) The corresponding electropherogram 
demonstrating the heterozygous form (arrowed) of the single base deletion sequenced in the forward 
(5'→3') orientation.  Note the doubling in sequence after the deletion site. 
 
The polymorphism causes a deletion of a single thymine base at nucleotide position 221, 
resulting in (i) an alternative stop codon and consequently, a shortened protein by 38 amino acids 
and (ii) an alternative COOH terminal by 28 amino acids (Figure 17). 
 
                      10        20        30        40        50        60 
           ....|....|....|....|....|....|....|....|....|....|....|....|
LGALS13wt    MSSLPVPYKLPVSLSVGSCVIIKGTPIHSFINDPQLQVDFYTDMDEDSDIAFRFRVHFGN 
   
LGALS13delT  MSSLPVPYKLPVSLSVGSCVIIKGTPIHSFINDPQLQVDFYTDMDEDSDIAFRFRVHFGN 
   
 
 
 
             61       70        80        90       100        110       120 
             ....|....|....|....|....|....|....|....|....|....|....|....| 
LGALS13wt    HVVMNRREFGIWMLEETTDYVPFEDGKQFELCIYVHYNEYEIKVNGIRIYGFVHRIPPSF 
LGALS13delT  HVVMNRREFGIWMWRRQQTTCPLRMANNLSCASTYITMSMR*                   
Cys 19 
 
Cys 92 
Tyr 41 Ser 48 
Tyr 80 
  
 Trp 72  
 
             121      130       140    
             ....|....|....|....| 
LGALS13wt    VKMVQVSRDISLTSVCVCN*  
LGALS13delT                        Cys 136  Cys 138  
 
Figure 17: Sequence alignment of the wildtype and predicted 221delT (L74W) PP13 protein isoforms. 
Cysteine residues (shown in red) are involved in dimerisation via disulphide bonds and the serine and 
tyrosine residues (shown in blue) are located on the outer surface of PP13 molecule and contribute to 
phosphorylation (Than et al., 2004). 
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The 221delT genotypes were in Hardy Weinberg equilibrium (Table 19). There were no 
individuals’ homozygous (delT/delT) for the variant.  Adverse pregnancy outcome (P=0.028) 
and preterm labour (P=0.031) compared to controls differed significantly in the analysis of the 
total cohort. Carriers of the 221delT were more common in the adverse outcome group than in 
controls, with a relative risk of 2.27 (95% CI 1.20-4.29, P=0.027) and an odds of 3.27 (95% CI 
1.18-9.11, P=0.030) developing preterm labour. No association was demonstrated in the overall 
hypertension group, but the delT/- genotype frequency was higher than controls, 5.7% vs. 2.4%, 
respectively. 
 
Table 19: Genotype and allele frequencies of the 221delT variant determined in the total cohort. Hardy 
Weinberg Equilibrium (HWE) was determined for each individual group. Statistical analysis was 
performed using Fisher's exact test analog to determine associations at both genotype and allele level. The 
corresponding P values are shown at the bottom of the table.  Statistically significant P values are shown 
in bold. 
 
Total Cohort (N=421) 
Genotype Total 
 (N=421) 
Controls 
(N=338) 
Adverse   
 (N=83) 
PTL 
(N=33) 
Hypertension 
(N=35) 
- / - 407 (96.7%) 330 (97.6%) 77 (92.8%) 30 (90.9%) 33 (94.3%) 
-/del 14 (3.3%)  8 (2.4%) 6 (7.2%) 3 (9.1%) 2 (5.7%) 
del/del 0 0 0 0 0 
- allele 0.983 0.988 0.964 0.955 0.971 
del allele 0.017 0.012 0.036 0.045 0.029 
HWE 0.942 0.976 0.943 0.963 0.985 
Controls vs. Adverse: P=0.028 (allele); Controls vs. Preterm labour: P=0.031 (allele); Controls vs. Hypertension: 
P=0.246 (allele). 
 
Table 20 is a summary of the allele and genotype frequencies determined for 221delT in the 
Coloured population.  The genotypes did not deviate from Hardy Weinberg equilibrium.  The 
heterozygous status frequency in the adverse outcome group was much higher than in controls, 
7.2% vs. 1.7%, respectively and demonstrated a statistically significant difference (P=0.017) 
with a 2-fold risk of developing an adverse pregnancy outcome (RR 2.58 95% CI 1.38-4.81, 
P=0.0163). No significant association was demonstrated in either the preterm labour or 
hypertension groups; however the frequency of the heterozygous status genotype was 7.4% and 
6.9%, respectively, compared to healthy controls.  This lack of association may of course reflect 
the difference in sample size between the control (N=237) and sub-grouped PTL (N=27) and 
Hypertension (N=29) groups. 
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Table 20: Genotype and allele frequencies of the 221delT variant in the Coloured population. Hardy 
Weinberg Equilibrium (HWE) was determined for each individual group. Statistical analysis was 
performed using Fisher's exact test analog to determine associations at both genotype and allele level. The 
corresponding P values are shown at the bottom of the table.  Statistically significant P values are shown 
in bold. 
 
Coloured Females (N=306) 
Genotype Total 
 (N=306) 
Controls 
(N=237) 
Adverse   
 (N=69) 
PTL 
(N=27) 
Hypertension 
(N=29) 
- / - 297 (97.1%) 233 (98.3%) 64 (92.8%) 25 (92.6%) 27 (93.1%) 
-/del   9 (2.9%)   4 (1.7%) 5 (7.2%) 2 (7.4%) 2 (6.9%) 
del/del 0 0 0 0 0 
- allele 0.985 0.992 0.964 0.963 0.966 
del allele 0.015 0.008 0.036 0.037 0.034 
HWE 0.966 0.992 0.952 0.9802 0.982 
Controls vs. Adverse: P=0.017 (allele); Controls vs. Preterm labour: P=0.060 (allele); Controls vs. Hypertension: 
P=0.076 (allele). 
 
Genotype and allele frequencies in the Black participants are shown in Table 21 and no 
significant association could be demonstrated, possibly due to the cohort being much healthier 
with fewer pregnancy complications.  
 
Table 21: Genotype and allele frequencies of the 221delT variant in the Black population. Hardy 
Weinberg Equilibrium (HWE) was determined for each individual group. 
 
Black Females (N=115) 
Genotype Total  
(N=115) 
Controls 
(N=101) 
Adverse   
(N=14) 
PTL 
(N=6) 
Hypertension 
(N=6) 
- / - 110 (95.7%) 97 (96%) 13 (92.9%) 5 (83.3%) 6 (100%) 
-/del   5 (4.3%) 4 (4%) 1 (7.1%) 1 (16.7%) 0 
del/del 0 0 0 0 0 
- allele 0.978 0.980 0.964 0.917 1.000 
del allele 0.022 0.020 0.036 0.083 0.000 
HWE 0.972 0.979 0.990 0.976 - 
Sample size insufficient to perform association analysis (P<0.05). 
 
3.1.3.3. Discussion 
 
In the analysis of our data, a novel exonic variant, 221delT, was found to be associated with 
adverse pregnancy outcome and preterm labour in the total cohort and subsequently, restricted to 
the adverse pregnancy outcome in Coloured women. Although an association was demonstrated, 
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the variant was only identified in eight of 338 individuals (2.4%) in the controls and six of 83 
(7.2%) women in the adverse pregnancy outcome group.  
 
As previously mentioned, the primary strength of our study was the screening of a large cohort 
(N=421). Patients were recruited from a single institution, Paarl hospital, and diagnosed by a 
single clinician. This study is the first to report on the genetic screening of the LGALS13 gene. 
One limitation of our study includes the lack of corresponding PP13 levels measured during the 
course of the pregnancy.  This would facilitate our understanding of whether certain variants 
may (i) be linked to an altered protein level and to (ii) confirm the feasibility of PP13 as an early 
biomarker for pregnancy-related complications (Than et al., 2005). The genomic regions 
encompassing the promoter and intronic sequences (by gene annotation) are thought to contain 
six SNPs, of which only three were identified in this study. The variants not identified in our 
study were relatively rare, with the exception of a single intronic variant found commonly in the 
European population (NCBI). The use of the Multiphor SSCP-HD mutation screening procedure 
utilised in our study has a reported sensitivity of up to 97% (Liechti-Gallati et al. 1999). The 
conventional use as SSCP-HD technique as the sole method for mutation screening could 
possibly have failed to detect variants due to its limited sensitivity. Furthermore, unidentified 
variants residing further upstream within the promoter and regulatory regions of gene, which 
have not yet been screened, could inevitably influence transcriptional efficiency of this gene.  
Consequently, all 5' and 3' regulatory regions should be included in future screening approaches. 
 
The novel coding variant identified in exon three of the LGALS13 gene represents a deletion of a 
single thymine base at nucleotide position 221, resulting in the substitution of a leucine (L) with 
an tryptophan (W) residue at amino acid position 74. The result is a disruption of the open 
reading frame (ORF) leading to the production of an altered and truncated protein. The 
truncation removes 37 amino acids corresponding to LGALS13 exon three, which is regarded as 
vital for its function (Sammar et al., 2006).  
 
The 221delT also removes Cys136 and Cys138 residues, important for sugar binding and 
dimerisation. Than et al., postulated if PP13 dimerises as galectin-1 and galectin-2 do, then the 
Cys136 residue may participate in dimerisation, whereas if PP13 dimerises more like galectin-7, 
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then dimerisation may involve Cys19, Cys92 and Cys136. The data described by Than et al., is not 
enough to establish the precise mechanism of dimerisation (Than et al., 2004a). The feature of 
dimerisation of disulphide bonds via cysteine residues may contribute to a change in oxygenation 
in the placenta (Than et al., 2004b). Interestingly, no homozygous variant genotypes were 
detected in the course of the study (involving >478 typings), possibly suggesting that delT 
homozygosity is incompatible with life. Further studies are required to elucidate the role of this 
frameshift mutation, by measuring the levels of PP13 in pregnancy of those individuals 
harbouring this mutation to determine whether it impacts on circulating PP13 levels. The delT 
homozygosity issue could be addressed by typing products of conception which can be collected 
following missed abortions (usually first trimester).  The presence of delT homozygosity in such 
tissue would provide evidence for the severe impact of this variant on pregnancy maintenance 
and outcome. 
 
It was interesting to identify a variant such as the delT, in a region that demonstrates (i) 
functional significance i.e., the exon three region encodes the carbohydrate recognition domain 
(CRD) of PP13 and, (ii) linkage disequilibrium, which signifies evolutionary conservation.  This 
in itself may provide ‘circumstantial’ evidence of the potential negative impact of the delT 
variant. 
 
Additional novel exonic variants identified include two non-synonymous variants in exon three 
(M44V, N=2 and K87R, N=1) and a silent mutation in exon four (P117P, N=1), all identified 
within individuals from the control cohort. In addition to that, Multiphor SSCP/HD analysis 
revealed an 11bp exonic region within which six bases are polymorphic (consequently, denoted 
as the ‘hotspot’). Translation of the genomic region with substitutions of the ‘hotspot’ using 
BioEdit Sequence Alignment Editor (Isis Pharmaceutical, Carlsbad, California, USA), revealed 
three amino acids changes: T77N, T78L and D79H. No significant difference was observed in 
the genotype and allele frequencies in the control vs. adverse pregnancy outcome subgroups. The 
observed genotype frequency of the ‘hotspot’ in the combined Black and Coloured control group 
was 7.7% vs. 4.8% in the adverse outcome group. Although no association was demonstrated, 
the ‘hotspot’ appears to be more prevalent in healthy individuals, which could possibly underlie 
a protective effect.  
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 SNPs occurring in the coding region of a gene resulting in amino acid substitutions may alter 
structure, function, receptor interaction and / or catalytic properties of a given protein. These 
mutations can also result in disruption of the open reading frame (ORF) causing aberrant 
translation that may lead to the production of short, very long or dysfunctional amino acid 
protein sequences (Orsi et al., 2007). According to SIFT (Sorting Intolerant From Tolerant, 
http://blocks.fhcrc.org/sift/SIFT.html) analysis on the above-mention exonic variants, all amino 
acid changes were tolerated and were predicted to not affect protein function. However, some 
mutations in the protein coding regions may inactivate an exonic splicing enhancer (ESE), 
resulting in an exon being skipped and consequently, having a dramatic effect on the protein 
product (Cartegni et al., 2003). All exonic variants examined by ESEfinder 
(http://rulai.cshl.edu/tools/ESE2/) were predicted to affect splicing by generating and / or 
eliminating putative ESE motifs. The M44V mutation abolished a SRp40 ESE motif, while the 
K87R and P117P mutations created new ESE motifs for the SF2/ASF protein, including an 
additional motif for the SRp40 protein created by the P117P mutation. ESE predictions for the 
mutated ‘hotspot’ sequence, removed two SF2/ASF, two SRp40, and a SRp55 motif, while 
creating a novel SRp40 motif. Confirmations of these predictions can be sought by testing the 
splicing capacity of the wildtype and variant sequences, using minigene constructs (Cooper, 
2005).  
 
Several intronic variants identified include a cluster of three variants in the 5' flanking region of 
exon 3 (IVS2-36 G/A (novel), IVS2-22 A/G and IVS2-15 G/A (novel)) and 1 in the 3' region 
(IVS3+72 T/A). Intronic variants may effect protein structure and function by (1) affecting 
transcription, (2) altering splicing or (3) impacting on the stability of mRNA and the relative 
amount and magnitude of isoforms that can possibly be pathogenic leading to physiological 
outcomes (Harrison and Weinberger, 2005). ASSP (Alternative Splice Site Predictor, 
http://es.embnet.org/~mwang/assp.html) analysis revealed that the cluster of variants identified 
in intron 2 did not appear to alter predictive splice sites. However, analysis of the IVS3+72 T/A 
showed that the acceptor site of the wildtype (T-allele) is abolished and a new site is created with 
the substitution of an A-allele, much earlier in the sequence. When a mutation abolishes a natural 
occurring splice site, the mechanism employed by the spliceosome selects the next best splice 
site in close proximity (Krawczak et al., 2007). Whether or not these intronic variants affect 
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splicing, should be addressed by comparing wildtype and variant mRNA transcripts using a 
minigene assay (Baralle et al., 2003). 
 
An additional variant identified in the 5' promoter region of the LGALS13 gene is the -98 A/C 
variant [dbSNP: rs 3764843]. No association was demonstrated in the different subgroups. 
Although, subdivision of late-onset pre-eclamptic individuals (>37 weeks of gestation), revealed 
that there was a significant difference in the distribution of genotypes between controls and late 
onset pre-eclampsia, in both the total cohort (N=24, P=0.019) and Coloured individuals (N=19, 
P=0.038). However, these genotypes did not segregate under the assumptions of Hardy 
Weinberg equilibrium. Recruitment of additional late onset pre-eclamptic individuals are 
required to establish if there is a link between developing late onset pre-eclampsia and carriage 
of the -98 A-allele. Analysis using the Luciferase Reporter Assay is in progress to determine the 
effect of the -98 variant allele on promoter activity and gene expression. Furthermore, analysis 
should be extended to include screening sequences further upstream of exon one, to identify 
additional variants that may impact on transcriptional activity and gene regulation.  
 
Most studies have relied on genetic susceptibility as the underlying cause of preterm labour. 
Studies focusing on the true genetic contribution to pregnancy complications are problematic, as 
these complex conditions involve multiple genes, non-Mendelian transmission, gene-
environment and gene-gene interactions. The most frequently investigated genetic markers 
include point mutations in both the coding and non-coding regions (Orsi et al., 2007). These 
alterations or SNPs may help identify candidate genes or pinpoint regions that may have an 
important role in the etiology of preterm birth (Esplin, 2006). Candidate genes considered to 
influence susceptibility, with possible biological importance in pathogenesis, are of particular 
interest (Genc and Schantz-Dunn, 2007). 
 
The most sensitive and accurate technique for mutation screening is direct sequencing. However, 
DNA sequencing applied to gene of interest is expensive, time-consuming and technically 
demanding (Gross et al., 1999). This study utilized Multiphor SSCP/HD mutation screening of 
promoter and intronic regions encompassing exonic sequences. This method has a reported 
sensitivity of 97.5% combining SSCP and HD analysis for increased detection. The method 
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described by Liechti-Gallati et al., extended the limitations of amplicons of up to 500-600bp in 
size, compared to conventional SSCP fragments sizes of ~300bp. The conformational structures 
of a given mutation are very sensitive to environmental influences such as (a) temperature, (b) 
gel composition, (c) ionic strength, and (d) additives. The parameters optimized in our study 
included resolving gels at varied temperatures (4-11°C) and keeping amplicon sizes under 
300bp. The use of Multiphor SSCP/HD analysis in our study was found to be effective and fast. 
 
An alternative method for mutation screening is Denaturing High Performance Liquid 
Chromatography (DHPLC). In a comparative analysis of SSCP vs. DHPLC, it was found that 
DHPLC was superior, with a detection rate of 92-100% (Rickard et al., 2001), with screening of 
fragment lengths up to ~1500bp (O’Donovan et al., 1998). Several advantages of DHPLC over 
conventional gel-based mutation techniques are that it is undemanding, with consistent results 
(Rickard et al., 2001), as well as simple evaluation of DHPLC results discriminating between 
single and multiple peaks (Gross et al., 1999) rather than assigning and grouping conformational 
patterns. One drawback is the purchase of a DHPLC apparatus, requiring low running costs and 
reducing sequencing preparations and reactions, making this technique more appropriate for 
mutation screening (Gross et al., 1999). 
 
Investigation of PP13 in pregnancy pathologies has led to the identification of abnormal levels in 
various complications including pre-eclampsia, preterm delivery and IUGR, which contribute 
significantly to neonatal and maternal morbidity (Burger et al., 2004). It has been proposed that 
the PP13 molecule undergoes different cellular and molecular processing in pregnancies 
subsequently affected by pre-eclampsia, preterm delivery, HELLP syndrome (hemolysis, 
elevated liver enzymes and low platelets) and PIH (Sammar et al., 2005). The identification of 
biomarkers to predict and stratify maternal risk leading to adverse pregnancy outcome needs to 
be addressed by improving clinical trials for future research (Chafetz et al., 2007).  
 
A variety of proteins and hormones has been studied as promising candidate markers for 
pregnancy outcome. These include uterine artery ultrasonography and maternal serum/urinary 
levels of human chorionic gonadotrophin (β-hCG), inhibin A, activin A, pregnancy-associated 
plasma protein A (PAPP-A), sex hormone-binding globulin, placental growth factor and soluble 
 76
fms-like tyrosine kinase 1. Nevertheless, early screening of various pregnancy complications is 
insufficient and disappointing at most, because these marker levels become elevated only in the 
second trimester, when clinical symptoms of the given disease have already manifested (Chafetz 
et al., 2007). 
 
Burger et al., evaluated the use of PP13 as an initial biomarker for detecting various pregnancy 
complications by using a sensitive and reliable enzyme-linked immunosorbent assay (ELISA) 
test, with promising results (Burger et al., 2004). The use of this technique, being simple and 
non-invasive, can be routinely integrated into the clinical setting by measuring circulating levels 
at first booking and thereby predict via algorithms, those women at risk of developing adverse 
pregnancy outcomes (Chafetz et al., 2007). 
 
Secretion of PP13 into maternal serum is regulated by specific binding of annexin II and β/γ 
actin (Than et al., 2004a). The binding of annexin II facilitates the formation of a so-called 
“molecular bridge” functioning at the endometrium at the time of implantation, while β/γ actin is 
involved in migration of trophoblasts to the placental interface (Chafetz et al., 2007). The 
alteration of PP13 levels could therefore be attributed to (i) dysfunctional synthesis or (ii) 
transport or (iii) impaired primary structure (Burger et al., 2004).  
 
Therefore, future studies should include mutation screening of annexin II and β/γ actin-encoding 
genes for potential genetic variants that may influence the transport and binding of microvesicles 
responsible for the release of PP13 into maternal circulation. Whether genetic variants in the 
annexin II and β/γ actin encoding genes alter their circulating protein levels that can either 
increase or decrease the binding of PP13 within the placenta, also needs to be addressed. 
Although the role of PP13 in pregnancy pathologies is not fully understood, research provides a 
functional basis that this molecule is involved in various biochemical and physiological 
processes associated with implantation, blood pressure regulation and tissue oxygenation (Burger 
et al., 2004). 
 
In conclusion, we performed mutation detection in the LGALS13 gene of South African women 
with preterm labour and various other pregnancy complications. We identified three known and 
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seven novel genetic sequence variants, which will contribute to the NCBI genetic dataset, and 
our knowledge of PP13 as a potential biomarker for pregnancy complications. 
 
3.1.4. Genotype: phenotype interaction    
 
Significant association was demonstrated with three polymorphisms and gestation <37 weeks, 
and one variant with birth weight <2000g. The IL-10 -1082 A/G was significantly associated 
with adverse pregnancy outcome in the total cohort at both genotype and allele level, P=0.028 
and P=0.008, respectively. The distribution of genotypes in the controls (≥37 weeks) was 53% 
(A/A), 39.7% (A/G) and 7.3% (G/G) compared to 75.8% (A/A) and 24.2% (A/G) in the adverse 
outcome group of the total cohort. After adjusting for ethnicity, association held in the Coloured 
group at allele level (P=0.035). The sample group for Blacks was N=6, with all individuals being 
homozygous for the A-allele. The homozygous (G/G) variant genotype was restricted to controls. 
Furthermore, the IL-10 -1082 A/G variant was associated (P=0.05) with a low birth weight 
(<2000g) in the Coloured group, with genotype frequency distributions of 67.9% (A/A) and 
32.1% (A/G) versus 50.4% (A/A), 42.6% (A/G) and 7% (G/G) in controls (≥2000g). 
 
The coding variant, 221delT of the LGALS13 gene, was association with lower gestation in both 
the total cohort (P=0.048) and Coloured patients (P=0.006). Additionally, the IL-4 -590C/T 
locus differed significantly (P=0.035) in the dominant model (heterozygous C/T and 
homozygous variant T/T versus homozygous wildtype C/C) between gestation <37 weeks and 
the total cohort.  
 
Information presented and the remaining loci screened in this study for genotype-phenotype 
interactions are in Appendix 11. 
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4. Concluding remarks 
 
In the assessment of immunological gene variants, we found an association between the IL-1RN 
86 bp repeat, the TNFα -308 G/A polymorphism and pregnancy complications. Additional 
screening of the LGALS13 gene revealed an association with 221delT/L74W. The question 
however, remains as to whether identifying these in early pregnancy would make a difference in 
pregnancy outcome. 
 
Firstly, most patients ‘book late’ (first trimester) at obstetrics clinics.  Many of them are in the 
second or third trimester of pregnancy and have already started developing symptoms of 
complications; their fetuses are growth restricted, etc.  The identification of a specific genotype 
that places the woman in a “high-risk” category of pregnancy complication in these cases has 
very little value.   In addition, while late booking may not impact on genotyping i.e. genotypes 
are invariant and not influenced by the pregnancy state; it does influence the issues of clinical 
management and intervention. Critical decisions regarding fetal management (e.g., administering 
corticosteroids for lung maturation) often rest on accurate gestational dates.  These can be 
determined accurately by early (first trimester) ultrasonography.  In addition, early 
ultrasonography can facilitate the early detection of fetal anomalies – mild and severe. 
 
A recommendation would be to educate women to register at obstetrics units or with their care-
givers early in pregnancy. During this time, clinicians or nurses can inform the patient of the 
following: 
 
1. Possible tests, which include, among others, 
a. Ultrasonography to establish gestation, exclude multiple and abnormal 
pregnancies 
b. Amniocentesis for advanced maternal age 
2. The effect of possible tetratogens 
a. Such as alcohol, smoking and drug abuse. 
3. Managing maternal disease during pregnancy 
a. Such as hypertension, diabetes and epilepsy, etc. 
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4. Self-monitoring of their pregnancy 
      a.    Women identified as “high-risk cases” could be provided with detailed 
information about the relevant condition so that they can look out for symptoms; some which 
they could manage themselves (e.g., bed-rest), and others, which would require immediate 
hospitalisation. 
 
The feasibility of offering an effective genetic screening test to pregnant women should also be 
considered.  Such a test would involve patient recruitment and counseling, DNA extraction, PCR 
amplification, REA and / or gel electrophoresis, together with manual labour cost and specialised 
equipment.  It is likely to be quite costly, especially if every pregnant woman were to be 
screened. However, since primigravid status appeared to be a major risk factor for complications 
in our study, such a test could be implemented and provisionally limited to young, primgravid 
women.  
 
The current advances in technology could contribute to the development of a hybridisation ‘strip’ 
or “personalised” chip including variants such as IL-1RN, TNFα –308 and 221delT, in an attempt 
to reduce screening costs. However, before this can be realised, the ‘provisional’ data presented 
in this thesis needs to be confirmed or refuted in a larger cohort. It is recommended that the 
project be continued, but with the following inclusions: 
 
1. Measurement of levels of ILs, TNFα and PP13 by ELISA (maternal and fetal ) 
2. Cord blood (for fetal DNA and RNA, serum and plasma) 
3. Infection ‘profile’ (maternal) 
 
Regarding the size of this proposed extended study: we should aim to increase the population 
cohort (especially Black women) and design the study based on: 
 
1. Genetic power calculations 
a. At 80% power with 5% significance. 
2. Population stratification 
a. By matching patients to controls 
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b. Appropriate statistical methods to account for population structure 
 
This is important because these two population groups are very distinct at a genomic level due to 
ethnic specific distribution of genotype and allele frequencies. Thus, markers demonstrating an 
association in one population may not be representative in another.  
 
Another aspect to address in this study is the apparent healthier pregnancy status of Black 
women. The Paarl Hospital, obstetric unit, initially served largely Coloured individuals, but 
recently more Black women have started to use this facility. The observation in our study that 
Black women showed a relatively good pregnancy outcome is interesting. Why is this? 
 
The overall incidence of adverse pregnancy outcome observed in this study is largely attributed 
to by the Coloured population, which raises questions as to why. Is this trend due to pure 
environmental and cultural factors i.e. alcohol, smoking and diet or is there an underlying genetic 
component together with a changing environment?   
 
The observations that preterm labour and pre-eclampsia in Coloured women are the prevailing 
complications at Paarl Hospital will help determine whether the necessary facilities are in place 
to deal with these complications. The findings of our study will be reported back to Paarl 
Hospital as well as the Department of Health for comparison with previous statistics, to 
determine if there was an incline or decline in pregnancy complications and to establish if the 
current hospital care needs to be upgraded. The epidemiological information from this study 
should be made available to patients via clinicians or nurses, to inform them about possible risk 
factors, so that these women can adjust their lifestyle (and thereby improve their health and that 
of their baby). 
 
The complexity of preterm labour involves the relationship between multiple etiologies and risk 
factors. Epidemiological studies should implement a multidisciplinary approach combining 
sociology and genetics to understand the complex nature of pregnancy pathologies. Approaches 
which involve the evaluation of single or limited candidate markers should be restricted since it 
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is unlikely that single a gene variant or risk factor underlies the development of preterm labour 
(Esplin, 2006).  
 
Screening of multiple candidate markers with appropriate statistical methods to evaluate the 
underlying gene-gene and gene-environmental interactions holds great promise with increased 
power to detect the biological effects related to preterm labour and other pregnancy conditions. 
The investigation of multiple genes will help determine an underlying common pathway or 
function that may contribute to the development of preterm labour. PP13 for example interacts 
with annexin II and β/γ actin (Than et al., 2004a) - future investigations should include mutation 
screening and full characterisation of annexin II and β/γ actin. Recent research has identified a 
common promoter haplotype in the annexin A5 gene, which is similar to annexin II. It has been 
demonstrated that the annexin A5 haplotype impacts negatively on recurrent pregnancy loss 
(Bogdanova et al., 2007). Future investigations could include screening of this annexin A5 
haplotype in other pregnancy complications such as preterm labour and pre-eclampsia. 
 
An aspect not covered effectively in this project is the presence of infection. Evidence suggests 
that infection during pregnancy in the 1ste and 2nd trimester is commonly associated with fetal 
loss, chorioamnionitis, preterm labour, PPROM, prematurity, LBW infants and 
neonatal/maternal infectious morbidity (Genc and Schantz-Dunn, 2007). Future studies are 
warranted in our population to investigate the infectious status of women.  This could be 
incorporated into the routine screenings during clinical visits. Maternal inflammatory response to 
microbial agents is said to influence most cases of preterm birth and future analysis should focus 
on the evaluating the influences of gene-environment interaction (Genc and Schantz-Dunn, 
2007). 
  
The hope of incorporating genetic marker(s) in routine screening depends on the careful design 
of future studies.  In addition to strengthening our understanding of the pathophysiology 
underlying pregnancy complications such as preterm labour, much of this knowledge could be 
used to identify and develop effective treatment strategies and lead to a reduction in maternal and 
fetal morbidity and mortality. 
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6. Appendices 
Appendix 1: Ethical and Institutional consent 
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Appendix 2: Patient consent form 
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Appendix 3: Informed consent for DNA analysis and storage 
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Appendix 4: DNA extraction method  
 
Extraction buffers and chemicals used: 
 
 Nuclear Lysis Buffer (1L, pH 8.2 set with 1M NaOH, store at 4°C) 
  1.211g  Tris-Cl  0.01M 
 23.4g  NaCl  0.4M 
 0.6g  EDTA  0.002M 
 
 Cell Lysis Buffer (1L, pH 7.4 set with concentrated HCl, store at 4°C) 
   8.3g  NH4Cl  0.155M 
   1.1g  KHCO3 0.01M 
   0.03g  EDTA  0.0001M 
  
 Phosphate Buffered Saline (PBS) (1L, store at 4°C) 
   2g   KCl  0.027M 
   8g  NaCl  0.137M 
   1.14g  Na2HPO4 0.008M 
   0.2g  KH2PO4 0.0015M 
 
 10% SDS (100mL, store at room temperature to prevent precipitation) 
   10g  SDS 
   Work in vapour hood 
  
 Proteinase K (store at -20°C) 
   10mg/mL dissolved in dH2O, aliquot in 1.5mL Eppendorf tubes 
 
 NaCl (500mL, saturated solution) 
   175.32g NaCl  6M 
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Genomic DNA extractions from blood: 
Day 1: 
o Place ~10mL blood in a 50mL Falcon tube 
o Add 30mL Lysis Buffer 
o Place on ice for 15 min, shaking each 5 min interval 
o Centrifuge @ 1500rpm for 10 min 
o Poor off supernatant, keeping pellet 
o Add 10mL PBS and mix 
o Centrifuge @ 1500rpm for 10 min 
o Pour off supernatant, keeping pellet 
o Dissolve pellet in: 30mL Cell Lysis Buffer 
30μL Proteinase K (10mg/mL) 
300μL 10% SDS 
o Mix well and incubate overnight in 55°C water bath 
 
 
Day 2: 
o Add 1mL NaCl and shake for 1 min 
o Centrifuge @ 3500rpm for 30 min 
o Transfer supernatant to new tube and shake for 15sec 
o Centrifuge @ 2500rpm for 15 min 
o Transfer supernatant to new tube without foam or pellet 
o Add volumes ice cold 100% ethanol to precipitate DNA 
o Scoop DNA and place in Eppendorf tube with 500μL ethanol 
o Centrifuge @ 14 000rpm for 10 min @ 4°C 
o Dissolve pellet in 200-800μL ddH2O/TE buffer depending on pellet size 
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Appendix 5: NCBI LGALS13 annotated sequence 
Annotated sequence file: 
 
LOCUS       19 14952 bp DNA HTG 2-JUN-2005 
DEFINITION  Homo sapiens chromosome 19 NCBI35 partial sequence 
            44780004..44794955 reannotated via EnsEMBL 
ACCESSION   chromosome:NCBI35:19:44780004:44794955:1 
VERSION     chromosome:NCBI35:19:44780004:44794955:1 
KEYWORDS    . 
SOURCE      Human 
  ORGANISM  Homo sapiens 
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; 
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; 
            Hominidae; Homo. 
COMMENT     This sequence was annotated by the Ensembl system. Please visit 
the 
            Ensembl web site, http://www.ensembl.org/ for more information. 
COMMENT     All feature locations are relative to the first (5') base of the 
            sequence in this file.  The sequence presented is always the 
            forward strand of the assembly. Features that lie outside of the 
            sequence contained in this file have clonal location coordinates 
in 
            the format: .:.. 
COMMENT     The /gene indicates a unique id for a gene, 
            /note="transcript_id=..." a unique id for a transcript, 
/protein_id 
            a unique id for a peptide and note="exon_id=..." a unique id for 
an 
            exon. These ids are maintained wherever possible between 
versions. 
COMMENT     All the exons and transcripts in Ensembl are confirmed by 
            similarity to either protein or cDNA sequences. 
FEATURES             Location/Qualifiers 
     source          1..14952 
                     /organism="Homo sapiens" 
                     /db_xref="taxon:9606" 
     gene            5001..9952 
                     /gene=ENSG00000105198 
     mRNA            join(5001..5060,7079..7155,7655..7865,9700..9952) 
                     /gene="ENSG00000105198" 
                     /note="transcript_id=ENST00000221797" 
     CDS             join(5046..5060,7079..7155,7655..7865,9700..9816) 
                     /gene="ENSG00000105198" 
                     /protein_id="ENSP00000221797" 
                     /note="transcript_id=ENST00000221797" 
                     /db_xref="RefSeq_dna:NM_013268.2" 
                     /db_xref="AFFY_HG_U133_PLUS_2:220440_at" 
                     /db_xref="AFFY_HG_U133A:220440_at" 
                     /db_xref="AFFY_HG_U133A_2:220440_at" 
                     /db_xref="AFFY_HG_Focus:220440_at" 
                     /db_xref="AFFY_HG_U95C:63617_at" 
                     /db_xref="AFFY_U133_X3P:g7019496_3p_at" 
                     /db_xref="Uniprot/SWISSPROT:PP13_HUMAN" 
                     /db_xref="EMBL:AF117383" 
                     /db_xref="protein_id:AAF22001.1" 
                     /db_xref="EMBL:AY055826" 
 105
                     /db_xref="protein_id:AAL09162.1" 
                     /db_xref="EMBL:BC066304" 
                     /db_xref="protein_id:AAH66304.1" 
                     /db_xref="PDB:1F87" 
                     /db_xref="MIM:608717" 
                     /db_xref="RefSeq_peptide:NP_037400.1" 
                     /db_xref="EntrezGene:29124" 
                     /db_xref="GO:GO:0016787" 
                     /db_xref="GO:GO:0016042" 
                     /db_xref="GO:GO:0005529" 
                     /db_xref="GO:GO:0006644" 
                     /db_xref="GO:GO:0004622" 
                     /db_xref="GO:GO:0004759" 
                     /db_xref="HUGO:LGALS13" 
                     /db_xref="IPI:IPI00002276.1" 
                     
/translatioN="MSSLPVPYKLPVSLSVGSCVIIKGTPIHSFINDPQLQVDFYTDM 
                     
DEDSDIAFRFRVHFGNHVVMNRREFGIWMLEETTDYVPFEDGKQFELCIYVHYNEYEI 
                     KVNGIRIYGFVHRIPPSFVKMVQVSRDISLTSVCVCN" 
     exon            9700..9952 
                     /note="exon_id=ENSE00000877684" 
     exon            7079..7155 
                     /note="exon_id=ENSE00000877685" 
     exon            5001..5060 
                     /note="exon_id=ENSE00001058171" 
     exon            7655..7865 
                     /note="exon_id=ENSE00000706133" 
     variation       269..269 
                     /replace="C/T" 
                     /db_xref="dbSNP:rs6508879" 
     variation       318..318 
                     /replace="C/A" 
                     /db_xref="dbSNP:rs8106020" 
     variation       434..434 
                     /replace="T/A" 
                     /db_xref="dbSNP:rs8107128" 
     variation       2355..2355 
                     /replace="A/G" 
                     /db_xref="dbSNP:rs10401220" 
     variation       3065..3065 
                     /replace="A/G" 
                     /db_xref="dbSNP:rs12610294" 
     variation       3197..3197 
                     /replace="G/C" 
                     /db_xref="dbSNP:rs11881603" 
     variation       3538..3538 
                     /replace="A/G" 
                     /db_xref="dbSNP:rs13345852" 
     variation       4294..4294 
                     /replace="C/T" 
                     /db_xref="dbSNP:rs2233702" 
     variation       4444..4444 
                     /replace="C/T" 
                     /db_xref="dbSNP:rs2233703" 
     variation       4585..4585 
                     /replace="G/C" 
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                     /db_xref="dbSNP:rs3764842" 
     variation       4694..4694 
                     /replace="T/G" 
                     /db_xref="dbSNP:rs2233704" 
     variation       4740..4740 
                     /replace="A/G" 
                     /db_xref="dbSNP:rs2233705" 
     variation       4948..4948 
                     /replace="C/A" 
                     /db_xref="dbSNP:rs3764843" 
     variation       5164..5164 
                     /replace="C/T" 
                     /db_xref="dbSNP:rs3764844" 
     variation       5758..5758 
                     /replace="T/C" 
                     /db_xref="dbSNP:rs1986156" 
     variation       6080..6080 
                     /replace="C/T" 
                     /db_xref="dbSNP:rs2158964" 
     variation       6365..6365 
                     /replace="A/G" 
                     /db_xref="dbSNP:rs1014206" 
     variation       7308..7308 
                     /replace="T/C" 
                     /db_xref="dbSNP:rs10426654" 
     variation       7633..7633 
                     /replace="A/G" 
                     /db_xref="dbSNP:rs2233706" 
     variation       7926..7926 
                     /replace="T/C" 
                     /db_xref="dbSNP:rs2233707" 
     variation       7937..7937 
                     /replace="T/A" 
                     /db_xref="dbSNP:rs2233708" 
     variation       7964..7964 
                     /replace="C/T" 
                     /db_xref="dbSNP:rs2233709" 
     variation       8555..8555 
                     /replace="C/A" 
                     /db_xref="dbSNP:rs12978134" 
     variation       9458..9458 
                     /replace="G/C" 
                     /db_xref="dbSNP:rs9917050" 
     variation       9527..9527 
                     /replace="C/T" 
                     /db_xref="dbSNP:rs17795657" 
     variation       9589..9589 
                     /replace="A/G" 
                     /db_xref="dbSNP:rs2233710" 
     variation       9740..9740 
                     /replace="G/A" 
                     /db_xref="dbSNP:rs2233711" 
     variation       9829..9829 
                     /replace="C/G" 
                     /db_xref="dbSNP:rs1801654" 
     variation       11227..11227 
                     /replace="C/T" 
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                     /db_xref="dbSNP:rs9916956" 
     variation       11495..11495 
                     /replace="A/G" 
                     /db_xref="dbSNP:rs7246392" 
     variation       11640..11640 
                     /replace="T/C" 
                     /db_xref="dbSNP:rs11881743" 
     variation       11735..11737 
                     /replace="AAA/-" 
                     /db_xref="dbSNP:rs10565549" 
     variation       11967..11967 
                     /replace="C/T" 
                     /db_xref="dbSNP:rs12980535" 
     variation       12285..12285 
                     /replace="A/G" 
                     /db_xref="dbSNP:rs16973535" 
     variation       12289..12289 
                     /replace="A/G" 
                     /db_xref="dbSNP:rs12981089" 
     variation       13989..13989 
                     /replace="G/A" 
                     /db_xref="dbSNP:rs10411383" 
     variation       14023..14023 
                     /replace="T/A" 
                     /db_xref="dbSNP:rs10412744" 
     variation       14371..14371 
                     /replace="G/A" 
                     /db_xref="dbSNP:rs10412234" 
     variation       14381..14381 
                     /replace="A/G" 
                     /db_xref="dbSNP:rs10411717" 
     STS             complement(9715..9904) 
                     /standard_name="26666" 
                     /db_xref="unists:26666" 
                     /note="map_weight=1" 
BASE COUNT  4404 a 3198 c 3071 g 4279 t 
ORIGIN 
 
1-4680 
 
  4681 ggtatattct gca^tagatga gaaaaggctt gagaggcata aaggctgggc tttacaacc^a
       (4694)(t/g)(dbSNP:rs2233704), (4740)(a/g)(dbSNP:rs2233705) 
  4741 ctaccgctca ctccatcatc tttatctatg catttccctg gtaacccaat ccacagcctg 
  4801 gtaactcccc cactgtcact tctgctgcat tacagataca gacctgcaaa tagctatggt 
  4861 tgtgactgag tttcttccta acaactaaac ctgtctaaag ctgcaaggaa atcttgctgg 
  4921 gaggagcttg gaatctggaa tgaagcc^cga gggcaaggct gaagtgggtc atttaaatgc 
       (4948)(c/a)(dbSNP:rs3764843) 
LGALS13-Exon1 (5001-5060 -> 60bp)                          
  4981 ^tgcaactcag agattcactc AGAAGACTGG ACTCAATTCT GAAGGTCGCC AAGAAGGAGA 
       (4981)(branch site - YRYRAY) 
  5041 GAACA^ATGTC TTCTTTACCC gtgagttgaa aaggcacagc cttcaaaaat ttcgtgtcac 
             start 
  5101 acaaaccaag aaagaaatgg gagattttat gagatgaaaa tatgagcatt tttgctgtga 
  5161 atg^ctttact tagagctatt gaggtgtgga atagaaaccc tgaggctatg gtatctgaga 
       (5164)(c/t)(dbSNP:rs3764844) 
  5221 tgcttgtggg gattgcggtg tggaccctgg accagtgtaa ccttcggtga gtgtgaggtg 
  5281 gtgtctgatg agcataaact ctgcggagat aatgtgactt taagtgggag gtggattacc 
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 5341-6720  
 
  6721 acttttacat gtattaactc cctattacgg agaacatcct acaaagtaga aattcctgat 
  6781 aatcctcgtt gtcctaggga aaatgaggga gagttcaagt agcaaatcta agactgcact 
  6841 gctagtaaaa ggcagaatga ggactggaat ccaggcatcc tggctcctga acccttgctc 
  6901 taacttatgg gtccgccata tcttcaggaa tatggggccc tgaatgcggt agggttaaag 
  6961 aggagagtcc acagagtctg ccctttcatc tccaacctcc tgcaccatga gaatatgtta 
LGALS13-Exon2 (7079-7155 -> 77bp)                          
  7021 caggagggga gactgcacct gaccctgcac ctctcactta c^tctcaatac tctggcagGT 
       (7062)(branch site - YNYYRAY) 
  7081 GCCATACAAA CTGCCTGTGT CTTTGTCTGT TGGTTCCTGC GTGATAATCA AAGGGACACC 
  7141 AATCCACTCT TTTATgtgag tactccatgg tccaatggag gggttggaga agaagggaga 
  7201 atatttgcga agatttgacc ttacatgtgg gtgatgtgga aatgtctagt tggcagaatg 
  7261 gaggccccat gcaggtgcag gtcttggaga ccctccagca ccaggca^tga gacccacagc 
       (7308)(t/c)(dbSNP:rs10426654) 
  7321 aactgcatgt gggccagcca tggggcctac aggaggagaa cactcagtgg gttggggctg 
  7381 tggctcttta tcagggggca tagaattttc gggaatgaac aagtcatagg cccaggtcag 
  7441 tgactgtggc tcagttttca tctggggatg aggagcacag aatctccctg cctgggggca 
  7501 tgaggagctg aagcatcccc acagggacct ggccatcagt attatctggg agactttttc 3.1 
  7561 cctaggtaaa tgggggaagg gatttgtgtg tgtgtcgagt gtgtgtctgc gcaagggagg 
LGALS13-Exon3 (7655-7865 -> 211bp)                          
  7621 gacctgccca ac^attctgcg tgcttcaccc tcagCAATGA CCCACAGCTG CAGGTGGATT 
       (7633)(a/g)(dbSNP:rs2233706) 
  7681 TCTACACTGA CATGGATGAG GATTCAGATA TTGCCTTCCG TTTCCGAGTG CACTTTGGCA 3.2 
  7741 ATCATGTGGT CATGAACAGG CGTGAGTTTG GGATATGGAT GTTGGAGGAG ACAACAGACT
  7801 ACGTGCCCTT TGAGGATGGC AAACAATTTG AGCTGTGCAT CTACGTACAT TACAATGAGT 
  7861 ATGAGgtgag catcccagga gctcccagca cccaggctct gtgggctccc aaaacaggag 
  7921 gcagc^tctca ttgatc^tggc ctcagtagtc cgtcagggtc cat^ctcccat aactactcct 
       (7926)(t/c)(dbSNP:rs2233707), (7937)(t/a)(dbSNP:rs2233708), 
(7964)(c/t)(dbSNP:rs2233709) 
  7981 gcccctggtt ttcatcacag agcaccccct gcttgcactg ccatcctcag ctctttccca 
  8041 aatctgacca atgtcaaggt cagctcacct gacatttccc ccaaagtaga taatctcctc 
  8101 tgtcttttca catactgctc atttctactt atgccattat ttaaattttc atttagctga 
 
  8161-9300 
 
  9301 atcacagttc atggaactga aaagtatgca ttcaacgaac atggtctagc actaaccctg 
  9361 tggcaggtcc tgtgcgagat gcagggtctc aagttcctga gacacagtcc ctggcgatgg 
  9421 ggatcttcca ggttagaagg gaggctgagt aagcaaa^gac tttgtgacac agagtataga 
       (9458)(g/c)(dbSNP:rs9917050) 
  9481 acttcgctag aggaatgagt ggaaacatta gaaataaagt cgggta^ctgt ctcaaatagg 
       (9527)(c/t)(dbSNP:rs17795657) 
  9541 cacaaaacgt catctgtaaa cataagtgta tctaatacgt taacttgt^at aactaggaat 
       (9589)(a/g)(dbSNP:rs2233710) 
  9601 tttctt
LGALS13-Exon4 (9700-9952 -> 253bp)                         
gggg aatgttattt gtaccaggac agagtggaga ggaggccgaa aacttgtttg 4.1 
TOP
  9661 gtggcatgct ttct^ttctga tgcatttttc ctcttgtagA TAAAGGTCAA TGGC^ATACGC 
       (9675)(branch site - YNYYRAY), (9715-9904)(STS:26666) 
  9721 ATTTACGGCT TTGTCCATC^G AATCCCGCCA TCATTTGTGA AGATGGTGCA AGTGTCGAGA 4.2 
       (9740)(g/a)(dbSNP:rs2233711) 
  9781 GATATCTCCC TGACCTCAGT GTGTGTCTGC AAT^TGAGGGA GATGATCA^CA CTCCTCATTG 
       stop, (9829)(c/g)(dbSNP:rs1801654) 
  9841 TTGAGGAATC CCTCTTTCTA CCTGACCATG GGATTCCCAG AACCTGCTAA CAGAATAATC 
  9901 CCTGCTCACA TTTTCCCCTA CACTTTGTCA TTAAAACAGC ACGAAAACTC ACatgatttg 
  9961 gttcttgctt tcagagggga aaagaggaag ttgtcatccc caaggggggc cagggcattc 
 10021 tatgggaggc atcaggaaat caaaggggat aaaccttcct gtgacaaagg gagtgagtga 
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 10081 caaggtccgt ggaatgtctg agaagacatt agaaacagca tccttctata gcacgtagtt 
 10141 gacctcagac agtctgagct aaaatactta cccaatctca aatgactcaa ggcacttaaa 
 10201 tgttaggtag ctgtttacag ccacgcaagt gtacatggtg gctttgggga aaatctgtaa 
 
10261-14952 
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Appendix 6: Multiphor SSCP/HD protocol 
 
Multiphor Solutions: 
 
40% acrylamide PDA solution: 1L 
 
396g acrylamide 
4g Piperazine diacrylamide 
bring to volume (1L) with dH2O (keep in foil in fridge) 
 
 
0,75M TRIS- Formate Buffer: 1L 
 
90.8g TRIS 
600ml dH2O (dissolve) 
pH = 9.0 with formic acid 
bring to volume (1L) with dH2O 
 
41% Glycerol: 100mL 
 
41mL glycerol 
59mL dH2O 
 
TRIS- Borate Buffer: 1L 
 
125.9g TRIS 
17.3g Boric acid 
700mL dH2O (dissolve) 
pH = 9.0 
50μL Bromophenol Blue (4% solution) 
bring to volume (1L) with dH2O 
 
SSCP loading Dye: 50mL 
 
47.5mL 95% Formamide 
0.16g 100mM NaOH 
0.125g 0.25% Bromophenol Blue 
0.125g 0.25% Xylene cyanol 
bring to volume (50mL) with dH2O 
 
 
10% APS: 1.5mL      10% acetic acid (plate glue): 
 
0.15g APS       200μL Trimethoxysily 
bring to volume (1.5mL) with dH2O    50 mL 100% EtOH 
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Gel mix: X10       Per 1 Gel: 
 
53mL 40% acrylamide-PDA     15ml Gel Mix 
85mL Tris-Formate Buffer     150μL 10% APS 
30mL 41% Glycerol      15μL TEMED 
keep in foil in fridge 
 
Silver Staining solutions: 
 
Solution I: 1L 
 
 0.1% silver nitrate: 1g silver nitrate 
  1L dH2O 
   Max. 2 days in the dark 
 
15% Formaldehyde: 10mL (must be fresh each time!) 
 
3.75mL 40% Formaldehyde stock 
6.25mL dH2O 
 
Solution II: 1L 
 
15g NaOH 
1L dH2O 
10mL 15% Formaldehyde (FRESH!) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 112
Multiphor Protocol: 
 
Gel Plates preparation: do everything in quick succession 
 
• Wash plates 4X with ethanol 
• Every 4 runs clean plate with blocks with gelslick (80μL) especially over blocks 
• Put 80μL plateglue and 8μL 10% acetic acid on plate without blocks 
• Wipe well until resistance is felt and wash a few times with ethanol 
• Clean spacers and place them on plates 
• Camp well on both short sides and long area close to blocks and then place upside down 
on bench 
• Prepare gel mix and pour quickly using a syringe 
• Allow to set at room temp for 30min (can stand for 3 days -don’t wrap! It shrinks)  
 
 
• Separate plates (gel should be on one without blocks) 
• Put water on surface of multiphor 
• Don’t get water on plates when placing on multiphor apparatus 
• Slide plate facing upwards over water (no bubbles) 
• Use 2 buffer strips/gel-side/2h run soaked in TRIS-borate buffer 
• Place strips on both sides of gel close to the wells 
• Wash electrodes of multiphor gently each time before use 
 
PCR Products: 
 
• Take 3-5μL PCR product and 3-5μL SSCP loading dye (all on ice) 
• Denature @ 95°C for 5min in PCR thermocycler 
• Place on ice immediately for 3 min 
• Load 3μL (skipping ends of gel) onto gel and run @ 9°C first ( if resolution not good, run 
at 11°C) 
• 2h at 355V 
 
Visualization of bands: 
 
• remove gel from apparatus 
• rinse X2 in dH2O ( remove buffer because it interferes with the stain) 
• incubate for 10min @room temp in solution I (silver nitrate intercalates with DNA) 
• rinse X2 with dH2O 
• incubate for 10min @room temp in solution II 
• rinse X2 with dH2O 
• blot dry with paper towel 
• cover with filter paper  
• leave overnight, then put paper off glass and label paper with dried gel 
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Appendix 7: DNA purification protocol 
 
Bioline SureClean ® (Bioline, UK) 
 
 Column-free protocol: 
o Add an equal volume of Bioline SureClean to the amplified nucleic acid sample and 
incubate at room temperature for 10 min 
o Centrifuge at 13 000rpm for 10 min and remove supernatant  
o Add 100μL of 70% ethanol and vortex for 30sec 
o Centrifuge at 13 000rpm for 10 min, remove supernatant and air-dry pellet 
o Resuspend in Nuclease-free water (starting volume) 
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Appendix 8: The remaining immunological gene variants screened in this study 
TNFα -238 G/A  
 
 
 
 
 
 
 
Figure 18: Agarose gel (2%) demonstrating the three genotypes of the TNFα -238 polymorphism 
detected by ARMS PCR (Yamamoto-Furusho et al., 2004). Lane 1 represents a 100 bp ladder 
(Fermentas). Lanes 2a and b represent a heterozygous genotype (209bp and 449 bp), Lanes 3a&b and 
4a&b represents homozygosity for the TNFα-238 G-allele (449bp). 
 
 
Table 22: Genotype and allele frequencies of the TNFα -238 G/A polymorphism for the total cohort. 
Hardy Weinberg equilibrium (HWE) was determined for each individual group. Statistical analysis was 
performed using Fisher's exact test analog to determine associations at both genotype and allele level. The 
corresponding P values are shown at the bottom of the table.   
 
Total cohort (N=421) 
Genotype Total 
 (N=421) 
Controls 
(N=338) 
Adverse 
 (N=83) 
PTL 
(N=33) 
Hypertension 
(N=35) 
G/G 315 (74.8%) 258 (76.3%) 57 (68.7%) 24 (72.7%) 23 (65.7%) 
G/A 106 (25.2%)   80 (23.7%) 26 (31.3%)   9 (27.3%) 12 (33.4%) 
A/A 0 0 0 0 0 
G-allele 0.874 0.882 0.843 0.864 0.829 
A-allele 0.126 0.118 0.157 0.136 0.171 
HWE 0.0127 0.048 0.436 0.663 0.473 
Total cohort and controls did not reach HWE significance (P<0.05). Controls vs. Adverse: P=0.183 (allele); 
Controls vs. Preterm labour: P=0.667 (allele); Controls vs. Hypertension: P=0.199 (allele). 
 
Table 23: Genotype and allele frequencies of the TNFα -238 G/A polymorphism in the Coloured 
population. Hardy Weinberg equilibrium (HWE) was determined for each individual group. Statistical 
analysis was performed using Fisher's exact test analog to determine associations at both genotype and 
allele level. The corresponding P values are shown at the bottom of the table.   
 
Coloured Females (N=306) 
Genotype Total 
 (N=306) 
Controls  
(N=237) 
Adverse 
 (N=69) 
PTL 
(N=27) 
Hypertension 
(N=29) 
G/G 217 (70.9%) 172 (72.6%) 45 (65.2%) 19 (70.4%) 18 (62.1%) 
G/A     89 (29.8%)   65 (27.4%) 24 (34.8%)   8 (29.6%) 11 (37.9%) 
A/A 0 0 0    0 0 
G-allele 0.855 0.863 0.826 0.852 0.810 
A-allele 0.145 0.137 0.174 0.148 0.190 
HWE 0.012 0.050 0.217 0.665 0.452 
 
608bp (constant band) 
449bp 
209bp 
    1    2a     b    3a   b     4a    b 
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Controls vs. Adverse: P=0.281 (allele); Controls vs. Preterm labour: P=0.824 (allele); Controls vs. Hypertension: 
P=0.281 (allele). 
Table 24: Genotype and allele frequencies of the TNFα -238 G/A polymorphism in the Black 
population. Hardy Weinberg equilibrium (HWE) was determined for each individual group.  
 
Black Females (N=115) 
Genotype Total  
(N=115) 
Controls 
(N=101) 
Adverse 
 (N=14) 
PTL 
(N=6) 
Hypertension 
(N=6) 
G/G 71 (61.7%) 86 (85.1%) 12 (85.7%) 5 (83.3%) 5 (83.3%) 
G/A 44 (38.3%) 37 (14.9%) 2 (14.3%) 1 (16.7%) 1 (16.7%) 
A/A 0 0 0 0 0 
G-allele 0.809 0.926 0.929 0.917 0.917 
A-allele 0.191 0.074 0.071 0.083 0.083 
HWE 0.004 0.723 0.959 0.976 0.976 
Sample size insufficient to perform association analysis (P<0.05). 
 
TNFα +488 G/A  
 
 
 
Figure 19: Agarose gel (2%) demonstrating the three genotypes of the TNFα +488 G/A polymorphism, 
detected by restriction enzyme analysis with NlaIII (37˚C). Lane 1 is a 100 bp ladder (New England 
Biolabs). Lanes 2-4 and 7-8 represents the G/G genotype at 341 and 247 bp. Lanes 5-6 the heterozygous 
genotype (G/A) at 341, 247 and 160 bp. 
 
Table 25: Genotype and allele frequencies of the TNFα +488 G/A polymorphism for the total cohort. 
Hardy Weinberg equilibrium (HWE) was determined for each individual group. Statistical analysis was 
performed using Fisher's exact test analog to determine associations at both genotype and allele level. The 
corresponding P values are shown at the bottom of the table.   
 
Total Group (N=403) 
Genotype Total (N=403) Controls 
(N=327) 
Adverse 
(N=76) 
PTL 
(N=30) 
Hypertension 
(N=32) 
G/G 369 (91.6%) 296 (90.5%) 73 (96%) 30 29 (90.6%) 
G/A 34 (8.4%)     31 (9.5%) 3 (4%) 0 3 (9.4%) 
A/A 0 0 0 0 0 
G-allele 0.958 0.953 0.976 1.000 0.953 
A-allele 0.042 0.047 0.024 0.000 0.047 
HWE 0.677 0.667 0.9814 - 0.962 
 
341bp  
449bp 
209bp 
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Controls vs. Adverse: P=0.126 (allele); Controls vs. Preterm labour: P=0.085 (allele); Controls vs. Hypertension: 
P=0.986 (allele). 
Table 26: Genotype and allele frequencies of the TNFα +488 G/A polymorphism in the Coloured 
population. Hardy Weinberg equilibrium (HWE) was determined for each individual group. Statistical 
analysis was performed using Fisher's exact test analog to determine associations at both genotype and 
allele level. The corresponding P values are shown at the bottom of the table.   
 
Coloured Females (N=306) 
Genotype Total 
 (N=291) 
Controls  
(N=228) 
Adverse 
 (N=63) 
PTL 
(N=25) 
Hypertension 
(N=26) 
G/G  262 (90.0%) 202 (88.6%) 60 (95.2%) 25 23 (88.5%) 
G/A      29 (10.0%)   26 (11.4%) 3 (4.8%) 0  3 (11.5%) 
A/A 0 0 0 0 0 
G-allele 0.950 0.943 0.976 1.000 0.942 
A-allele 0.050 0.057 0.024 0.000 0.058 
HWE 0.6702 0.659 0.9814 - 0.952 
Controls vs. Adverse: P=0.129 (allele); Controls vs. Preterm labour: P=0.083 (allele); Controls vs. Hypertension: 
P=0.984 (allele). 
 
Table 27: Genotype and allele frequencies of the TNFα +488 G/A polymorphism in the Black 
population. Hardy Weinberg equilibrium (HWE) was determined for each individual group.  
 
Black Females (N=112) 
Genotype Total  
(N=112) 
Controls 
(N=99) 
Adverse 
 (N=13) 
PTL 
(N=5) 
Hypertension 
(N=6) 
G/G 107 (61.7%) 94 (94.9%) 13 5 6 
G/A    5 (38.3%) 5 (5.1%) 0 0 0 
A/A 0 0 0 0 0 
G-allele 0.978 0.975 1.000 1.000 1.000 
A-allele 0.022 0.025 0.000 0.000 0.000 
HWE 0.9712 0.967 - - - 
Sample size insufficient to perform association analysis (P<0.05). 
 
IL-10 -1082 A/G  
 
 
 
280bp 
253bp 
 
 
Figure 20: Agarose gel (2%) demonstrating the three genotypes of the IL-10 -1082 A/G polymorphism, 
detected by restriction enzyme analysis with EcoNI (37˚C). Lane 1 is a 100 bp ladder (Fermentas). Lanes 
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4 and 5 illustrates the A/A genotype at 280 bp and lanes 6 and 8 the G/G genotype at 253 bp. Lanes 2, 3, 
7 and 9 represent the heterozygous genotype. 
 
Table 28: Genotype and allele frequencies of the IL-10 -1082 A/G polymorphism for the total cohort. 
Hardy Weinberg equilibrium (HWE) was determined for each individual group. Statistical analysis was 
performed using Fisher's exact test analog to determine associations at both genotype and allele level. The 
corresponding P values are shown at the bottom of the table.   
 
Total Cohort (N=421) 
Genotype Total (N=421) Controls 
(N=338) 
Adverse 
 (N=83) 
PTL 
(N=33) 
Hypertension 
(N=35) 
A/A 228 (54.2%) 178 (52.7%) 50 (60.2%) 21 (63.6%) 19 (54.3%) 
A/G 166 (39.4%) 135 (39.9%) 31 (37.2%) 11 (33.3%) 15 (42.9%) 
G/G 27 (6.4%) 25 (7.4%) 2 (2.4%) 1 (3.0%) 1 (2.8%) 
A-allele 0.739 0.726 0.789 0.803 0.757 
G-allele 0.261 0.274 0.211 0.197 0.243 
HWE 0.908 0.996 0.5373 0.954 0.620 
Controls vs. Adverse: P=0.182 (genotype) and P=0.099 (allele); Controls vs. Preterm labour: P=0.401 (genotype) 
and P=0.179 (allele); Controls vs. Hypertension: P=0.600 (genotype) and P=0.581 (allele). 
 
Table 29: Genotype and allele frequencies of the IL-10 -1082 A/G polymorphism in the Coloured 
population. Hardy Weinberg equilibrium (HWE) was determined for each individual group. Statistical 
analysis was performed using Fisher's exact test analog to determine associations at both genotype and 
allele level. The corresponding P values are shown at the bottom of the table.   
 
Coloured Females (N=306) 
Genotype Total 
 (N=306) 
Controls  
(N=237) 
Adverse 
 (N=69) 
PTL 
(N=27) 
Hypertension 
(N=29) 
A/A 158 (51.6%) 118 (49.8%) 40 (58%)    17 (63%) 15 (51.7%) 
A/G   130 (42.5%) 103 (43.4%)   27 (39.1%)      9 (33.3%) 13 (44.8%) 
G/G 18 (5.9%) 16 (6.8%)   2 (2.9%)      1 (3.7%) 1 (3.5%) 
A-allele 0.729 0.715 0.775 0.796 0.741 
G-allele 0.271 0.285 0.225 0.204 0.259 
HWE 0.4267 0.590 0.592 0.990 0.661 
Controls vs. Adverse: P=0.320 (genotype) and P=0.162 (allele); Controls vs. Preterm labour: P=0.415 (genotype) 
and P=0.207 (allele); Controls vs. Hypertension: P=0.790 (genotype) and P=0.676 (allele). 
 
Table 30: Genotype and allele frequencies of the IL-10 -1082 A/G polymorphism in the Black 
population. Hardy Weinberg equilibrium (HWE) was determined for each individual group.  
 
Black Females (N=115) 
Genotype Total  
(N=115) 
Controls 
(N=101) 
Adverse 
 (N=14) 
PTL 
(N=6) 
Hypertension 
(N=6) 
A/A 70 (60.9%) 60 (59.4%) 10 (71.4%) 4 (66.7%) 4 (66.7%) 
A/G 36 (31.3%) 32 (31.7%) 4 (28.6%) 2 (33.3%) 2 (33.3%) 
G/G 9 (7.8%) 9 (8.9%) 0 0 0 
A-allele 0.765 0.752 0.857 0.833 0.833 
G-allele 0.235 0.248 0.143 0.167 0.167 
HWE 0.385 0.324 0.823 0.887 0.887 
Sample size insufficient to perform association analysis (P<0.05). 
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IL-10 -819 C/T /-592 C/A (Complete linkage disequilibrium) 
Results on: IL-10 -592 C/A 
 
 
 
311bp 
 
240bp 
 
116bp (constant band) 
 
 
Figure 21: Agarose gel (2%) demonstrating the three genotypes of the IL-10 -592 C/A polymorphism, 
detected by restriction enzyme analysis with RsaI (37˚C). Lane 1 is a 100 bp ladder (Fermentas). Lanes 2, 
6, 7 and 9 illustrates the C/C genotype at 311 bp and lanes 3, 5 and 8 the A/A genotype 4 and 10 at 240 
bp. Lanes 4 and 10 represent the heterozygous genotype. 
 
Table 31: Genotype and allele frequencies of the IL-10 -592 C/A polymorphism for the total cohort. 
Hardy Weinberg equilibrium (HWE) was determined for each individual group. Statistical analysis was 
performed using Fisher's exact test analog to determine associations at both genotype and allele level. The 
corresponding P values are shown at the bottom of the table.   
 
Total Group (N=421) 
Genotype Total (N=421) Controls 
(N=338) 
Adverse 
 (N=83) 
PTL 
(N=33) 
Hypertension 
(N=35) 
C/C 151 (36.1%) 126 (37.3%) 25 (31.3%) 9 (27.3%) 11 (31%) 
C/A 228 (53.9%) 176 (51.1%) 52 (61.5%) 22 (66.7%) 20 (57%) 
A/A 42 (9.9%)  36 (10.6%) 6 (7.2%)      2 (6%)   4 (11%) 
C-allele 0.629 0.633 0.614 0.606 0.600 
A-allele 0.371 0.367 0.386 0.394 0.400 
HWE 0.004 0.085 0.0134 0.075 0.530 
Controls vs. Adverse: P=0.211 (genotype) and P=0.655 (allele); Controls vs. Preterm labour: P=0.266 (genotype) 
and P=0.664 (allele); Controls vs. Hypertension: P=0.791 (genotype) and P=0.585 (allele). 
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Table 32: Genotype and allele frequencies of the IL-10 -592 C/A polymorphism in the Coloured 
population. Hardy Weinberg Equilibrium (HWE) was determined for each individual group. Statistical 
analysis was performed using Fisher's exact test analog to determine associations at both genotype and 
allele level. The corresponding P values are shown at the bottom of the table.   
 
Coloured Females (N=306) 
Genotype Total 
 (N=306) 
Controls  
(N=237) 
Adverse 
 (N=69) 
PTL 
(N=27) 
Hypertension 
(N=29) 
C/C  107 (35%)   87 (36.7%)    20 (29%)  7 (25.9%)         9 (31%) 
C/A     168 (54.9%)  124 (52.3%) 44 (63.8%) 18 (66.7%)       17 (59%) 
A/A       31 (10.1%)     26 (11%) 5 (7.2%) 2 (7.4%)  3 (10%) 
C-allele 0.624 0.629 0.609 0.593 0.603 
A-allele 0.376 0.371 0.391 0.407 0.397 
HWE 0.012 0.178 0.019 0.141 0.480 
Controls vs. Adverse: P=0.232 (genotype) and P=0.670 (allele); Controls vs. Preterm labour: P=0.366 (genotype) 
and P=0.604 (allele); Controls vs. Hypertension: P=0.805 (genotype) and P=0.708 (allele). 
 
Table 33: Genotype and allele frequencies of the IL-10 -592 C/A polymorphism in the Black population. 
Hardy Weinberg equilibrium (HWE) was determined for each individual group 
 
Black Females (N=115) 
Genotype Total  
(N=115) 
Controls 
(N=101) 
Adverse 
 (N=14) 
PTL 
(N=6) 
Hypertension 
(N=6) 
C/C 44 (38.3%)  39 (38.6%) 5 (36%) 2 (33.3%) 2 (33.3%) 
C/A 60 (52.2%)  52 (51.5%) 8 (57%) 4 (66.7%)       3 (50%) 
A/A 11 (9.6%) 10 (9.9%)       1 (7%) 0 1 (16.7%) 
C-allele 0.643 0.644 0.643 0.667 0.582 
A-allele 0.357 0.356 0.357 0.333 0.417 
HWE 0.339 0.470 0.658 0.472 0.998 
Sample size insufficient to perform association analysis (P<0.05). 
 
IL-1β +3954 C/T 
 
 
 
250bp 
 
136bp 
 
114bp 
 
Figure 22: Agarose gel (2%) demonstrating the three genotypes of the IL-1β +3954 C/T polymorphism, 
detected by restriction enzyme analysis with TaqαI (37˚C). Lane 1 is a 100 bp ladder (Fermentas). Lanes 
3, 8 and 9 illustrates the C/C genotype at 114 and 136 bp and lane 6 the T/T genotype at 250 bp. Lanes 2, 
4, 5 and 7 represent the heterozygous genotype.
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Figure 23: Electropherogram demonstrating the heterozygous form (arrowed) of the +3594 C/T 
sequenced in the forward (5'→3') direction.  
 
Table 34: Genotype and allele frequencies of the IL-1β +3954 C/T polymorphism in the total cohort. 
Hardy Weinberg equilibrium (HWE) was determined for each individual group. Statistical analysis was 
performed using Fisher's exact test analog to determine associations at both genotype and allele level. The 
corresponding P values are shown at the bottom of the table.   
 
Total Group (N=421) 
Genotype Total (N=421) Controls 
(N=338) 
Adverse 
 (N=83) 
PTL 
(N=33) 
Hypertension 
(N=35) 
C/C   316 (75.1%) 253 (74.8%) 63 (75.9%) 23 (69.7%) 31 (88.6%) 
C/T  98 (22.3%)  80 (23.7%)    18 (21.7%)     8 (24.2%)  4 (11.4%) 
T/T  7 (1.7%)  5 (1.5%) 2 (2.4%) 2 (6.1%) 0 
C-allele 0.867 0.867 0.867 0.818 0.943 
T-allele 0.133 0.133 0.133 0.182 0.057 
HWE 0.9822 0.897 0.875 0.568 0.938 
Controls vs. Adverse: P=0.791 (genotype) and P=0.984 (allele); Controls vs. Preterm labour: P=0.178 (genotype) 
and P=0.273 (allele); Controls vs. Hypertension: P=0.182 (genotype) and P=0.068 (allele). 
 
Table 35: Genotype and allele frequencies of the IL-1β +3954 C/T polymorphism in the Coloured 
population. Hardy Weinberg equilibrium (HWE) was determined for each individual group. Statistical 
analysis was performed using Fisher's exact test analog to determine associations at both genotype and 
allele level. The corresponding P values are shown at the bottom of the table.   
 
Coloured Females (N=306) 
Genotype Total 
 (N=306) 
Controls  
(N=237) 
Adverse 
 (N=69) 
PTL 
(N=27) 
Hypertension 
(N=29) 
C/C 228 (74.5%) 174 (73.4%) 54 (78.3%)  19 (70.4%) 26 (89.7%) 
C/T     74 (24.2%)  59 (24.9%) 15 (21.7%)   8 (29.6%)   3 (10.3%) 
T/T   4(1.3%)  4 (1.7%) 0 0 0 
C-allele 0.866 0.859 0.891 0.852 0.948 
T-allele 0.134 0.141 0.109 0.148 0.052 
HWE 0.763 0.926 0.599 0.665 0.958 
Controls vs. Adverse: P=0.460 (genotype) and P=0.322 (allele); Controls vs. Preterm labour: P=0.704 (genotype) 
and P=0.892 (allele); Controls vs. Hypertension: P=0.154 (genotype) and P=0.056 (allele). 
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Table 36: Genotype and allele frequencies of the IL-1β +3954 C/T polymorphism in the Black 
population. Hardy Weinberg equilibrium (HWE) was determined for each individual group 
 
Black Females (N=115) 
Genotype Total  
(N=115) 
Controls 
(N=101) 
Adverse 
 (N=14) 
PTL 
(N=6) 
Hypertension 
(N=6) 
C/C 88 (76.5%) 79 (78.2%) 9 (64.3%) 4 (66.7%) 5 (83.3%) 
C/T 24 (20.9%) 21 (20.8%) 3 (21.4%) 0 1 (16.7%) 
T/T 3 (2.6%)      1 (1%) 2 (14.3%) 2 (33.3%) 0 
C-allele 0.870 0.886 0.750 0.667 0.917 
T-allele 0.130 0.114 0.250 0.333 0.083 
HWE 0.692 0.955 0.277 0.049 0.976 
Sample size insufficient to perform association analysis (P<0.05). 
 
IL-4 –590 C/T 
 
 
 
 
252bp 
 
192bp 
 
 
Figure 24: Agarose gel (2%) demonstrating the three genotypes of the IL-4 -590 C/T polymorphism, 
detected by restriction enzyme analysis with BsmfI (37˚C). Lane 1 is a 100 bp ladder (Fermentas). Lanes 
4, 6 and 8 illustrates the C/C genotype at 192 bp and lane 2, 3, 5, 7, 11 and 12 the T/T genotype at 252 bp. 
Lanes 9 and 10 represent the heterozygous genotype.  
 
Table 37: Genotype and allele frequencies of the IL-4 -590 C/T polymorphism for the total cohort. 
Hardy Weinberg equilibrium (HWE) was determined for each individual group. Statistical analysis was 
performed using Fisher's exact test analog to determine associations at both genotype and allele level. The 
corresponding P values are shown at the bottom of the table.   
 
Total Group (N=420) 
Genotype Total (N=420) Controls 
(N=338) 
Adverse 
 (N=82) 
PTL 
(N=33) 
Hypertension 
(N=34) 
C/C  67 (15.9%)  58 (17.2%)   9 (11%) 2 (6.1%)  6 (17.6%) 
C/T 182 (43.2%) 141 (41.7%) 41 (50%) 17 (51.5%) 15 (44.1%) 
T/T 172 (40.9%) 139 (41.1%) 32 (39%) 14 (42.4%) 13 (38.2%) 
C-allele 0.375 0.380 0.360 0.318 0.397 
T-allele 0.625 0.620 0.640 0.682 0.603 
HWE 0.278 0.108 0.742 0.561 0.900 
Controls vs. Adverse: P=0.259 (genotype) and P=0.628 (allele); Controls vs. Preterm labour: P=0.225 (genotype) 
and P=0.321 (allele); Controls vs. Hypertension: P=0.947 (genotype) and P=0.785 (allele). 
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Table 38: Genotype and allele frequencies of the IL-4 -590 C/T polymorphism in the Coloured 
population. Hardy Weinberg equilibrium (HWE) was determined for each individual group. Statistical 
analysis was performed using Fisher's exact test analog to determine associations at both genotype and 
allele level. The corresponding P values are shown at the bottom of the table.   
 
Coloured Females (N=305) 
Genotype Total 
 (N=305) 
Controls  
(N=237) 
Adverse 
 (N=68) 
PTL 
(N=27) 
Hypertension 
(N=28) 
C/C  59 (19.3%)   51 (21.5%)  8 (11.8%) 2 (7.4%)  5 (17.9%) 
C/T   138 (45.2%) 103 (43.5%) 35 (51.5%) 14 (51.9%) 13 (46.4%) 
T/T 108 (35.4%) 83 (35%) 25 (36.8%) 11 (40.7%) 10 (35.7%) 
C-allele 0.420 0.432 0.375 0.333 0.411 
T-allele 0.580 0.568 0.625 0.667 0.589 
HWE 0.463 0.211 0.721 0.687 0.977 
Controls vs. Adverse: P=0.183 (genotype) and P=0.231 (allele); Controls vs. Preterm labour: P=0.222 (genotype) 
and P=0.162 (allele); Controls vs. Hypertension: P=0.899 (genotype) and P=0.756 (allele). 
 
Table 39: Genotype and allele frequencies of the IL-4 -590 C/T polymorphism in the Black population. 
Hardy Weinberg equilibrium (HWE) was determined for each individual group.  
 
Black Females (N=115) 
Genotype Total  
(N=115) 
Controls 
(N=101) 
Adverse 
 (N=14) 
PTL 
(N=6) 
Hypertension 
(N=6) 
C/C      8 (6.9%) 7 (6.9%) 1 (7.1%) 0   1 (16.7%) 
C/T 44 (38.3%) 38 (37.6%)   6 (42.9%) 3 (50%)   2 (33.3%) 
T/T 63 (54.8%) 56 (55.4%)      7 (50%) 3 (50%) 3 (50%) 
C-allele 0.261 0.257 0.286 0.250 0.333 
T-allele 0.739 0.743 0.714 0.750 0.667 
HWE 0.997 0.987 0.983 0.717 0.829 
Sample size insufficient to perform association analysis (P<0.05). 
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Appendix 9: LGALS13 gene variants diagrammatically illustrated 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. -98A/C (dbSNP rs: 3764843) 
2. IVS2-36 G/A (novel) 
3. IVS2-22 A/G (dbSNP rs: 2233706) 
4. IVS2-15 G/A (novel) 
5. 130 A→G / M44V (novel) 
6. 221delT / L74W (novel) 
7. Hotspot / T77N, T78L, D79H (novel) 
8. 260 A→G / K87R (novel) 
9. IVS3+72 T/A (dbSNP rs: 2233708) 
10. 351 G→A / P117P (novel) 
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Appendix 10: The remaining LGALS13 gene variants screened in this study 
-98 A/C (dbSNP rs: 3764843) 
 
 
 
Figure 25: Three conformational banding patterns for the -98 A/C ‘promoter’ variant detected by 
Multiphor SSCP/HD analysis, demonstrated only in the SSCP component of the analysis. 
 
 
 AA      CC      CC       AA      CC       AC 
 
 
292bp 
 
244bp 
 
 
Figure 26: This documented variant was screened using restriction enzyme analysis. Agarose gel (2%) 
demonstrating the different genotypes of the -98 A/C promoter variant, detected by restriction enzyme 
analysis with AvaI (37˚C). Lane 1 is a 100 bp ladder. Lanes 3, 5 and 7 corresponds to the A/A genotype 
(292 bp), Lanes 2, 4 and 8 the heterozygous genotype (A/C) and Lane 6 represents the homozygous C/C 
genotype (244 bp).
 
Table 40: Genotype and allele frequencies of the -98 A/C variant for the total cohort. Hardy Weinberg 
equilibrium (HWE) was determined for each individual group. Statistical analysis was performed using 
Fisher's exact test analog to determine associations at both genotype and allele level. The corresponding P 
values are shown at the bottom of the table.   
 
Total Cohort (N=421) 
Genotype Total (N=421) Controls 
(N=338) 
Adverse 
 (N=83) 
PTL 
(N=33) 
Hypertension 
(N=35) 
A/A 220 (52.3%) 176 (52.1%) 44 (53.7%) 16 (48.5%)     23 (65.7%) 
A/C 171 (40.6%) 139 (41.1%) 32 (37.8%) 15 (45.5%) 8 (22.9%) 
C/C 30 (7.1%) 23 (6.8%) 7 (8.5%)      2 (6%) 4 (11.4%) 
A-allele 0.726 0.726 0.723 0.712 0.771 
C-allele 0.274 0.274 0.277 0.288 0.224 
HWE 0.918 0.818 0.943 0.823 0.257 
Controls vs. Adverse: P=0.832 (genotype) and P=0.929 (allele); Controls vs. Preterm labour: P=0.889 (genotype) 
and P=0.805 (allele); Controls vs. Hypertension: P=0.094 (genotype) and P=0.418 (allele). 
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Table 41: Genotype and allele frequencies of the -98 A/C variant in the Coloured population. Hardy 
Weinberg equilibrium (HWE) was determined for each individual group. Statistical analysis was 
performed using Fisher's exact test analog to determine associations at both genotype and allele level. The 
corresponding P values are shown at the bottom of the table.   
 
Coloured Females (n=306) 
Genotype Total 
 (N=306) 
Controls  
(N=237) 
Adverse 
 (N=69) 
PTL 
(N=27) 
Hypertension 
(N=29) 
A/A 160 (52.3%) 125 (53%) 35 (50.7%) 11 (40.7%)      19 (66%) 
A/C   122 (39.9%)  93 (39%)    29 (42%) 14 (51.9%)        7 (24%) 
C/C 24 (7.8%) 19 (8%) 5 (7.2%) 2 (7.4%) 3 (10%) 
A-allele 0.722 0.724 0.717 0.667 0.776 
C-allele 0.278 0.276 0.283 0.333 0.224 
HWE 0.994 0.958 0.983 0.687 0.257 
Controls vs. Adverse: P=0.911 (genotype) and P=0.886 (allele); Controls vs. Preterm labour: P=0.440 (genotype) 
and P=0.378 (allele); Controls vs. Hypertension: P=0.284 (genotype) and P=0.398 (allele). 
 
Table 42: Genotype and allele frequencies of the -98 A/C variant in the Black population. Hardy 
Weinberg equilibrium (HWE) was determined for each individual group.  
 
Black Females (n=115) 
Genotype Total  
(N=115) 
Controls 
(N=101) 
Adverse 
 (N=14) 
PTL 
(N=6) 
Hypertension 
(N=6) 
A/A 60 (52.2%) 51 (50.5%) 9 (64.3%) 58 (83.3%) 4 (66.7%) 
A/C 49 (42.6%) 46 (45.5%) 3 (21.4%)   1 (16.7%) 1 (16.7%) 
C/C 6 (5.2%)      4 (4%) 2 (12.3%) 0 1 (16.7%) 
A-allele 0.735 0.733 0.750 0.771 0.750 
C-allele 0.265 0.267 0.250 0.29 0.250 
HWE 0.607 0.263 0.277 0.115 0.396 
Sample size insufficient to perform association analysis (P<0.05). 
 
IVS2-36 G/A (NOVEL) 
 
 
 
Figure 27: Multiphor SSCP/HD gel illustrating the different conformations for the IVS2-36 G/A variant 
detected in only the SSCP component of the analysis. The included table illustrates the cluster of variants 
in the 5' intronic region flanking exon three. 
Conformations 
    1            2          3         4          5          6 
  G/A    G/G    G/A    G/G     G/G    G/G 
IVS2-36 G/A 
Conformation IVS2-15 G/A IVS2-22 A/G IVS2-36 G/A
1 G/G A/A G/A
2 G/A A/A G/G
3 G/G A/G G/A
4 G/G G/G G/G
5 G/G A/G G/G
6 G/G A/A G/G
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Figure 28: Electropherogram depicting the heterozygous form (arrowed) of the IVS2-36 locus, 
sequenced in the forward (5'→3') direction. 
  
 
213bp 
 
 
121bp 
92bp
 
Figure 29: Agarose gel (2.5%) demonstrating the two genotypes of the IVS2-36 G/A variant, detected by 
restriction enzyme analysis with NlaIV (37˚C). Lane 1 is a 100 bp ladder (Fermentas). Lanes 2-7, 11 and 
12 represents the G/G genotype (121 and 92 bp). Lanes 8-10, 13 and 14 the heterozygous genotypes G/A 
(213, 121 and 92 bp). 
 
Table 43: Genotype and allele frequencies of the IVS2-36 G/A variant for the total cohort. Hardy 
Weinberg equilibrium (HWE) was determined for each individual group. Statistical analysis was 
performed using Fisher's exact test analog to determine associations at both genotype and allele level. The 
corresponding P values are shown at the bottom of the table.   
 
Total Cohort (N=421) 
Genotype Total (N=421) Controls 
(N=338) 
Adverse 
 (N=83) 
PTL 
(N=33) 
Hypertension 
(N=35) 
G//G 390 (92.6%) 311 (92%) 79 (95.2%) 33 34 (97.1%) 
GA 31 (7.4%) 27 (8%) 4 (4.8%) 0 1 (2.9%) 
A/A 0 0 0 0 0 
G-allele 0.963 0.960 0.976 1.000 0.986 
A-allele 0.037 0.040 0.024 0.000 0.014 
HWE 0.735 0.746 0.975 - 0.996 
Controls vs. Adverse: P=0.331 (allele); Controls vs. Preterm labour: P=0.098 (allele); Controls vs. Hypertension: 
P=0.282 (allele). 
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Table 44: Genotype and allele frequencies of the IVS2-36 G/A variant in the Coloured population. 
Hardy Weinberg equilibrium (HWE) was determined for each individual group. Statistical analysis was 
performed using Fisher's exact test analog to determine associations at both genotype and allele level. The 
corresponding P values are shown at the bottom of the table.   
 
Coloured Females (N=306) 
Genotype Total 
 (N=306) 
Controls  
(N=237) 
Adverse 
 (N=69) 
PTL 
(N=27) 
Hypertension 
(N=29) 
G/G 288 (94.1%) 222 (93.7%) 66 (95.7%) 27 28 (96.6%) 
G/A     18 (5.9%) 15 (6.3%) 3 (4.3%) 0 1 (3.4%) 
A/A 0 0 0 0 0 
G-allele 0.971 0.968 0.978 1.000 0.983 
A-allele 0.029 0.032 0.022 0.000 0.017 
HWE 0.869 0.881 0.983 - 0.996 
Controls vs. Adverse: P=0.544 (allele); Controls vs. Preterm labour: P=0.458 (allele); Controls vs. Hypertension: 
P=0.841 (allele). 
 
Table 45: Genotype and allele frequencies of the IVS2-36 G/A variant in the Black population. Hardy 
Weinberg equilibrium (HWE) was determined for each individual group.  
 
Black Females (N=115) 
Genotype Total  
(N=115) 
Controls 
(N=101) 
Adverse 
 (N=14) 
PTL 
(N=6) 
Hypertension 
(N=6) 
G/G 102 (88.7%) 89 (88.1%) 13 (92.9%) 6 6 
G/A   13 (11.3%) 12 (11.9%) 1 (7.1%) 0 0 
A/A 0 0 0 0 0 
G-allele 0.943 0.941 0.964 1.000 1.000 
A-allele 0.057 0.059 0.036 0.000 0.000 
HWE 0.814 0.818 0.990 - - 
Sample size insufficient to perform association analysis (P<0.05). 
 
IVS2-22 A/G (dbSNP rs: 2233706) 
 
Table 46: Genotype and allele frequencies of the IVS2-22 G/A variant in the Coloured population. 
Hardy Weinberg equilibrium (HWE) was determined for each individual group. Statistical analysis was 
performed using Fisher's exact test analog to determine associations at both genotype and allele level. The 
corresponding P values are shown at the bottom of the table.   
. 
Coloured Females (N=306) 
Genotype Total 
 (N=306) 
Good  
(N=237) 
Poor  
(N=69) 
PTL 
(N=27) 
Hypertension 
(N=29) 
A/A 231 (75.4%) 174 (73.4%) 57 (82.6%) 24 (88.9%) 22 (75.9%) 
A/G   71 (23.3%)   60 (25.3%) 11 (15.9%)  3 (11.1%)  6 (20.7%) 
G/G   4 (1.3%)  3 (1.3%) 1 (1.5%) 0 1 (3.4%) 
A-allele 0.871 0.861 0.906 0.944 0.862 
G-allele 0.129 0.139 0.094 0.056 0.138 
P value 0.856 0.688 0.861 0.954 0.783 
Controls vs. Adverse: P=0.268 (genotype) and P=0.165 (allele); Controls vs. Preterm labour: P=0.162 (genotype) 
and P=0.299 (allele); Controls vs. Hypertension: P=0.588 (genotype) and P=0.978 (allele). 
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Table 47: Genotype and allele frequencies of the IVS2-36 G/A variant in the Black population. Hardy 
Weinberg equilibrium (HWE) was determined for each individual group.  
 
Black Females (N=115) 
Genotype Total  
(N=115) 
Good  
(N=101) 
Poor  
(N=14) 
PTL 
(N=6) 
Hypertension 
(N=6) 
A/A 69 (60%)  59 (58.4%) 10 (71.4%) 4 (66.7%) 4 (66.7%) 
A/G    40 (34.8%)   37 (36.6%)  3 (21.4%) 1 (16.7%) 2 (33.3%) 
G/G   6 (5.2%) 5 (5%) 1 (7.1%) 1 (16.7%) 0 
A-allele 0.774 0.767 0.821 0.750 0.833 
G-allele 0.226 0.233 0.179 0.250 0.167 
P value 0.998 0.966 0.601 0.396 0.887 
Sample size insufficient to perform association analysis (P<0.05). 
 
IVS2-15 G/A (NOVEL) 
 
 
 
Conformations 
    1            2          3          4          5         6 
   G/G     G/A     G/G     G/G    G/G    G/G 
IVS2-15 G/A 
Conformation IVS2-15 G/A IVS2-22 A/G IVS2-36 G/A
1 G/G A/A G/A
2 G/A A/A G/G
3 G/G A/G G/A
4 G/G G/G G/G
5 G/G A/G G/G
6 G/G A/A G/G
Figure 30: Multiphor SSCP/HD demonstrating the different conformations of the IVS2-15 G/A detected 
in the SSCP component of the gel. The included table illustrates the cluster of variants in the 5' intronic 
region flanking exon three. 
 
 
 
Figure 31: Electropherogram depicting the heterozygous form (arrowed) of the IVS2-15 G/A variant, 
sequenced in the forward (5'→3') direction.  
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Table 48: Genotype and allele frequencies of the IVS2-15 G/A variant for the total cohort. Hardy 
Weinberg equilibrium (HWE) was determined for each individual group. Statistical analysis was 
performed using Fisher's exact test analog to determine associations at both genotype and allele level. The 
corresponding P values are shown at the bottom of the table.   
 
Total Group (n=421) 
Genotype Total (N=421) Controls 
(N=338) 
Adverse 
 (N=83) 
PTL 
(N=33) 
Hypertension 
(N=35) 
G/G 413 (74.8%) 332 (98.2%) 81 (97.6%) 32 (97%) 34 (97.1%) 
G/A    8 (25.2%)   6 (1.8%) 2 (2.4%) 1 (3%) 1 (2.9%) 
A/A 0 0 0 0 0 
G-allele 0.990 0.991 0.988 0.985 0.986 
A-allele 0.010 0.009 0.012 0.015 0.014 
HWE 0.981 0.987 0.994 0.996 0.996 
Controls vs. Adverse: P=0.706 (allele); Controls vs. Preterm labour: P=0.615 (allele); Controls vs. Hypertension: 
P=0.655 (allele). 
 
Table 49: Genotype and allele frequencies of the IVS2-22 G/A variant in the Coloured population. 
Hardy Weinberg equilibrium (HWE) was determined for each individual group. Statistical analysis was 
performed using Fisher's exact test analog to determine associations at both genotype and allele level. The 
corresponding P values are shown at the bottom of the table.   
 
Coloured Females (n=306) 
Genotype Total Controls  Adverse PTL 
(N=27) 
Hypertension 
 (N=306) (N=237)  (N=69) (N=29) 
G/G 300 (70.9%) 233 (98.3%) 67 (97.1%)  26 (96.3%) 28 (96.6%) 
G/A       6 (29.8%)  4 (1.7%) 2 (2.9%) 1 (3.7%) 1 (3.4%) 
A/A 0 0 0 0 0 
G-allele 0.990 0.992 0.986 0.981 0.983 
A-allele 0.010 0.008 0.014 0.019 0.017 
HWE 0.985 0.992 0.993 0.995 0.996 
Controls vs. Adverse: P=0.525 (allele); Controls vs. Preterm labour: P=0.469 (allele); Controls vs. Hypertension: 
P=0.512 (allele). 
 
Table 50: Genotype and allele frequencies of the IVS2-36 G/A variant in the Black population. Hardy 
Weinberg equilibrium (HWE) was determined for each individual group.  
 
Black Females (n=115) 
Genotype Total  
(N=115) 
Controls 
(N=101) 
Adverse 
 (N=14) 
PTL 
(N=6) 
Hypertension 
(N=6) 
G/G 113 (61.7%) 99 (98%) 14 6 6 
G/A    2 (38.3%) 2 (2%) 0 0 0 
A/A 0 0 0 0 0 
G-allele 0.991 0.990 1.000 1.000 1.000 
A-allele 0.009 0.010 0.000 0.000 0.000 
HWE 0.996 0.995 - - - 
Sample size insufficient to perform association analysis (P<0.05). 
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“Hotspot” (HS) (NOVEL) 
 
     1          2         3        4         5          6 
 
 
Figure 32: (a) Multiphor SSCP/HD conformation demonstrating the conformation of the “hotspot” 
detected in both the SSCP and HD component of the gel. (b) The corresponding electropherogram 
demonstrating the heterozygous form, sequenced in the forward (5'→3') direction. Sequence 
characterisation revealed an 11bp region of which six bases was mutated (arrowed). 
 
 
         
(a)     
         
(b)     
1        2      3 
265 bp 
168 bp 
 
97 bp 
         
HS    
 
Figure 33: Agarose gel (2.5%) demonstrating the 2 genotypes of the ‘hotspot’ sequence variant, detected 
by restriction enzyme analysis with ApoI (50˚C). Lane 1 is a 100 bp ladder (Fermentas). Lane represents 
the wildtype sequence and lane 3 the 11 bp region containing six mutated bases (265bp, 168bp and 97bp). 
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Table 51: Genotype and allele frequencies of the ‘hotspot’ sequence variant for the total cohort. Hardy 
Weinberg equilibrium (HWE) was determined for each individual group. Statistical analysis was 
performed using Fisher's exact test analog to determine associations at both genotype and allele level. The 
corresponding P values are shown at the bottom of the table.   
 
Total Group (n=421) 
Genotype Total (N=421) Controls 
(N=338) 
Adverse 
 (N=83) 
PTL 
(N=33) 
Hypertension 
(N=35) 
- / -  391 (92.9%) 312 (92.3%) 79 (95.2%) 33 34 (97.1%) 
- / HS 30 (7.1%) 26 (7.7%)     4 (4.8%) 0 1 (2.9%) 
HS / Hs 0 0 0 0 0 
- allele 0.964 0.981 0.976 1.000 0.986 
HS allele 0.036 0.019 0.024 0.000 0.014 
HWE 0.7503 0.944 0.975 - 0.996 
Controls vs. Adverse: P=0.371 (allele); Controls vs. Preterm labour: P=0.105 (allele); Controls vs. Hypertension: 
P=0.303 (allele). 
 
Table 52: Genotype and allele frequencies of the ‘hotspot’ sequence variant in the Coloured population. 
Hardy Weinberg equilibrium (HWE) was determined for each individual group. Statistical analysis was 
performed using Fisher's exact test analog to determine associations at both genotype and allele level. The 
corresponding P values are shown at the bottom of the table.   
 
Coloured Females (n=306) 
Genotype Total 
 (N=306) 
Controls  
(N=237) 
Adverse 
 (N=69) 
PTL 
(N=27) 
Hypertension 
(N=29) 
- / - 288 (94.1%) 222 (93.7%) 66 (95.7%) 27 28 (96.6%) 
- / HS     18 (5.9%) 15 (6.3%) 3 (4.3%) 0 1 (3.4%) 
HS / Hs 0 0 0 0 0 
- allele 0.971 0.968 0.978 1.000 0.983 
HS allele 0.029 0.032 0.022 0.000 0.017 
HWE 0.869 0.881 0.983 - 0.996 
Controls vs. Adverse: P=0.544 (allele); Controls vs. Preterm labour: P=0.185 (allele); Controls vs. Hypertension: 
P=0.544 (allele). 
 
Table 53: Genotype and allele frequencies of the ‘hotspot’ sequence variant in the Black population. 
Hardy Weinberg equilibrium (HWE) was determined for each individual group.  
 
Black Females (n=115) 
Genotype Total  
(N=115) 
Controls 
(N=101) 
Adverse 
 (N=14) 
PTL 
(N=6) 
Hypertension 
(N=6) 
- / - 103 (88.8%) 90 (90.1%) 13 (92.9%) 6 6 
- / HS   13 (11.2%) 11 (10.9%) 1 (7.1%) 0 0 
HS / Hs 0 0 0 0 0 
- allele 0.944 0.946 0.964 1.000 1.000 
HS allele 0.056 0.054 0.036 0.000 0.000 
HWE 0.815 0.846 0.990 - - 
Sample size insufficient to perform association analysis (P<0.05). 
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IVS3+72 T/A (dbSNP rs: 2233708) 
 
Table 54: Genotype and allele frequencies of the IVS3+72 T/A variant in the Coloured population. 
Hardy Weinberg equilibrium (HWE) was determined for each individual group. Statistical analysis was 
performed using Fisher's exact test analog to determine associations at both genotype and allele level. The 
corresponding P values are shown at the bottom of the table.   
 
 Coloured Females (n=306) 
Genotype Total 
 (N=306) 
Good  
(N=237) 
Poor  
(N=69) 
PTL 
(N=27) 
Hypertension 
(N=29) 
T/T 229 (74.8%) 172 (72.6%) 57 (82.6%) 23 (85.2%) 22 (75.9%) 
T/A  74 (24.3%)  63 (26.6%) 11 (15.9%)   4 (14.8%)  6 (20.7%) 
A/A  3 (0.9%)  2 (0.8%) 1 (1.5%) 0 1 (3.4%) 
T-allele 0.869 0.859 0.906 0.96 0.862 
A-allele 0.131 0.141 0.094 0.074 0.138 
P value 0.529 0.343 0.861 0.917 0.783 
Controls vs. Adverse: P=0.181 (genotype) and P=0.148 (allele); Controls vs. Preterm labour: P=0.178 (genotype) 
and P=0.482 (allele); Controls vs. Hypertension: P=0.379 (genotype) and P=0.944 (allele). 
 
Table 55: Genotype and allele frequencies of the IVS3+72 T/A variant in the Black population. Hardy 
Weinberg equilibrium (HWE) was determined for each individual group.  
 
 Black Females (n=115) 
Genotype Total  
(N=115) 
Good  
(N=91) 
Poor  
(N=14) 
PTL 
(N=6) 
Hypertension 
(N=6) 
T/T 71 (61.7%) 62 (61.4%) 9 (64.3%) 3 (50%) 4 (66.7%) 
T/A 39 (33.9%) 35 (34.7%) 4 (28.6%)    2 (33.7%) 2 (33.3%) 
A/A 5 (4.4%) 4 (3.9%)     1 (7.1%)    1 (16.7%) 0 
T-allele 0.787 0.787 0.786 0.667 0.833 
A-allele 0.213 0.213 0.214 0.333 0.16 
P value 0.993 0.943 0.852 0.89 0.887 
Sample size insufficient to perform association analysis (P<0.05). 
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The following variants were only identified in the control group: 
 
130 A→G /M44V (NOVEL) 
 2 individuals  
 
 
         
(a)     
         
(b)     
         
(i)      
         
(ii)     
 
Figure 34: (a) Multiphor SSCP/HD analysis of exon three revealed two distinct conformations in the 
SSCP component of the gel (arrowed), identified in the control cohort. (b) Sequencing analysis in the 
forward direction (5'→3') demonstrated a heterozygous from in these individuals, (130A→G /M44V). 
Individual (i) was heterozygous at both IVS2-36 and IVS2-22 loci, whereas individual (ii) was 
heterozygous at IVS2-36 and homozygous (A/A) at IVS2-22 loci. 
 
260 A→G /K87R (NOVEL) 
 1 individual 
 
 
 
Figure 35: (a) Multiphor SSCP/HD analysis of exon three identified a variant in both the SSCP and HD 
component of the gel (arrowed), identified in the control cohort. (b) Sequencing analysis in the forward 
direction (5'→3') demonstrated a heterozygous from of an exonic mutation, 260 A→G /K87R. 
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351 G→A / P117P (NOVEL) 
 1 individual 
 
 
 
Figure 36: (a) Multiphor SSCP/HD analysis of exon four identified a variant in only the SSCP 
component of the gel (arrowed), identified in the control cohort. (b) Sequencing analysis in the forward 
direction (5'→3') demonstrated a heterozygous from of a silent exonic mutation, 351 G→A / P117P. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 135
Appendix 11: Genotype-phenotype interactions  
 
Immunological gene variants 
 
TNFα -308 G/A 
 
Table 56: Genotype and allele frequencies of the TNFα-308 G/A polymorphism in the total cohort, 
Coloured, Black population and gestation. Hardy Weinberg Equilibrium (HWE) was determined for each 
individual group. Statistical analysis was performed using Fisher's exact test analog to determine 
associations at both genotype and allele level. The corresponding P values are shown at the bottom of the 
table.   
 
 ≥37 (Controls N=370) <37 (Adverse N=33) 
Genotype Total (N=370) 
Coloured 
(N=261) 
Black 
(N=109) 
Total  
(N=33) 
Coloured 
(N=27) 
Black  
(N=6) 
G/G 275 (74.3%) 206 (78.9%) 69 (63.3%) 20 (60.6%) 18 (66.7%) 2 (33.3%) 
G/A  94 (25.4%)  54 (20.7%) 40 (36.7%) 13 (39.4%)  9 (33.3%) 4 (66.7%) 
A/A  1 (0.3%)  1 (0.4%) 0 0 0 0 
G-allele 0.870 0.893 0.817 0.803 0.833 0.667 
A-allele 0.130 0.107 0.183 0.197 0.167 0.333 
HWE 0.055 0.432 0.064 0.371 0.583 0.472 
≥37 vs. <37weeks (group): P=0.212 (genotype); P=0.126 (allele), ≥37 vs. <37weeks (CF): P=0.307 (genotype); 
P=0.1892 (allele), ≥37 vs. <37weeks (BF): Sample size insufficient 
  
 
Table 57: Genotype and allele frequencies of the TNFα-308 G/A polymorphism in the total cohort, 
Coloured, Black population birth weight. Hardy Weinberg Equilibrium (HWE) was determined for each 
individual group. Statistical analysis was performed using Fisher's exact test analog to determine 
associations at both genotype and allele level. The corresponding P values are shown at the bottom of the 
table.   
 
 ≥2000g (Controls N=367) <2000g(Adverse N=31) 
Genotype Total N=367 
Coloured 
N=256 
Black 
N=111 
Total 
N=31 
Coloured 
(N=28) 
Black 
(N=3) 
G/G 270 (73.5%) 201 (78.5%) 69 (62.2%) 20 (64.5%) 19 (67.9%) 1 (33.3%) 
G/A  96 (26.2%)  54 (21.1%) 42 (37.8%) 11 (35.5%)   9 (32.1%) 2 (66.7%) 
A/A  1 (0.3%)  1 (0.4%) 0 0 0 0 
G-allele 0.866 0.819 0.804 0.823 0.839 0.667 
A-allele 0.134 0.109 0.196 0.177 0.161 0.333 
HWE 0.044 0.417 0.139 0.486 0.599 0.687 
≥2000g vs. <2000g (group): not HWE, ≥2000g vs. <2000g (CF): P=0.6969 (allele), ≥2000g vs. <2000g (BF): 
Sample size insufficient 
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TNFα -238 G/A 
 
 
Table 58: Genotype and allele frequencies of the TNFα-238 G/A polymorphism in the total cohort, 
Coloured, Black population and gestation. Hardy Weinberg Equilibrium (HWE) was determined for each 
individual group. Statistical analysis was performed using Fisher's exact test analog to determine 
associations at both genotype and allele level. The corresponding P values are shown at the bottom of the 
table.   
 
 ≥37 (Controls N=370) <37 (Adverse N=33) 
Genotype Total (N=370 
Coloured 
(N=216) 
Black 
(N=109) 
Total 
(N=33) 
Coloured 
(N=27) 
Black 
(N=6) 
G/G 286 (77.3%) 193 (73.9%) 93 (85.3%) 22 (66.7%) 17 (63%) 5 (83.3%) 
G/A  84 (22.7%)  68 (26.1%) 16 (14.7%) 11 (33.3%) 10 (37%) 1 (16.7%) 
A/A 0 0 0 0 0 0 
G-allele 0.886 0.870 0.927 0.833 0.815 0.917 
A-allele 0.114 0.130 0.073 0.167 0.185 0.083 
HWE 0.048 0.054 0.710 0.517 0.498 0.976 
≥37 vs. <37weeks (group): P=0.199 (allele), ≥37 vs. <37weeks (CF): P=0.262 (allele), ≥37 vs. <37weeks (BF): 
Sample size insufficient 
 
 
Table 59: Genotype and allele frequencies of the TNFα-238 G/A polymorphism in the total cohort, 
Coloured, Black population and birth weight. Hardy Weinberg Equilibrium (HWE) was determined for 
each individual group. Statistical analysis was performed using Fisher's exact test analog to determine 
associations at both genotype and allele level. The corresponding P values are shown at the bottom of the 
table.   
 
 ≥2000g (Controls N=367) <2000g(Adverse N=31) 
Genotype Total 
N=367 
Coloured 
N=256 
Black 
N=111 
Total 
N=31 
Coloured 
(N=28) 
Black 
(N=3) 
G/G 283 (77.1%) 189 (73.8%) 94 (84.7%) 22 (71%) 19 (67.9%) 3 
G/A  84 (22.9%)  67 (26.2%)  17 (15.35%)  9 (29%)  9 (32.1%) 0 
A/A 0 0 0 0 0 0 
G-allele 0.886 0.869 0.923 0.855 0.839 1.000 
A-allele 0.114 0.131 0.077 0.145 0.161 0.000 
HWE 0.047 0.055 0.6827 0.639 0.599 - 
≥2000g vs. <2000g (group): P=0.469, ≥2000g vs. <2000g (CF): P=0.055 (allele), ≥2000g vs. <2000g (BF): Sample 
size insufficient 
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TNFα +488 G/A 
 
 
Table 60: Genotype and allele frequencies of the TNFα+488G/A polymorphism in the total cohort, 
Coloured, Black population and gestation. Hardy Weinberg Equilibrium (HWE) was determined for each 
individual group. Statistical analysis was performed using Fisher's exact test analog to determine 
associations at both genotype and allele level. The corresponding P values are shown at the bottom of the 
table.   
 
 ≥37 (Controls N=356) <37 (Adverse N=30) 
Genotype Total 
(N=356) 
Coloured 
(N=249) 
Black 
(N=107) 
Total 
(N=30) 
Coloured 
(N=25) 
Black 
(N=5) 
G/G 324 (91%) 222 (89.2%) 102 (95.3%) 29 (96.7%) 24 (96%) 5 
G/A 32 (9%)  27 (10.8%)  5 (4.7%) 1 (3.3%) 1 (4%) 0 
A/A 0 0 0 0 0 0 
G-allele 0.955 0.946 0.977 0.983 0.980 1.000 
A-allele 0.045 0.054 0.023 0.017 0.020 0.000 
HWE 0.674 0.664 0.969 0.996 0.995 - 
≥37 vs. <37weeks (group): P=0.298 (allele), ≥37 vs. <37weeks (CF): P=0.295 (allele), ≥37 vs. <37weeks (BF): 
Sample size insufficient 
 
 
Table 61: Genotype and allele frequencies of the TNFα+488G/A polymorphism in the total cohort, 
Coloured, Black population and birth weight. Hardy Weinberg Equilibrium (HWE) was determined for 
each individual group. Statistical analysis was performed using Fisher's exact test analog to determine 
associations at both genotype and allele level. The corresponding P values are shown at the bottom of the 
table.   
 
 ≥2000g (Controls) <2000g(Adverse) 
Genotype Total 
(N=353) 
Coloured 
(n=245) 
Black 
(N=108) 
Total 
(N=30) 
Coloured 
(N=27) 
Black 
(N=3) 
G/G 321 (90.9%) 218 (89%) 103 (95.4%) 29 (96.7%) 26 (96.3%) 3 
G/A 32 (9.1%)  27 (11%)  5 (4.6%) 1 (3.3%) 1 (3.7%) 0 
A/A 0 0 0 0 0 0 
G-allele 0.955 0.945 0.977 0.983 0.981 1.000 
A-allele 0.045 0.055 0.023 0.017 0.019 0.000 
HWE 0.672 0.659 0.970 0.996 0.995 - 
≥2000g vs. <2000g (group): P=0.294, ≥2000g vs. <2000g (CF): P=0.248 (allele), ≥2000g vs. <2000g (BF): Sample 
size insufficient 
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IL-10 -1082 A/G  
 
 
Table 62: Genotype and allele frequencies of the IL-10 -1082 A/G polymorphism in the total cohort, 
Coloured, Black population and gestation. Hardy Weinberg Equilibrium (HWE) was determined for each 
individual group. Statistical analysis was performed using Fisher's exact test analog to determine 
associations at both genotype and allele level. The corresponding P values are shown at the bottom of the 
table.  Statistically significant P values are shown in bold. 
 
 ≥37 (Controls N=370) <37 (Adverse N=33) 
Genotype Total 
(N=370) 
Coloured 
(N=261) 
Black 
(N=109) 
Total  
(N=33) 
Coloured 
(N=27) 
Black  
(N=6) 
A/A 196 (53%) 132 (50.6%)   64 (58.7%) 25 (75.8%) 19 (70.4%) 6 
A/G   147 (39.7%) 111 (42.5%) 36 (33%)   8 (24.2%)   8 (29.6%) 0 
G/G    27 (97.3%) 18 (6.9%)    9 (8.3%) 0 0 0 
A-allele 0.728 0.718 0.752 0.879 0.852 1.000 
G-allele 0.272 0.282 0.248 0.121 0.148 0.000 
HWE 0.997 0.711 0.494 0.731 0.665 - 
≥37 vs. <37weeks (group): P=0.028 (genotype); P=0.008 (allele), ≥37 vs. <37weeks (CF): P=0.097 (genotype); 
P=0.035 (allele), ≥37 vs. <37weeks (BF): Sample size insufficient 
 
 
 
Table 63: Genotype and allele frequencies of the IL-10 -1082 A/G polymorphism in the total cohort, 
Coloured, Black population and birth weight. Hardy Weinberg Equilibrium (HWE) was determined for 
each individual group. Statistical analysis was performed using Fisher's exact test analog to determine 
associations at both genotype and allele level. The corresponding P values are shown at the bottom of the 
table.  Statistically significant P values are shown in bold. 
 
 ≥2000g (Controls N=367) <2000g(Adverse N=31) 
Genotype Total 
N=367 
Coloured 
N=256 
Black 
N=111 
Total 
N=31 
Coloured 
(N=28) 
Black 
(N=3) 
A/A 196 (53.4%) 129 (50.4%) 67 (60.4% 21 (67.7%) 19 (67.9%) 2 (66.7%) 
A/G 144 (39.2%) 109 (42.6%)  35 (31.5%) 10 (32.3%)   9 (32.1%) 1 (33.3%) 
G/G 27 (7.4%)    18 (7%)    9 (8.15%) 0 0 0 
A-allele 0.730 0.692 0.761 0.839 0.839 0.833 
G-allele 0.270 0.308 0.239 0.161 0.161 0.167 
HWE 0.997 0.856 0.377 0.564 0.599 0.942 
≥2000g vs. <2000g (group): P=0.156 (genotype); P=0.062 (allele), ≥2000g vs. <2000g (CF): P=0.128 (genotype); 
P=0.050 (allele), ≥2000g vs. <2000g (BF): Sample size insufficient 
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IL-10 -819 C/T /-592 C/A 
 
 
Table 64: Genotype and allele frequencies of the IL-10 -592 C/A polymorphism in the total cohort, 
Coloured, Black population and gestation. Hardy Weinberg Equilibrium (HWE) was determined for each 
individual group. Statistical analysis was performed using Fisher's exact test analog to determine 
associations at both genotype and allele level.  
 
 ≥37 (Controls N=370) <37 (Adverse N=33) 
Genotype Total 
(N=370) 
Coloured 
(N=261) 
Black 
(N=109) 
Total  
(N=33) 
Coloured 
(N=27) 
Black  
(N=6) 
C/C 135 (36.5%) 94 (36%) 41 (37.6%) 9 (27.3%) 6 (22.2%) 3 (50%) 
C/A 198 (53.5%)   141 (54%) 57 (52.3%)  20 (60.6%)  17 (63%) 3 (50%) 
A/A    37 (10%)  26 (10%) 11 (10.1%) 4 (12.1%)    4 (14.85) 0 
C-allele 0.632 0.630 0.638 0.576 0.537 0.750 
A-allele 0.368 0.370 0.362 0.424 0.463 0.250 
HWE 0.015 0.037 0.389 0.385 0.384 0.7165 
≥37 vs. <37weeks (group): not HWE, ≥37 vs. <37weeks (CF): not HWE, ≥37 vs. <37weeks (BF): Sample size 
insufficient 
 
 
Table 65: Genotype and allele frequencies of the IL-10 -592 C/A polymorphism in the total cohort, 
Coloured, Black population and birth weight. Hardy Weinberg Equilibrium (HWE) was determined for 
each individual group. Statistical analysis was performed using Fisher's exact test analog to determine 
associations at both genotype and allele level.  
 
 ≥2000g (Controls N=367) <2000g(Adverse N=31) 
Genotype Total 
N=367 
Coloured 
N=256 
Black 
N=111 
Total 
N=31 
Coloured 
(N=28) 
Black 
(N=3) 
C/C 136 (37.1%) 93 (36.3%) 43 (38.7%) 6 (19.4%) 5 (17.9%) 1 (33.3%) 
C/A 195 (53.1%) 138 (53.9%) 57 (51.4%)  21 (67.7%)  19 (67.9%) 2 (66.7%) 
A/A 36 (9.8%)   25 (9.8%) 11 (9.9%) 4 (12.9%) 4 (14.2%) 0 
C-allele 0.636 0.633 0.644 0.532 0.518 0.667 
A-allele 0.364 0.367 0.356 0.468 0.482 0.333 
HWE 0.018 0.038 0.449 0.133 0.165 0.687 
≥2000g vs. <2000g (group): not HWE, ≥2000g vs. <2000g (CF): not HWE, ≥2000g vs. <2000g (BF): Sample size 
insufficient 
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IL-1β+3954C/T 
 
 
Table 66: Genotype and allele frequencies of the IL-1β +3954C/T polymorphism in the total cohort, 
Coloured, Black population and gestation. Hardy Weinberg Equilibrium (HWE) was determined for each 
individual group. Statistical analysis was performed using Fisher's exact test analog to determine 
associations at both genotype and allele level. The corresponding P values are shown at the bottom of the 
table.  
 
 ≥37 (Controls N=370) <37 (Adverse N=33) 
Genotype Total 
(N=370) 
Coloured 
(N=261) 
Black 
(N=109) 
Total  
(N=33) 
Coloured 
(N=27) 
Black  
(N=6) 
C/C 280 (75.7%)  195 (74.7%   85 (78%) 22 (66.7%) 19 (70.4%)    3 (50%) 
C/T  84 (22.7%)   62 (23.8%) 22 (20.2%) 10 (30.3%)  8 (29.6%) 2 (33.3%) 
T/T  6 (1.6%)  4 (1.5%) 2 (1.8%)     1 (3%) 0 1 (16.7%) 
C-allele 0.870 0.866 0.881 0.818 0.852 0.667 
T-allele 0.130 0.134 0.119 0.182 0.148 0.333 
HWE 0.995 0.934 0.919 0.994 0.665 0.829 
≥37 vs. <37weeks (group): P=0.491 (genotype); P=0.234 (allele), ≥37 vs. <37weeks (CF): P=0.663 (genotype); 
P=0.774 (allele), ≥37 vs. <37weeks (BF): Sample size insufficient 
 
 
Table 67: Genotype and allele frequencies of the IL-1β +3954C/T polymorphism in the total cohort, 
Coloured, Black population and birth weight. Hardy Weinberg Equilibrium (HWE) was determined for 
each individual group. Statistical analysis was performed using Fisher's exact test analog to determine 
associations at both genotype and allele level. The corresponding P values are shown at the bottom of the 
table.  
 
 ≥2000g (Controls N=367) <2000g(Adverse N=31) 
Genotype Total 
N=367 
Coloured 
N=256 
Black 
N=111 
Total 
N=31 
Coloured 
(N=28) 
Black 
(N=3) 
C/C 277 (75.5%) 191 (74.6%) 86 (77.5%) 23 (74.2%) 22 (78.6%) 1 (33.3%) 
C/T 83 (22.6%) 61 (23.8%) 22 (19.8%)   8 (25.8%)   6 (21.4%) 2 (66.7%) 
T/T 7 (1.9%) 4 (1.6%) 3 (2.7%) 0 0 0 
C-allele 0.868 0.865 0.874 0.871 0.893 0.667 
T-allele 0.132 0.135 0.126 0.129 0.107 0.333 
HWE 0.965 0.941 0.568 0.712 0.817 0.687 
≥2000g vs. <2000g (group): P=0.696 (genotype); P=0.944 (allele), ≥2000g vs. <2000g (CF): P=0.759 (genotype); 
P=0.5621 (allele), ≥2000g vs. <2000g (BF): Sample size insufficient 
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IL-1RN 
 
 
Table 68: Genotype and allele frequencies of the IL-1RN polymorphism in the total cohort, Coloured, 
Black population and gestation. Hardy Weinberg Equilibrium (HWE) was determined for each individual 
group. Statistical analysis was performed using Fisher's exact test analog to determine associations at both 
genotype and allele level. The corresponding P values are shown at the bottom of the table.  
 
 ≥37 (Controls N=333) <37 (Adverse N=31) 
Genotype Total 
(N=333) 
Coloured 
(N=236) 
Black 
(N=97) 
Total  
(N=31) 
Coloured 
(N=26) 
Black  
(N=5) 
1/1 227 (68.2%) 148 (62.7%) 79 (81%) 18 (58.1%) 15 (57.7%) 3 (60%) 
1/2 90 (27%)  73 (30.9%) 17 (18%) 12 (38.7%)  10 (38.5 %) 2 (40%) 
2/2 16 (4.8%) 15 (6.4%) 1 (1%) 1 (3.2%) 1 (3.8%) 0 
1-allele 0.817 0.782 0.902 0.774 0.769 0.667 
2-allele 0.183 0.218 0.098 0.226 0.231 0.333 
HWE 0.210 0.357 0.997 0.837 0.914 0.829 
≥37 vs. <37weeks (group): P=0.375 (genotype); P=0.410 (allele), ≥37 vs. <37weeks (CF): P=0.685 (genotype); 
P=0.836 (allele), ≥37 vs. <37weeks (BF): Sample size insufficient 
 
 
 
Table 69: Genotype and allele frequencies of the IL-1RN polymorphism in the total cohort, Coloured, 
Black population and birth weight. Hardy Weinberg Equilibrium (HWE) was determined for each 
individual group. Statistical analysis was performed using Fisher's exact test analog to determine 
associations at both genotype and allele level. The corresponding P values are shown at the bottom of the 
table.  
 
 ≥2000g (Controls N=331) <2000g(Adverse N=28) 
Genotype Total 
N=331 
Coloured 
N=231 
Black 
N=100 
Total 
N=28 
Coloured 
(N=27) 
Black 
(N=1) 
1/1 222 (67.1%) 141 (61%) 81 (81%)  18 (64.3%)    17 (63%) 1 
1/2  94 (28.4%)    76 (32.9%) 18 (18%)  9 (32.1%)    9 (33.3%) 0 
2/2 15 (4.5%)  14 (6.1%) 1 (1%) 1 (3.6%)  1 (3.7%) 0 
1-allele 0.813 0.772 0.900 0.804 0.796 1.000 
2-allele 0.187 0.228 0.100 0.196 0.204 0.000 
HWE 0.474 0.560 1.000 0.995 0.990 - 
≥2000g vs. <2000g (group): P=0.901 (genotype); P=0.867 (allele), ≥2000g vs. <2000g (CF): P=0.884 (genotype); 
P=0.721 (allele), ≥2000g vs. <2000g (BF): Sample size insufficient 
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IL-4 -590 C/T 
 
 
Table 70: Genotype and allele frequencies of the IL-4 -590 C/T polymorphism in the total cohort, 
Coloured, Black population and gestation. Hardy Weinberg Equilibrium (HWE) was determined for each 
individual group. Statistical analysis was performed using Fisher's exact test analog to determine 
associations at both genotype and allele level. The corresponding P values are shown at the bottom of the 
table.  
 
 ≥37 (Controls N=369) <37 (Adverse N=33) 
Genotype Total 
(N=369) 
Coloured 
(N=260) 
Black 
(N=109) 
Total  
(N=33) 
Coloured 
(N=27) 
Black  
(N=6) 
C/C 63 (17.1%) 55 (21.2%) 8 (7.3%) 1 (3%) 1 (3.7%) 0 
C/T 154 (41.7%) 113 (43.3%) 41 (37.6%) 17 (51.5%) 14 (51.9%) 3 (50%) 
T/T 152 (41.2%)  92 (35.4%) 60 (55.1%) 15 (45.5%) 12 (44.4%) 3 (50%) 
C-allele 0.379 0.429 0.261 0.288 0.296 0.250 
T-allele 0.621 0.571 0.739 0.712 0.704 0.750 
HWE 0.092 0.191 0.964 0.338 0.449 0.717 
≥37 vs. <37weeks (group): P=0.102 (genotype); P=0.141 (allele), ≥37 vs. <37weeks (CF): P=0.093 (genotype); 
P=0.060 (allele), ≥37 vs. <37weeks (BF): Sample size insufficient 
 
 
Table 71: Genotype and allele frequencies of the IL-4 -590 C/T polymorphism in the total cohort, 
Coloured, Black population and birth weight. Hardy Weinberg Equilibrium (HWE) was determined for 
each individual group. Statistical analysis was performed using Fisher's exact test analog to determine 
associations at both genotype and allele level. The corresponding P values are shown at the bottom of the 
table.  
 
 ≥2000g (Controls N=367) <2000g(Adverse N=31) 
Genotype Total 
N=367 
Coloured 
N=256 
Black 
N=111 
Total 
N=31 
Coloured 
(N=28) 
Black 
(N=3) 
C/C  61 (16.6%) 53 (20.7%) 8 (7.2%) 31 (10%)  3 (11.1%) 0 
C/T  154 (42%) 113 (44.1%) 41 (36.9%)   16 (53.3%)  14 (51.9%) 2 (66.7%) 
T/T 152 (41.4%) 90 (35.2%) 62 (55.9%)   11 (36.7%)   10 (37%) 1 (33.3%) 
C-allele 0.376 0.428 0.257 0.367 0.370 0.333 
T-allele 0.624 0.572 0.743 0.633 0.630 0.667 
HWE 0.128 0.289 0.944 0.719 0.845 0.687 
≥2000g vs. <2000g (group): P=0.418 (genotype); P=0.886 (allele), ≥2000g vs. <2000g (CF): P=0476 (genotype); 
P=0.417 (allele), ≥2000g vs. <2000g (BF): Sample size insufficient 
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LGALS13 gene variants 
 
-98 A/C 
 
Table 72: Genotype and allele frequencies of the -98 A/C variant in the total cohort, Coloured, Black 
population and birth weight. Hardy Weinberg Equilibrium (HWE) was determined for each individual 
group. Statistical analysis was performed using Fisher's exact test analog to determine associations at both 
genotype and allele level. The corresponding P values are shown at the bottom of the table.  
 
 ≥37 (Controls N=370) <37 (Adverse N=33) 
Genotype Total 
(N=370) 
Coloured 
(N=261) 
Black 
(N=109) 
Total  
(N=33) 
Coloured 
(N=27) 
Black  
(N=6) 
A/A 194 (52.4%) 137 (52.5%) 57 (52.3%) 16 (48.5%) 14 (50%)     3 (50%) 
A//C  148 (40%) 100 (38.3%)   48 (44%) 15 (45.5%) 14 (50%)    1 (16.7%) 
C/C 28 (7.6%) 24 (9.2%) 4 (3.7%)     2 (6%) 0    2 (33.3%) 
A-allele 0.724 0.716 0.743 0.712 0.750 0.583 
C-allele 0.276 0.284 0.257 0.288 0.250 0.417 
HWE 0.999 0.655 0.277 0.823 0.211 0.274 
≥37 vs. <37weeks (group): P=0.816 (genotype); P=0.832 (allele), ≥37 vs. <37weeks (CF): P=0.176 (genotype); 
P=0.596 (allele), ≥37 vs. <37weeks (BF): Sample size insufficient 
 
 
Table 73: Genotype and allele frequencies of the -98 A/C variant in the total cohort, Coloured, Black 
population and birth weight. Hardy Weinberg Equilibrium (HWE) was determined for each individual 
group. Statistical analysis was performed using Fisher's exact test analog to determine associations at both 
genotype and allele level. The corresponding P values are shown at the bottom of the table. 
 
 ≥2000g (Controls N=367) <2000g(Adverse N=31) 
Genotype Total 
N=367 
Coloured 
N=256 
Black 
N=111 
Total 
N=31 
Coloured 
(N=28) 
Black 
(N=3) 
A/A 191 (52%) 133 (52%) 58 (52.3%) 15 (48.4%) 14 (50%) 1 (33.3%) 
A/C   147 (40.1%)     99 (38.7%) 48 (43.2%) 15 (48.4%) 14 (50%) 1 (33.3%) 
C/C   29 (7.9%)   24 (9.3%) 5 (4.5%) 1 (3.2%) 0 1 (33.3%) 
A-allele 0.721 0.713 0.739 0.726 0.750 0.5 
C-allele 0.279 0.287 0.261 0.274 0.250 0.5 
HWE 0.995 0.676 0.448 0.4862 0.211 0.847 
≥2000g vs. <2000g (group): P=0.499 (genotype); P=0.932 (allele), ≥2000g vs. <2000g (CF): P=0.177 (genotype); 
P=0.559 (allele), ≥2000g vs. <2000g (BF): Sample size insufficient 
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IVS2-36 G/A 
 
 
Table 74: Genotype and allele frequencies of the IVS2-36 G/A variant in the total cohort, Coloured, 
Black population and gestation. Hardy Weinberg Equilibrium (HWE) was determined for each individual 
group. Statistical analysis was performed using Fisher's exact test analog to determine associations at both 
genotype and allele level. The corresponding P values are shown at the bottom of the table. 
 
 ≥37 (Controls N=370) <37 (Adverse N=33) 
Genotype Total 
(N=370) 
Coloured 
(N=261) 
Black 
(N=109) 
Total  
(N=33) 
Coloured 
(N=27) 
Black  
(N=6) 
G/G 343 (92.7%) 246 (94.3%) 97 (89%) 31 (93.9%) 26 (96.3%) 5 (83.3%) 
G/A 27 (7.3%) 15 (5.7%) 12 (11%) 2 (6.1%) 1 (3.7%) 1 (16.7%) 
A/A 0 0 0 0 0 0 
G-allele 0.964 0.971 0.945 0.970 0.981 0.917 
A-allele 0.036 0.029 0.055 0.030 0.019 0.083 
HWE 0.767 0.892 0.831 0.984 0.995 0.976 
≥37 vs. <37weeks (group): P=0.796 (allele), ≥37 vs. <37weeks (CF): P=0.082 (allele), ≥37 vs. <37weeks (BF): 
Sample size insufficient 
 
 
Table 75: Genotype and allele frequencies of the IVS2-36 G/A variant in the total cohort, Coloured, 
Black population and birth weight. Hardy Weinberg Equilibrium (HWE) was determined for each 
individual group. Statistical analysis was performed using Fisher's exact test analog to determine 
associations at both genotype and allele level. The corresponding P values are shown at the bottom of the 
table. 
 
 ≥2000g (Controls N=367) <2000g(Adverse N=31) 
Genotype Total 
N=367 
Coloured 
N=256 
Black 
N=111 
Total 
N=31 
Coloured 
(N=28) 
Black 
(N=3) 
G/G 340 (92.6%) 241 (94.1%) 99 (89.2%) 29 (93.5%) 27 (96.4%) 2 (66.7%) 
G/A 27 (7.4%) 15 (5.9%) 12 (10.8%) 2 (6.5%) 1 (3.6%) 1 (33.3%) 
A/A 0 0 0 0 0 0 
G-allele 0.963 0.971 0.946 0.968 0.982 0.833 
A-allele 0.037 0.029 0.054 0.032 0.018 0.167 
HWE 0.765 0.890 0.834 0.983 0.995 0.942 
≥37 vs. <37weeks (group): P=0.855 (allele), ≥37 vs. <37weeks (CF): P=0.623 (allele), ≥37 vs. <37weeks (BF): 
Sample size insufficient 
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IVS2-22 A/G 
 
 
Table 76: Genotype and allele frequencies of the IVS2-22 G/A variant in the total cohort, Coloured, 
Black population and gestation. Hardy Weinberg Equilibrium (HWE) was determined for each individual 
group. Statistical analysis was performed using Fisher's exact test analog to determine associations at both 
genotype and allele level. The corresponding P values are shown at the bottom of the table. 
 
 ≥37 (Controls N=370) <37 (Adverse N=33) 
Genotype Total 
(N=370) 
Coloured 
(N=261) 
Black 
(N=109) 
Total  
(N=33) 
Coloured 
(N=27) 
Black  
(N=6) 
A/A 258 (69.7%) 194 (74.3%) 64 (58.7%) 28 (84.8%) 23 (85.2%) 5 (83.3%) 
A/G 102 (27.6%) 63 (24.1%) 39 (35.8%)  5 (15.2%)   4 (14.8%) 1 (16.7%) 
G/G 10 (2.7%) 4 (1.5%) 6 (5.5%) 0 0 0 
A-allele 0.835 0.864 0.766 0.924 0.926 0.917 
G-allele 0.165 0.136 0.234 0.076 0.074 0.083 
HWE 0.9998 0.909 0.9998 0.896 0.917 0.976 
≥37 vs. <37weeks (group): P=0.163 (genotype); P=0.057 (allele), ≥37 vs. <37weeks (CF): P=0.425 (genotype); 
P=0.198 (allele), ≥37 vs. <37weeks (BF): Sample size insufficient 
 
 
Table 77: Genotype and allele frequencies of the IVS2-22 G/A variant in the total cohort, Coloured, 
Black population and birth weight. Hardy Weinberg Equilibrium (HWE) was determined for each 
individual group. Statistical analysis was performed using Fisher's exact test analog to determine 
associations at both genotype and allele level. The corresponding P values are shown at the bottom of the 
table. 
 
 ≥2000g (Controls N=367) <2000g(Adverse N=31) 
Genotype Total 
N=367 
Coloured 
N=256 
Black 
N=111 
Total 
N=31 
Coloured 
(N=28) 
Black 
(N=3) 
A/A 259 (70.6%)  194 (75.8%)   65 (58.6%) 24 (77.4%)   21 (75%) 3 
A/G   99 (27%)    59 (23%) 40 (36%)  6 (19.4%)   6 (21.4%) 0 
G/G 9 (2.4%) 3 (1.2%)   6 (5.4%) 1 (3.2%) 1 (3.6%) 0 
A-allele 0.841 0.873 0.766 0.871 0.857 1.000 
G-allele 0.159 0.127 0.234 0.129 0.143 0.000 
HWE 0.992 0.817 0.999 0.742 0.804 - 
≥2000g vs. <2000g (group): P=0.642 (genotype); P=0.528 (allele), ≥2000g vs. <2000g (CF): P=0.588 (genotype); 
P=0.736 (allele), ≥2000g vs. <2000g (BF): Sample size insufficient 
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IVS2-15 G/A 
 
 
Table 78: Genotype and allele frequencies of the IVS2-15 G/A variant in the total cohort, Coloured, 
Black population and gestation. Hardy Weinberg Equilibrium (HWE) was determined for each individual 
group. Statistical analysis was performed using Fisher's exact test analog to determine associations at both 
genotype and allele level. The corresponding P values are shown at the bottom of the table. 
 
 ≥37 (Controls N=370) <37 (Adverse N=33) 
Genotype Total 
(N=370) 
Coloured 
(N=261) 
Black 
(N=109) 
Total  
(N=33) 
Coloured 
(N=27) 
Black  
(N=6) 
G/G 36 (97.8%) 255 (97.7%) 107 (98.2%) 33 27 6 
G/A 8 (2.2%)  6 (2.3%)  2 (1.8%) 0 0 0 
A/A 0 0 0 0 0 0 
G-allele 0.989 0.989 0.991 1.000 1.000 1.000 
A-allele 0.011 0.011 0.009 0.000 0.000 0.000 
HWE 0.978 0.953 0.995 - - - 
≥37 vs. <37weeks (group): P=0.396 (allele), ≥37 vs. <37weeks (CF): P=0.428 (allele), ≥37 vs. <37weeks (BF): 
Sample size insufficient 
 
 
Table 79: Genotype and allele frequencies of the IVS2-15 G/A variant in the total cohort, Coloured, 
Black population and birth weight. Hardy Weinberg Equilibrium (HWE) was determined for each 
individual group. Statistical analysis was performed using Fisher's exact test analog to determine 
associations at both genotype and allele level. The corresponding P values are shown at the bottom of the 
table. 
 
 ≥2000g (Controls N=367) <2000g(Adverse N=31) 
Genotype Total 
N=367 
Coloured 
N=256 
Black 
N=111 
Total 
N=31 
Coloured 
(N=28) 
Black 
(N=3) 
G/G 360 (98.1%) 251 (98%) 109 (98.2%) 30 (96.8%) 27 (96.4%) 3 
G/A 7 (0.9%)  5 (2%)  2 (1.8%) 1 (3.2%) 1 (3.6%) 0 
A/A 0 0 0 0 0 0 
G-allele 0.990 0.990 0.990 0.984 0.982 1.000 
A-allele 0.010 0.010 0.010 0.016 0.018 0.000 
HWE 0.983 0.988 0.995 0.996 0.995 - 
≥2000g vs. <2000g (group): P=0.617 (allele), ≥2000g vs. <2000g (CF): P=0.574 (allele), ≥2000g vs. <2000g (BF): 
Sample size insufficient 
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‘Hotspot’ 
 
 
Table 80: Genotype and allele frequencies of the ‘hotspot’ variant in the total cohort, Coloured, Black 
population and gestation. Hardy Weinberg Equilibrium (HWE) was determined for each individual group. 
Statistical analysis was performed using Fisher's exact test analog to determine associations at both 
genotype and allele level. The corresponding P values are shown at the bottom of the table. 
 
 ≥37 (Controls N=370) <37 (Adverse N=33) 
Genotype Total 
(N=370) 
Coloured 
(N=261) 
Black 
(N=109) 
Total  
(N=33) 
Coloured 
(N=27) 
Black  
(N=6) 
- / - 344 (93%) 246 (94.3%) 98 (89.9%) 31 (93.9%) 26 (96.3%) 5 (83.3%) 
- / HS 26 (7%) 15 (5.7%) 11 (10.1%) 2 (6.1%) 1 (3.7%) 1 (16.7%) 
HS / HS 0 0 0 0 0 0 
- allele 0.965 0.971 0.950 0.970 0.981 0.917 
HS allele 0.035 0.029 0.050 0.030 0.019 0.083 
HWE 0.783 0.892 0.857 0.984 0.995 0.976 
≥37 vs. <37weeks (group): P=0.837 (allele), ≥37 vs. <37weeks (CF): P=0.664 (allele), ≥37 vs. <37weeks (BF): 
Sample size insufficient 
 
 
Table 81: Genotype and allele frequencies of the ‘hotspot’ variant in the total cohort, Coloured, Black 
population and birth weight. Hardy Weinberg Equilibrium (HWE) was determined for each individual 
group. Statistical analysis was performed using Fisher's exact test analog to determine associations at both 
genotype and allele level. The corresponding P values are shown at the bottom of the table. 
 
 ≥2000g (Controls N=367) <2000g(Adverse N=31) 
Genotype Total 
N=367 
Coloured 
N=256 
Black 
N=111 
Total 
N=31 
Coloured 
(N=28) 
Black 
(N=3) 
- / - 341 (92.9%) 241 (94.1%) 100 (90.1%) 29 (93.5%) 27 (96.4%) 2 (66.7%) 
- / HS 26 (7.01%) 15 (5.9%) 11 (9.9%) 2 (6.5%) 1 (3.6%) 1 (33.3%) 
HS / HS 0 0 0 0 0 0 
- allele 0.965 0.971 0.950 0.968 0.982 0.833 
HS allele 0.035 0.029 0.050 0.032 0.018 0.167 
HWE 0.781 0.890 0.860 0.983 0.995 0.942 
≥2000g vs. <2000g (group): P=0.897 (allele), ≥2000g vs. <2000g (CF): P=0.623 (allele), ≥2000g vs. <2000g (BF): 
Sample size insufficient 
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221delT/ L74W 
 
 
Table 82: Genotype and allele frequencies of the 221delT in the total cohort, Coloured, Black 
population and gestation. Hardy Weinberg Equilibrium (HWE) was determined for each individual group. 
Statistical analysis was performed using Fisher's exact test analog to determine associations at both 
genotype and allele level. The corresponding P values are shown at the bottom of the table.  Statistically 
significant P values are shown in bold. 
 
 ≥37 (Controls N=370) <37 (Adverse N=33) 
Genotype Total 
(N=370) 
Coloured 
(N=261) 
Black 
(N=109) 
Total  
(N=33) 
Coloured 
(N=27) 
Black  
(N=6) 
- / - 360 (97.3%) 256 (98.1%) 104 (95.4%) 30 (90.9%) 24 (88.9%) 6 
- / del 10 (2.7%)    5 (1.95%)  5 (4.6%) 3 (9.1%)   3 (11.1%) 0 
del / del 0 0 0 0 0 0 
- allele 0.986 0.990 0.977 0.955 0.944 1.000 
del allele 0.014 0.010 0.023 0.045 0.056 0.000 
HWE 0.966 0988 0.970 0.963 0.954 - 
≥37 vs. <37weeks (group): P=0.048 (allele), ≥37 vs. <37weeks (CF): P=0.006 (allele), ≥37 vs. <37weeks (BF): 
Sample size insufficient 
 
 
Table 83: Genotype and allele frequencies of the 221delT in the total cohort, Coloured, Black 
population and birth weight. Hardy Weinberg Equilibrium (HWE) was determined for each individual 
group. Statistical analysis was performed using Fisher's exact test analog to determine associations at both 
genotype and allele level. The corresponding P values are shown at the bottom of the table.   
 
 ≥2000g (Controls N=367) <2000g(Adverse N=31) 
Genotype Total 
N=367 
Coloured 
N=256 
Black 
N=111 
Total 
N=31 
Coloured 
(N=28) 
Black 
(N=3) 
- / - 357 (9.3%) 250 (97.7%) 107 (96.4%) 29 (93.5%) 27 (96.4%) 2 (33.7%) 
- / del   10 (2.7%)  6 (2.3%)  4 (3.6%) 2 (6.5%) 1 (3.6%) 1 (33.3%) 
del / del 0 0 0 0 0 0 
- allele 0.986 0.988 0.982 0.968 0.982 0.833 
del allele 0.014 0.012 0.018 0.032 0.018 0.167 
HWE 0.966 0.982 0.982 0.983 0.995 0.942 
≥2000g vs. <2000g (group): P=0.248 (allele), ≥2000g vs. <2000g (CF): P=0.693 (allele), ≥2000g vs. <2000g (BF): 
Sample size insufficient 
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IVS3+72 T/A 
 
 
Table 84: Genotype and allele frequencies of the IVS3+72 T/A in the total cohort, Coloured, Black 
population and gestation. Hardy Weinberg Equilibrium (HWE) was determined for each individual group. 
Statistical analysis was performed using Fisher's exact test analog to determine associations at both 
genotype and allele level. The corresponding P values are shown at the bottom of the table.   
 
 ≥37 (Controls N=370) <37 (Adverse N=33) 
Genotype Total 
(N=370) 
Coloured 
(N=261) 
Black 
(N=109) 
Total  
(N=33) 
Coloured 
(N=27) 
Black  
(N=6) 
T/T 260 (70.3%) 193 (73.9%) 67 (61.5%) 27 (81.8%) 23 (85.2%) 4 (66.7%) 
T/A 102 (27.6%)  65 (24.9%) 37 (33.9%)  6 (18.2%)   4 (14.8%) 2 (33.3%) 
A/A  8 (2.1%) 3 (1.2%) 5 (4.6%) 0 0 0 
T-allele 0.841 0.864 0.784 0.909 0.926 0.833 
A-allele 0.159 0.136 0.216 0.091 0.074 0.167 
HWE 0.861 0.629 0.999 0.848 0.917 0.887 
≥37 vs. <37weeks (group): P=0.320 (genotype); P=0.139 (allele), ≥37 vs. <37weeks (CF): P=0.414 (genotype); 
P=0.198 (allele), ≥37 vs. <37weeks (BF): Sample size insufficient 
 
 
Table 85: Genotype and allele frequencies of the IVS3+72 T/A in the total cohort, Coloured, Black 
population and birth weight. Hardy Weinberg Equilibrium (HWE) was determined for each individual 
group. Statistical analysis was performed using Fisher's exact test analog to determine associations at both 
genotype and allele level. The corresponding P values are shown at the bottom of the table.   
 
 ≥2000g (Controls N=367) <2000g(Adverse N=31) 
Genotype Total 
N=367 
Coloured 
N=256 
Black 
N=111 
Total 
N=31 
Coloured 
(N=28) 
Black 
(N=3) 
T/T 260 (70.8%) 193 (75.4%) 67 (60.4%) 24 (77.4%) 21 (75%) 3 
T/A 100 (27.2%) 61 (23.8%) 39 (35.1%)  6 (19.4%)     6 (21.4%) 0 
A/A 7 (2%) 2 (0.8%) 5 (4.5%) 1 (3.2%)   1 (3.6%) 0 
T-allele 0.845 0.873 0.779 0.871 0.857 1.000 
A-allele 0.155 0.127 0.221 0.129 0.143 0.000 
HWE 0.762 0.487 0.975 0.742 0.804 - 
≥2000g vs. <2000g (group): P=0.580 (genotype); P=0.581 (allele), ≥2000g vs. <2000g (CF): P=0.382 (genotype); 
P=0.736 (allele), ≥2000g vs. <2000g (BF): Sample size insufficient 
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Appendix 12: 2X2 contingency analyses of associations demonstrated in this study 
 
CF-Coloured females; BF-Black females 
Genotype analysis 
 
IL-1RA (raw analysis) 
  
Hardy-Weinberg 
 Controls Poor outcome PTL Hypertension 
 Cohort CF BF Cohort CF BF Cohort CF BF Cohort CF BF 
1/1 212 
70.2% 
138 
65.1% 
74 
82.2% 
42 
(53.2%) 
34 
(50.7%) 
8 
66.7% 
15 
48.4% 
12 
46.2% 
3 
60% 
15 
44.1% 
11 
39.3% 
4 
66.7% 
1/2 77 
25.5% 
62 
29.2% 
15 
16.7% 
  32 
(40.5%) 
28 
(41.8%) 
4 
33.3% 
15 
48.4% 
13 
50% 
2 
40% 
15 
44.1% 
13 
46.4% 
2 
33.3% 
2/2 13 
4.3% 
12 
5.7% 
1 
1.1% 
5 
(6.3%) 
 5 
(7.5%) 
0 1 
3.2% 
1 
3.8% 
0 4 
11.8% 
4 
14.3% 
0 
1  0.829 0.797 0.906 0.734 0.716 0.833 0.726 0.712 0.800 0.662 0.625 0.833 
2 0.171 0.203 0.094 0.266 0.284 0.167 0.274 0.288 0.200 0.338 0.375 0.167 
P 0.229 0.379 0.971 0.945 0.973 0.787 0.486 0.539 0.855 0.996 0.999 0.887 
 
Fishers Exact Test  
 Control vs. Poor (Cohort) Control vs. Poor (CF) Control vs. Poor (BF) 
 Genotype Allele Genotype Allele Genotype Allele 
P 0.017 0.0066 0.108 0.050 0.362 0.2741 
 
 Control vs. PTL (Cohort) Control vs. PTL (CF) Control vs. PTL (BF) 
 Genotype Allele Genotype Allele Genotype Allele 
P 0.025 0.0431 0.099 0.154 0.410 0.2788 
 
 Control vs. Hyper (Cohort) Control vs. Hyper (CF) Control vs. Hyper (BF) 
 Genotype Allele Genotype Allele Genotype Allele 
P 0.006 0.0008 0.021 0.0036 0.572 0.4172 
 
2X2 Tables 
Good vs. Poor (Cohort)     
1/1&1/2 vs. 2/2         
OR 1.50 (0.41-4.66) 
RR 1.36 (0.63-2.95) 
Uncorrected 0.4502 
Mantel-Haenszel 0.4508 
Yates corrected 0.6475 
1-tailed 0.3092 
2-tailed 0.5494 
5 13 
74 289 
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1/1 vs. 1/2&2/2        
OR 2.08 (1.20-3.55) 
RR 1.76 (1.20-2.60) 
Uncorrected 0.0042 
Mantel-Haenszel 0.0043 
Yates corrected 0.0064 
37 90 
42 212 
 
Good vs. Poor (CF)          
1/1&1/2 vs. 2/2        
OR 1.34 (0.36-4.29) 
RR 1.24 (0.58-2.68) 
Uncorrected 0.5909 
Mantel-Haenszel 0.5915 
Yates corrected 0.8067 
1-tailed 0.3873 
2-tailed 0.5660 
5 12 
62 200 
     
1/1 vs. 1/2&2/2         
OR 1.86 (1.03-3.39) 
RR 1.60 (1.05-2.43) 
Uncorrected 0.0277 
Mantel-Haenszel 0.0280 
Yates corrected 0.0398 
33 74 
34 138 
 
Good vs. Poor (BF)         
1/1&1/2 vs. 2/2       
OR 0.00 (0.00-292.50) 
RR - 
Uncorrected 0.7137 
Mantel-Haenszel 0.7150 
Yates corrected 0.2330 
1-tailed 0.8824 
2-tailed 1.0000 
0 1 
12 89 
     
1/1 vs. 1/2&2/2         
OR 2.31 (0.45-9.90) 
RR 2.05 (0.68-6.14) 
Uncorrected 0.2023 
Mantel-Haenszel 0.2046 
Yates corrected 0.3746 
1-tailed 0.1832 
2-tailed 0.2446 
4 16 
8 74 
 
 
 
 152
Good vs. PTL (Cohort)         
1/1&1/2 vs. 2/2         
OR 0.74 (0.02-5.28) 
RR 0.76 (0.11-5.18) 
Uncorrected 0.7756 
Mantel-Haenszel 0.7759 
Yates corrected 0.8533 
1-tailed 0.6188 
2-tailed 1.000 
1 13 
30 289 
     
1/1 vs. 1/2&2/2         
OR 2.51 (1.12-5.64) 
RR 2.28 (1.17-4.44) 
Uncorrected 0.0130 
Mantel-Haenszel 0.0132 
Yates corrected 0.0226 
16 90 
15 212 
 
     
Good vs. PTL (CF)         
1/1&1/2 vs. 2/2        
OR 0.67 (0.02-4.89) 
RR 0.69 (0.10-4.72) 
Uncorrected 0.7008 
Mantel-Haenszel 0.7014 
Yates corrected 0.9418 
1-tailed 0.5734 
2-tailed 1.0000 
1 12 
25 200 
     
1/1 vs. 1/2&2/2         
OR 2.18 (0.89-5.33) 
RR 1.99 (0.96-4.10) 
Uncorrected 0.0589 
Mantel-Haenszel 0.0595 
Yates corrected 0.0943 
14 74 
12 138 
 
Good vs. PTL (BF)         
1/1&1/2 vs. 2/2         
OR 0.00 (0.00-702.00) 
RR - 
Uncorrected 0.8127 
Mantel-Haenszel 0.8137 
Yates corrected 0.0439 
1-tailed 0.9474 
2-tailed 1.0000 
0 1 
5 89 
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1/1 vs. 1/2&2/2         
OR 3.08 (0.24-28.84) 
RR 2.85 (0.51-15.83) 
Uncorrected 0.2171 
Mantel-Haenszel 0.2196 
Yates corrected 0.5170 
1-tailed 0.2386 
2-tailed 0.2386 
2 16 
3 74 
 
Good vs. Hypertension (Cohort)  
1/1&1/2 vs. 2/2        
OR 2.96 (0.66-10.37) 
RR 2.50 (0.99-6.29) 
Uncorrected 0.0599 
Mantel-Haenszel 0.0603 
Yates corrected 0.1418 
1-tailed 0.0803 
2-tailed 0.0803 
4 13 
30 289 
     
1/1 vs. 1/2&2/2         
OR 2.98 (1.37-6.51) 
RR 2.64 (1.39-4.99) 
Uncorrected 0.0021 
Mantel-Haenszel 0.0021 
Yates corrected 0.0039 
19 90 
15 212 
 
 
Good vs. Hypertension (CF)  
1/1&1/2 vs. 2/2         
OR 2.78 (0.60-10.10) 
RR 2.33 (0.92-5.91) 
Uncorrected 0.0855 
Mantel-Haenszel 0.0861 
Yates corrected 0.1879 
1-tailed 0.1002 
2-tailed 0.1002 
4 12 
24 200 
     
1/1 vs. 1/2&2/2         
OR 2.88 (1.20-6.99) 
RR 2.53 (1.24-5.16) 
Uncorrected 0.0082 
Mantel-Haenszel 0.0083 
Yates corrected 0.0148 
17 74 
11 138 
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Good vs. Hypertension (BF)  
1/1&1/2 vs. 2/2        
OR 0.00 (0.00-585.00) 
RR - 
Uncorrected 0.7952 
Mantel-Haenszel 0.7963 
Yates corrected 0.0692 
1-tailed 0.9375 
2-tailed 1.0000 
0 1 
6 89 
     
1/1 vs. 1/2&2/2         
OR 2.31 (0.27 
RR 2.17 (0.43-10.93) 
Uncorrected 0.3445 
Mantel-Haenszel 0.3471 
Yates corrected 0.6854 
1-tailed 0.3130 
2-tailed 0.3130 
2 16 
4 74 
 
 
TNF-308 G/A 
Hardy-Weinberg 
 Controls Poor outcome PTL Hypertension 
 Cohort CF BF Cohort CF BF Cohort CF BF Cohort CF BF 
G/G 253 74.9% 
189 
79.7% 
64 
63.4% 
54 
(65.1%) 
47 
(68.1%) 
7 
50% 
20 
60.6% 
17 
63% 
3 
50% 
24 
68.6% 
20 
69% 
4 
66.7% 
G/A 85 25.1% 
48 
20.3% 
37 
36.6% 
28 
(33.7%) 
21 
(30.4%) 
7 
50% 
12 
36.4% 
9 
33.3% 
3 
50% 
11 
31.4% 
9 
31% 
2 
33.3% 
A/A 0  
0 0 1 
(1.2%) 
1 
(1.5%) 
0 1 
3% 
1 
3.7% 
0 0 0 0 
G 0.874 0.899 0.817 0.819 0.833 0.75 0.788 0.796 0.75 0.843 0.845 0.833 
A 0.124 0.101 0.183 0.183 0.167 0.25 0.212 0.204 0.25 0.157 0.155 0.167 
P 0.030 0.222 0.079 0.436 0.729 0.459 0.880 0.99 0.717 0.544 0.613 0.887 
 
Fishers Exact Test  
 Control vs. Poor (Cohort) Control vs. Poor (CF) Control vs. Poor (BF) 
 Genotype Allele Genotype Allele Genotype Allele 
P Not HWE Not HWE 0.033 0.0347 - 0.3995 
 
 Control vs. PTL (Cohort) Control vs. PTL (CF) Control vs. PTL (BF) 
 Genotype Allele Genotype Allele Genotype Allele 
P Not HWE Not HWE 0.003 0.0236 - 0.564 
 
 Control vs. Hyper (Cohort) Control vs. Hyper (CF) Control vs. Hyper (BF) 
 Genotype Allele Genotype Allele Genotype Allele 
P Not HWE Not HWE - 0.2102 - 0.8856 
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2X2 Tables 
Good vs. Poor (Cohort) Not HWE     
G/G&G/A vs. A/A            
G/G vs. G/A&A/A         
 
Good vs. Poor (CF)         
G/G&G/A vs. A/A         
OR Undefined 
RR 4.49 (3.64-5.53) 
Uncorrected 0.0630 
Mantel-Haenszel 0.0638 
Yates corrected 0.5106 
1-tailed 0.2255 
2-tailed 0.2255 
1 0 
68 237 
     
G/G vs. G/A&A/A         
OR 1.84 (0.96-3.47) 
RR 1.58 (1.03-2.43) 
Uncorrected 0.0429 
Mantel-Haenszel 0.0433 
Yates corrected 0.0627 
22 48 
47 189 
 
Good vs. Poor (BF)        
G/G&G/A vs. A/A         
OR 1.73 (0.50-6.05) 
RR 1.61 (0.61-4.29) 
Uncorrected 0.3349 
Mantel-Haenszel 0.3369 
Yates corrected 0.5022 
7 37 
7 64 
 
Good vs. PTL (CF)         
G/G&G/A vs. A/A         
OR Undefined 
RR 10.12 (7.02-14.57) 
Uncorrected 0.0029 
Mantel-Haenszel 0.0030 
Yates corrected 0.1885 
1-tailed 0.1022 
2-tailed 0.1022 
1 0 
26 237 
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G/G vs. G/A&A/A         
OR 2.32 (0.92-5.78) 
RR 2.09 (1.01-4.31) 
Uncorrected 0.0459 
Mantel-Haenszel 0.0464 
Yates corrected 0.0800 
10 48 
17 189 
 
Good vs. PTL (BF)        
G/G&G/A vs. A/A         
OR 1.73 (0.50-6.05) 
RR 1.61 (0.61-4.29) 
Uncorrected 0.3349 
Mantel-Haenszel 0.337 
Yates corrected 0.5022 
7 37 
7 64 
 
Good vs. Hypertension (CF)           
G/G&G/A vs. A/A         
OR 1.77 (0.70-4.43) 
RR 0.65 (0.80-3.42) 
Uncorrected 0.0792 
Mantel-Haenszel 0.0799 
Yates corrected 0.1327 
9 48 
20 189 
 
Good vs. Hypertension (BF)        
G/G&G/A vs. A/A        
OR 0.86 (0.19-3.35) 
RR 0.87 (0.17-4.54) 
Uncorrected 0.8704 
Mantel-Haenszel 0.871 
Yates corrected 0.7846 
1-tailed 0.6194 
2-tailed 1.0000 
2 37 
4 64 
 
LGALS13 221delT 
 
Hardy-Weinberg 
 Controls Poor outcome PTL Hypertension 
 Cohort CF BF Cohort CF BF Cohort CF BF Cohort CF BF 
- / - 330 
97.6% 
233 
98.3% 
97 
96% 
77 
(92.8%) 
64 
(92.8%) 
13 
92.9% 
30 
90.9% 
25 
92.6% 
5 
83.3% 
33 
94.3% 
27 
93.1% 
6 
- / del 8 
2.4% 
4 
1.7% 
4 
4% 
6 
(7.2%) 
5 
(7.2%) 
1 
7.1% 
3 
9.1% 
2 
7.4% 
1 
16.7% 
2 
5.7% 
2 
6.9% 
0 
del/del 0 
 
0 0 0 0 0 0 0 0 0 0 0 
- 0.988 0.992 0.980 0.964 0.964 0.964 0.955 0.963 0.917 0.971 0.966 1.000 
del 0.012 0.008 0.020 0.036 0.036 0.036 0.045 0.037 0.083 0.029 0.034 0.000 
P 0.976 0.992 0.979 0.943 0.952 0.990 0.963 0.9802 0.976 0.985 0.982 - 
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Fishers Exact Test  
 Control vs. Poor (Cohort) Control vs. Poor (CF) Control vs. Poor (BF) 
 Genotype Allele Genotype Allele Genotype Allele 
P - 0.0282 - 0.017 - 0.5884 
 
 Control vs. PTL (Cohort) Control vs. PTL (CF) Control vs. PTL (BF) 
 Genotype Allele Genotype Allele Genotype Allele 
P - 0.031 - 0.0603 - 0.1569 
 
 Control vs. Hyper (Cohort) Control vs. Hyper (CF) Control vs. Hyper (BF) 
 Genotype Allele Genotype Allele Genotype Allele 
P - 0.2464 - 0.0762 - 0.6227 
 
2X2 Tables 
Good vs. Poor (Cohort)       
- -vs. - /del&del/del        
OR 3.21 (0.89-10.08) 
RR 2.27 (1.20-4.29) 
Uncorrected 0.0269 
Mantel-Haenszel 0.0270 
Yates corrected 0.0612 
1-tailed 0.0385 
2-tailed 0.0385 
6 8 
77 330 
      
Good vs. Poor (CF)           
- -vs. - /del&del/del         
OR 4.55 (0.94-23.48) 
RR 2.58 (1.38-4.81) 
Uncorrected 0.0162 
Mantel-Haenszel 0.0163 
Yates corrected 0.0455 
1-tailed 0.0301 
2-tailed 0.0301 
5 4 
64 233 
 
Good vs. Poor (BF)           
- -vs. - /del&del/del         
OR 1.87 (0.04-20.74) 
RR 1.69 (0.27-10.51) 
Uncorrected 0.5842 
Mantel-Haenszel 0.5859 
Yates corrected 0.8791 
1-tailed 0.4839 
2-tailed 0.4839 
1 4 
13 97 
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Good vs. PTL (Cohort)           
- -vs. - /del&del/del         
OR 4.13 (0.67-18.26) 
RR 3.27 (1.18-9.11) 
Uncorrected 0.0297 
Mantel-Haenszel 0.0299 
Yates corrected 0.1018 
1-tailed 0.0647 
2-tailed 0.0647 
3 8 
30 330 
     
Good vs. PTL (CF)           
- -vs. - /del&del/del         
OR 4.66 (0.40-34.09) 
RR 3.44 (1.05-11.32) 
Uncorrected 0.0588 
Mantel-Haenszel 0.0593 
Yates corrected 0.2270 
1-tailed 0.1169 
2-tailed 0.1169 
2 4 
25 233 
 
Good vs. PTL (BF)           
- -vs. - /del&del/del         
OR 4.85 (0.08-62.31) 
RR 4.08 (0.58-28.69) 
Uncorrected 0.1519 
Mantel-Haenszel 0.1539 
Yates corrected 0.6619 
1-tailed 0.2549 
2-tailed 0.2549 
1 4 
5 97 
 
Good vs. Hypertension (Cohort)    
- -vs. - /del&del/del         
OR 2.50 (0.25-13.22) 
RR 2.20 (0.61-7.93) 
Uncorrected 0.2432 
Mantel-Haenszel 0.2438 
Yates corrected 0.5369 
1-tailed 0.2392 
2-tailed 0.2392 
2 8 
33 330 
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Good vs. Hypertension (CF)  
- -vs. - /del&del/del         
OR 4.31 (0.37-31.47) 
RR 3.21 (0.98-10.52) 
Uncorrected 0.0746 
Mantel-Haenszel 0.0751 
Yates corrected 0.2624 
1-tailed 0.1306 
2-tailed 0.1306 
2 4 
27 233 
 
Good vs. Hypertension (BF)  
- -vs. - /del&del/del         
OR 0.00 (0.00-29.55) 
RR - 
Uncorrected 0.6193 
Mantel-Haenszel 0.6209 
Yates corrected 0.5414 
1-tailed 0.7911 
2-tailed 1.0000 
0 4 
6 97 
 
   
Genotype-phenotype interactions 
 
IL-4 -590 C/T (gestation) 
 
Hardy-Weinberg 
 ≥37 <37 
 Cohort CF BF Cohort CF BF 
C/C 63 
17.1% 
55 
35% 
8 
7.3% 
1 
3% 
1 
3.7% 
0 
C/T 154 
41.7% 
10 
6.4% 
41 
37.6% 
17 
51.5% 
14 
51.9%
3 
50% 
T/T 152 
41.2% 
92 
58.6% 
60 
55.1% 
15 
45.5% 
12 
44.4%
3 
50% 
C 0.379 0.382 0.261 0.288 0.296 0.250
T 0.621 0.618 0.739 0.712 0.704 0.750
P 0.092 0.000 0.964 0.338 0.449 0.717
 
Fishers Exact Test  
 ≥37 vs. <37 weeks (cohort) ≥37 vs. <37 weeks (CF) ≥37 vs. <37 weeks (BF) 
 Genotype Allele Genotype Allele Genotype Allele 
P 0.102 0.1405 NOT HWE NOT HWE 0.707 0.9298 
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2X2 Tables 
≥37 vs. <37 weeks (cohort)        
C/C&C/T vs. T/T         
OR 1.19 (0.55-2.57) 
RR 1.17 (0.61-2.26) 
Uncorrected 0.6341 
Mantel-Haenszel 0.6345 
Yates corrected 0.7705 
15 152 
18 217 
     
C/C vs. C/T&T/T       
OR 6.59 (1.06-272.45) 
RR 6.06 (0.84-43.55) 
Uncorrected 0.0346 
Mantel-Haenszel 0.0349 
Yates corrected 0.0623 
32 306 
1 63 
 
≥37 vs. <37 weeks (CF)         
Not HWE 
 
≥37 vs. <37 weeks (BF)      
C/C&C/T vs. T/T        
OR 0.82 (0.11-6.38) 
RR 0.83 (0.17-3.92) 
Uncorrected 0.8089 
Mantel-Haenszel 0.8098 
Yates corrected 0.8575 
1-tailed 0.5652 
2-tailed 1.0000 
3 60 
3 49 
 
C/C vs. C/T&T/T       
OR 0.00 (0.00-12.98) 
RR - 
Uncorrected 0.4915 
Mantel-Haenszel 0.4934 
Yates corrected 0.8917 
1-tailed 0.6423 
2-tailed 1.0000 
0 8 
6 101 
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Appendix 13: Nomenclature 
 
 Primer sequences and restriction enzyme conditions obtained from Genc et al., 2002 for 
the screening of IL-1β +3953 C/G in this study were actually the +3954 C/T, determined 
upon sequencing, after dbSNP number could not be obtained. 
 
 Discrepancies in the nature of the polymorphism at position -1082 of the IL-10 gene. 
o Makris et al., 2005 [IL-10 -1082 G→A] 
o dbSNP rs:1800896 [IL-10 -1082 A→G] 
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Appendix 14: Fetal growth chart 
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Appendix 15: Congress outputs 
 
Presented at the 12th South African Society for Human Genetics (SASHG), Bloemfontein, 
Golden Gate Mountain Resort, March 2007. 
 
INVESTIGATION OF THE LGALS - 13 GENE VARIANTS AS MARKERS FOR POOR 
PREGNANCY OUTCOME: A PROSPECTIVE STUDY 
 
N Bruiners1, GS Gebhardt2, G Rebello3, R Hillermann1
 
1Department of Genetics and 2Department of Obstetrics and Gynaecology, Tygerberg Campus, 
Stellenbosch University, 3Division of Human Genetics, University of Cape Town, South Africa. 
 
Introduction: Placental insufficiency is responsible for among others, low birth weight, gestational hypertension 
and proteinuria, newborn mortality and life-long morbidity. Although the function of placental protein 13 (PP-13) in 
pregnancy remains unknown, several studies provide evidence for its effect on the trophoblast membrane in terms of 
implantation, blood pressure regulation and tissue oxygenation. The aim of the study was to investigate whether 
variants in the encoding gene, LGALS13, contribute to poor pregnancy outcome which includes preterm labour, pre-
eclampsia, abruptio placentae and intra-uterine death. 
 
Methods: We performed a prospective study involving 275 Coloured participants recruited at first booking at Paarl 
hospital. Variants in the coding region of the LGALS13 gene were detected by a combination of heteroduplex-SSCP 
gel electrophoresis, automated sequencing and restriction enzyme analysis, where applicable. 
 
 
Results and Conclusion: To date, 164 women have delivered.  Of these deliveries, 125 (0.76) have normal clinical 
outcomes, and 39 (0.24) are complicated.  Significant associations have been demonstrated between poor pregnancy 
outcome and variant alleles at the following known loci: -98 A/C [dbSNP:rs3764843], IVS2-36 G/A 
[dbSNP:rs2233706] and IVS3+72 T/A [dbSNP:rs2233708]. A similar trend was observed at novel loci IVS2-22 
A/G and IVS2-15 G/A. Statistical analysis and clinical correlation should be performed again upon completion of 
this pilot study, when the sample sizes should be more adequate and all patients delivered. Future analysis should 
involve characterisation of the promoter variant and intronic variants (novel and previously documented) identified 
in this study. 
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